Anti-galectin-9 antibodies and uses thereof

By combining antibodies that bind human galactose lectin-9 with checkpoint inhibitors, interfering with the immunosuppression of galactose lectin-9 in the tumor microenvironment, it solves the existing therapies for invasive pancreatic ductal adenocarcinoma and bile ducts. The problem of poor treatment of cancer and colorectal cancer has significantly improved the treatment effect.

CN119033928APending Publication Date: 2024-11-29NEW YORK UNIV +1
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411238025.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-05-01
Filing Date
2020-05-01
Publication Date
2024-11-29

AI Technical Summary

Technical Problem

Existing immunotherapy is not ideal for invasive pancreatic ductal adenocarcinoma, cholangiocarcinoma and colorectal cancer, and galactose lectin-9 is overexpressed in these tumors, involved in immune escape, leading to treatment challenges.

Method used

Antibodies that bind human galectin-9, either alone or in combination with checkpoint inhibitors, such as anti-PD-1 antibodies, are used to interfere with the interaction between galectin-9 and its receptors, and block them. Immunosuppressive effects in tumor microenvironment.

Benefits of technology

By blocking the signaling pathway of galactose lectin-9, the anti-tumor immune response is enhanced and the therapeutic effect is improved, especially in patients with ineffective or resistant to previous treatments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033928A_ABST
    Figure CN119033928A_ABST
Patent Text Reader

Abstract

Disclosed herein are methods for treating solid tumors (e.g., pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC), or bile duct cancer, etc.), including but not limited to metastatic tumors, using an anti-galectin-9 antibody.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the patent application with application number 202080047488.7.

[0002] Related Applications

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 841,732, filed May 1, 2019, which is incorporated herein by reference in its entirety. Background of the Invention

[0005] The immune system has great potential to recognize and destroy cancer cells, but the complex network that controls tumor immune escape is an obstacle to widespread effective immune regulation (Martinez-Bosch N et al., Immune Evasion in Pancreatic Cancer: From Mechanisms to Therapy. Cancers (Basel). 2018; 10 (1)). Approved immuno-oncology (IO) drugs provide progressive survival improvements for a variety of tumor types (e.g., melanoma, lung cancer, kidney cancer, bladder cancer, certain colon cancers, etc.), and are rapidly being integrated into standard care in addition to and in conjunction with surgery, chemotherapy, and radiotherapy. However, there are still major gaps in the treatment and survival rates of a variety of other aggressive malignancies. For example, the 5-year survival rates of metastatic pancreatic ductal adenocarcinoma (PDAC or PDA), cholangiocarcinoma (CCA), and colorectal cancer (CRC) are still <9%, <5%, and <15%, respectively. These gastrointestinal tumors are very aggressive, many patients present with advanced disease, and the effectiveness of approved immunotherapies is suboptimal (Rizvi et al., Cholangiocarcinoma-evolving concepts and therapeutic strategies; Nat Rev Clin Oncol. 2018; 15(2):95-111; Kalyan et al., Updates on immunotherapy for colorectal cancer; J Gastrointest Oncol. 2018; 9(1):160-169).

[0006] The success of the first generation of checkpoint inhibitors (anti-PD1, anti-PDL1, and anti-CTLA4) has led to an explosion of new IO clinical trials in efficacy and differentiation (Holl et al., Examining Peripheral and Tumor Cellular Immunome in Patients With Cancer; Front Immunol. 2019; 10: 1767). However, along with the success, there have also been many unfortunate development failures, and therefore, there is still a need for more novel and effective treatments.

[0007] Galectin-9 is a tandem repeat lectin consisting of two carbohydrate recognition domains (CRDs) and was first discovered and described in patients with Hodgkin lymphoma (HL) in 1997 (Tureci et al., J. Biol. Chem. 1997, 272, 6416-6422). There are three isoforms and can be located intracellularly or extracellularly. Elevated galectin-9 levels have been observed in a variety of cancers, including melanoma, Hodgkin lymphoma, hepatocellular carcinoma, pancreatic cancer, gastric cancer, colon cancer, and clear cell renal cell carcinoma (Wdowiak et al. Int. J. Mol. Sci. 2018, 19, 210). In renal cancer, patients with high expression of galectin-9 showed more advanced disease progression and had larger tumor volumes (Kawashima et al.; BJU Int. 2014; 113: 320-332). In melanoma, galectin-9 is expressed in 57% of tumors and is significantly increased in the plasma of patients with advanced melanoma compared with healthy controls (Enninga et al., Melanoma Res. 2016 Oct; 26(5): 429-441). Many studies have shown the utility of galectin-9 as a prognostic marker and, more recently, as a potential new drug target (Enninga et al., 2016; Kawashima et al. BJU Int 2014; 113: 320-332; Kageshita et al., Int J Cancer. 2002 Jun 20; 99(6): 809-16, and references therein).

[0008] Galectin-9 has been described to play an important role in many cellular processes, such as adhesion, cancer cell aggregation, apoptosis, and chemotaxis. Recent studies have shown that galectin-9 plays a role in tumor-supporting immunomodulation, for example, by negatively regulating Th1-type responses, Th2 polarization, and polarization of macrophages to an M2 phenotype. This work also includes studies showing that galectin-9 is involved in the direct inactivation of T cells through interaction with the T cell immunoglobulin and mucin 3 (TIM-3) receptor (Dardalhon et al., J Immunol., 2010, 185, 1383-1392; Sanchez-Fueyo et al., Nat Immunol., 2003, 4, 1093-1101).

[0009] Galectin-9 has also been found to play a role in polarizing T cells toward a tumor suppressor phenotype, as well as in promoting tolerogenic macrophage programming and adaptive immunosuppression (Daley et al., Nat Med., 2017, 23, 556-567). In a mouse model of pancreatic ductal adenocarcinoma (PDA), blockade of checkpoint interactions between galectin-9 and the receptor Dectin-1 found on innate immune cells in the tumor microenvironment (TME) has been shown to increase anti-tumor immune responses in the TME and slow tumor progression (Daley et al., Nat Med., 2017, 23, 556-567). It was also found that galectin-9 binds to CD206 (a surface marker of M2 macrophages), leading to a decrease in the secretion of CVL22 (MDC), a macrophage-derived chemokine that is associated with longer survival and lower risk of recurrence in lung cancer (Enninga et al., J Pathol. 2018 Aug;245(4):468-477). SUMMARY OF THE INVENTION

[0011] The present disclosure is based, at least in part, on the development of treatment regimens for solid tumors (e.g., metastatic solid tumors), such as pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CAA), involving antibodies that can bind to human galectin-9, alone or in combination with checkpoint inhibitors (e.g., anti-PD-1 antibodies).

[0012] Thus, one aspect of the present disclosure provides a method of treating a solid tumor in a subject by administering an antibody that binds to human galectin-9. In some embodiments, the solid tumor is pancreatic cancer (PDA), colorectal cancer (CRC) or hepatocellular carcinoma (HCC) or cholangiocarcinoma. In some embodiments, the method comprises administering an effective amount of an antibody that binds to human galectin-9 (referred to herein as an anti-Gal 9 antibody or anti-galectin-9 antibody) to a subject with a solid tumor, such as PDA, CRC, HCC or CCA.

[0013] In some embodiments, the anti-Galectin-9 antibody is antibody G9.2-17, the structure of which is provided herein. In some embodiments, the anti-Galectin-9 antibody comprises the same heavy chain complementary determining region (CDR) and / or the same light chain CDR as reference antibody G9.2-17, the sequence of which is provided herein. In some embodiments, the anti-Galectin-9 antibody comprises the heavy chain variable domain of antibody G9.2-17 and / or the light chain variable domain of antibody G9.2-17.

[0014] In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4.

[0015] In some embodiments, the anti-galectin-9 antibody is administered to a subject at a dose of about 1 mg / kg to about 30 mg / kg (e.g., about 3 mg / kg to about 15 mg / kg or about 2 mg / kg to about 16 mg / kg) once every 2-3 weeks. In some embodiments, the anti-galectin-9 antibody is administered to a subject at a dose selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg, or 16 mg / kg. In some embodiments, the antibody is administered once every 2 weeks. In some embodiments, the anti-galectin-9 antibody is administered to a subject at a dose selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg, or 16 mg / kg once every 2 weeks. In some embodiments, the anti-galectin-9 antibody is administered once every 2 weeks for one cycle, once every 2 weeks for two cycles, once every 2 weeks for 3 cycles, once every 2 weeks for 4 cycles, or once every 2 weeks for more than 4 cycles. In some embodiments, the duration of treatment is 0-3 months, 3-6 months, 12-24 months or longer. In some embodiments, the duration of treatment is 12-24 months or longer. In some embodiments, the cycle lasts for a duration of 3 to 6 months, or 6 to 12 months, or 12 to 24 months or longer. In some embodiments, the cycle length is modified, for example, temporarily or permanently modified to a longer duration, such as 3 weeks or 4 weeks. In some embodiments, the anti-galectin-9 antibody is administered to the subject by intravenous infusion. In some embodiments, the cancer is a metastatic cancer, including metastatic cancer of any of the above cancers. In some embodiments, the treatment method comprising administering an anti-galectin-9 antibody does not include any other concurrent anti-cancer therapy.

[0016] In some embodiments, the treatment method using an anti-galectin-9 antibody includes another concurrent anti-cancer therapy. Therefore, in some embodiments, the treatment method using an anti-galectin-9 antibody further includes administering an immune checkpoint inhibitor to the subject. In some embodiments, the immune checkpoint inhibitor is an antibody that binds to PD-1, for example, pembrolizumab, nivolumab, tislelizumab, or cimiprilimab. In some embodiments, the antibody that binds to PD-1 is nivolumab, which is administered to the subject at a dose of 240 mg once every two weeks. In some embodiments, the antibody that binds to PD-1 is nivolumab, which is administered to the subject at a dose of 480 mg once every 4 weeks. In some embodiments, the antibody that binds to PD-1 is pembrolizumab, which is administered at a dose of 200 mg once every 3 weeks. In some embodiments, the antibody that binds to PD-1 is cimiprilimab, which is administered at a dose of 350 mg once every 3 weeks. In some embodiments, the antibody that binds to PD-1 is tislelizumab, which is administered at a dose of 200 mg once every 3 weeks. In some embodiments, the immune checkpoint inhibitor is administered by intravenous infusion.

[0017] In some embodiments, the anti-galectin-9 antibody comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6 and / or comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3. In some embodiments, the anti-galectin-9 antibody comprises a heavy chain variable domain of SEQ ID NO: 7 and / or a light chain variable domain of SEQ ID NO: 8. In some embodiments, the anti-galectin-9 antibody is a full-length antibody. In some embodiments, the anti-galectin-9 antibody is an IgG1 or IgG4 molecule. In some embodiments, the anti-galectin-9 antibody is a human IgG4 molecule having a modified Fc region of human IgG4. In some embodiments, the modified Fc region of human IgG4 comprises the amino acid sequence of SEQ ID NO: 14. In some embodiments, the modified Fc region of human IgG4 comprises the amino acid sequence of SEQ ID NO: 21. In some embodiments, the anti-Galectin-9 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19 and a light chain comprising the amino acid sequence of SEQ ID NO: 15. In some embodiments, the anti-Galectin-9 antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 23 and a light chain comprising the amino acid sequence of SEQ ID NO: 15.

[0018] In any method disclosed herein, the subject (e.g., a human patient) may have undergone one or more previous anticancer therapies, such as surgery, chemotherapy, immunotherapy, radiotherapy, therapy involving biologically targeted small molecules, hormone agents, or a combination thereof. In some embodiments, the subject has disease progression in one or more previous anticancer therapies. In other embodiments, the subject has resistance (e.g., de novo or acquired) to one or more previous therapies. In other embodiments, the subject relapses after one or more previous therapies.

[0019] In any of the treatment methods disclosed herein, the subject can be a human patient having elevated levels of Galectin-9 relative to a control value. In some embodiments, the human patient has elevated serum or plasma levels of Galectin-9 relative to a control value. In some embodiments, the human patient has elevated levels of Galectin-9 expressed on the surface of cells derived from the human patient relative to a control value. Such cells can be cancer cells and / or immune cells in a tumor and / or in the blood of a cancer patient. In some instances, the cancer cells are located in a tumor organoid derived from a human patient. In some embodiments, the control value is based on a value obtained from a healthy human subject.

[0020] Any treatment method disclosed herein may also include monitoring the occurrence of adverse reactions in the subject. In the case of adverse reactions (e.g., the occurrence of one or more serious adverse reactions), the dose of the anti-galectin-9 antibody (e.g., G9.2-17) or the dose of the checkpoint inhibitor (e.g., anti-PD-1 antibody such as nivolumab) (if used together) or both may be reduced.

[0021] Also included within the scope of the present disclosure are pharmaceutical compositions for treating solid tumors (e.g., those described herein and including metastatic solid tumors), as well as the use of any anti-Galectin-9 antibody for the manufacture of a medicament for treating solid tumors, wherein in some embodiments, the uses disclosed herein involve one or more treatment conditions (e.g., dosage, dosing regimen, route of administration, etc.) as also disclosed herein.

[0022] The details of one or more embodiments of the invention are set forth in the following description. Other features and advantages of the invention are apparent from the following drawings and detailed description of several embodiments, and from the appended claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0024] The following drawings constitute a part of this specification and are included to further illustrate certain aspects of the present disclosure, which may be better understood by reference to the drawings in combination with the detailed description of specific embodiments presented herein.

[0025] Figure 1 is a graph showing a representative size exclusion chromatography (SEC) profile of an anti-Galectin-9 antibody. The high molecular weight peak is labeled.

[0026] Figures 2A-2FIncluded are bar graphs showing the levels of Galectin-9 expression measured in T cells (CD3+), macrophages (CD11b+), and tumor cells (Epcam+) in S2 and S3 organoid fractions from pancreatic cancer biopsies using anti-Galectin-9 G9.2-17 Fab fragments and commercially available anti-Galectin-9 antibodies (9M1-3). S2 fraction: organoids. S3 fraction: single cells. The corresponding isoforms of G9.2-17 Fab ("Fab Isoforms") and "Fluorescence Minus One" (FMO) 9M1-3 ("Gal9 FMO") were used as controls for specificity, background staining, and fluorescence bleed-through from other channels. Figure 2A Shown are the levels of Galectin-9 in CD3+ cells measured in the S3 fraction. Figure 2B Shown are the levels of Galectin-9 in CD11b+ cells measured in the S3 fraction. Figure 2C Shown are the levels of Galectin-9 in Epcam+ cells measured in the S3 fraction. Figure 2D Shown are the levels of Galectin-9 in CD3+ cells measured in the S2 fraction. Figure 2E Shown are the levels of Galectin-9 in CD11b+ cells measured in the S2 fraction. Figure 2F Shown are the levels of Galectin-9 in Epcam+ cells measured in the S2 fraction.

[0027] Figures 3A-3F Included are bar graphs showing the levels of Galectin-9 expression measured in T cells (CD3+), macrophages (CD11b+), and tumor cells (Epcam+) in S2 and S3 organoid fractions from colorectal cancer biopsies using the anti-Galectin-9 G9.2-17 Fab fragment and a commercially available anti-Galectin-9 antibody (9M1-3). S2 fraction: organoids. S3 fraction: single cells. The corresponding isoforms of G9.2-17 Fab ("Fab isoforms") and FMO 9M1-3 ("Gal9FMO") were used as controls for specificity, background staining, and fluorescence bleed-through from other channels. Figure 3A Shown are the levels of Galectin-9 in CD3+ cells measured in the S3 fraction. Figure 3B Shown are the levels of Galectin-9 in CD11b+ cells measured in the S3 fraction. Figure 3C Shown are the levels of Galectin-9 in Epcam+ cells measured in the S3 fraction. Figure 3D Shown are the levels of Galectin-9 in CD3+ cells measured in the S2 fraction. Figure 3E Shown are the levels of Galectin-9 in CD11b+ cells measured in the S2 fraction. Figure 3FShown are the levels of Galectin-9 in Epcam+ cells measured in the S2 fraction.

[0028] Figures 4A-4F Included are bar graphs showing the levels of Galectin-9 expression measured in T cells (CD3+), macrophages (CD11b+), and tumor cells (Epcam+) in S2 and S3 organoid fractions from a second pancreatic cancer biopsy using the anti-Galectin-9 G9.2-17 Fab fragment and a commercially available anti-Galectin-9 antibody (9M1-3). S2 fraction: organoids. S3 fraction: single cells. The corresponding isoforms of G9.2-17 Fab ("Fab isoforms") and FMO 9M1-3 ("Gal9 FMO") were used as controls for specificity, background staining, and fluorescence bleed-through from other channels. Figure 4A Shown are the levels of Galectin-9 in CD3+ cells measured in the S3 fraction. Figure 4B Shown are the levels of Galectin-9 in CD11b+ cells measured in the S3 fraction. Figure 4C Shown are the levels of Galectin-9 in Epcam+ cells measured in the S3 fraction. Figure 4D Shown are the levels of Galectin-9 in CD3+ cells measured in the S2 fraction. Figure 4E Shown are the levels of Galectin-9 in CD11b+ cells measured in the S2 fraction. Figure 4F Shown are the levels of Galectin-9 in Epcam+ cells measured in the S2 fraction.

[0029] Figures 5A-5C Included are photographs of immunohistochemical analysis of various tumors using the anti-Galectin-9 antibody 1G3. All magnifications are 200X. Figure 5A Shown are chemotherapy-treated colorectal cancers with heterogeneous intensity scores 2 and 3 (intermediate and high) of galectin-9 expression. Galectin-9 staining was observed specifically at the cell membrane; in addition, intraglandular macrophages were moderately positive, and stromal reactions in the tumors showed multinucleated macrophage giant cells with moderate intensity of galectin-9 expression. Figure 5B A liver metastasis of colorectal cancer with high (intensity score 3) expression of Galectin-9 is shown. Staining is localized in the membrane and cytoplasm. Figure 5C Galectin-9 positive (intensity score 2) entrapped bile duct and Galectin-9 negative cancer are shown.

[0030] Figure 6Includes a graph showing the fraction of annexin V- and propidium iodide (PI)-positive cells drawn as a function of the antibody concentration used. MOLM-13 cells were incubated with various concentrations of G9.2-17 or human IgG4 isotype antibodies and recombinant human galectin-9 for 16 hours. Before flow cytometry analysis, cells were stained with annexin V and propidium iodide. Each condition was performed in triplicate. Analyzed on FlowJo software.

[0031] Fig. 7A and 7B Depicted are graphs showing the results of a study in which mice were treated with G9.2-17mIgG2a alone or in combination with αPD1 mAb. Mice (n=10 / group) orthotopically implanted with KPC tumors were treated once a week for three weeks with commercial αPD-1 (200 μg) mAb or G9.2-17mIg2a (200 μg) or a combination of G9.2-17 and αPD-1 or matched isoforms. Tumors were removed and weighed ( Fig. 7A ), followed by processing and staining for flow cytometry ( Figure 7B ). Each point represents one mouse; *p<0.05; **p<0.01; ***p<0.001; ***p<0.0001; by unpaired Student's t-test.

[0032] Figure 7B The bar graph depicted shows that tumors were excised from control and treated animals at the end of the experiment (day 18) and processed for flow cytometry of intratumoral immune cells and related activation and immunosuppression markers. Mouse tumors were digested before flow. Flow cytometry was performed on an Attune NxT flow cytometer (ThermoFisher Scientific, Waltham, MA). Data were analyzed using FlowJo v.10.1 (Treestar, Ashland, OR).

[0033] Fig. 8A and 8B Depicted is a graph showing the use of G9.2-17 in IgG1 format ( Fig. 8A ) and the IgG4 form of G9.2-17 ( Figure 8B ). As expected for a human IgG4 mAb, G9.2-17 did not mediate ADCC ( Figure 8B This was tested against the IgG1 human counterpart of G9.2-17 (which mediates both ADCC and ADCP) as a positive control, as expected ( Fig. 8A ).

[0034] Fig. 9A and 9BDepicted are graphs showing the effect of 9.2-17 in the B16F10 subcutaneous syngeneic model. Tumors were implanted subcutaneously and treated with G9.2-17 IgG1 mouse mAb, anti-PD1 antibody, or a combination of G9.2-17 IgG1 mouse mAb and anti-PD1 antibody. Fig. 9A Graphs showing the effect on tumor volume are depicted. Fig. 9B A graph showing CD8 T cell infiltration within the tumor is depicted. The results show that the presence of effector T cells within the tumor was enhanced in the combination arm.

[0035] Fig. 10A and 10B Included is a graph showing ex vivo tumor cultures (organoids) derived from cholangiocarcinoma patients treated with G9.2-17. Patient-derived ex vivo tumor cultures (organoids) were treated with G9.2-17 or isotype control for three days. CD44 ( Fig. 10A ) and TNFα( Fig. 10B ) expression. DETAILED DESCRIPTION OF THE INVENTION

[0037] Provided herein are methods of treating solid tumors (e.g., pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC), and cholangiocarcinoma) using anti-galectin-9 antibodies (e.g., G9.2-17). In some embodiments, the cancer is metastatic. In some embodiments, the methods disclosed herein provide specific doses and / or dosing regimens. In some cases, the methods disclosed herein are directed to specific patient populations, e.g., patients who have received prior treatment and have shown disease progression in prior treatment, or patients who are resistant (de novo or acquired) to prior treatment.

[0038] Galectin-9 (a tandem repeat lectin) is a β-galactoside binding protein that has been shown to play a role in regulating cell-cell and cell-matrix interactions. It is found to be strongly overexpressed in Hodgkin's disease tissue and other pathological states. In some cases, it is also found circulating in the tumor microenvironment (TME).

[0039] Galectin-9 was found to interact with Dectin-1, an innate immune receptor that is highly expressed on macrophages of PDA as well as on cancer cells (Daley et al. Nat Med. 2017; 23(5):556-6). Regardless of the source of galectin-9, disruption of its interaction with Dectin-1 has been shown to result in CD4 + and CD8 +Cells are reprogrammed into indispensable mediators of anti-tumor immunity. Therefore, Galectin-9 serves as a valuable therapeutic target for blocking signaling mediated by Dectin-1. Thus, in some embodiments, the anti-Galectin-9 antibodies described herein disrupt the interaction between Galectin-9 and Dectin-1.

[0040] It was also found that galectin-9 interacts with TIM-3, a type I cell surface glycoprotein expressed on the surface of leukemic stem cells in all acute myeloid leukemias (except M3 (acute promyelocytic leukemia)), but not expressed in normal human hematopoietic stem cells (HSC). It has been found that TIM-3 signaling generated by galectin-9 engagement has pleiotropic effects on immune cells, inducing Th1 cell apoptosis (Zhu et al., Nat Immunol., 2005, 6: 1245-1252) and stimulating the secretion of tumor necrosis factor-α (TNF-α), causing monocytes to mature into dendritic cells, leading to inflammation through innate immunity (Kuchroo et al., Nat Rev Immunol., 2008, 8: 577-580). It was further found that galectin-9 / TIM-3 signaling co-activates NF-κB and β-catenin signaling, which are two pathways that promote LSC self-renewal (Kikushige et al., Cell Stem Cell, 2015, 17(3): 341-352). Anti-galectin-9 antibodies that interfere with galectin-9 / TIM-3 binding may have therapeutic effects, especially for leukemia and other hematological malignancies. Therefore, in some embodiments, the anti-galectin-9 antibodies described herein disrupt the interaction between galectin-9 and TIM-3.

[0041] In addition, galectin-9 was found to interact with CD206, a mannose receptor highly expressed on M2 polarized macrophages, thereby promoting tumor survival (Enninga et al., J Pathol. 2018 Aug; 245(4): 468-477). Tumor-associated macrophages expressing CD206 are mediators of tumor immunosuppression, angiogenesis, metastasis, and recurrence (see, e.g., Scodeller et al., Sci Rep. 2017 Nov 7; 7(1): 14655, and references therein). Specifically, M1 (also known as classically activated macrophages) are triggered by Th1-related cytokines and bacterial products, express high levels of IL-12, and have tumoricidal effects. In contrast, M2 (so-called alternatively activated macrophages) are activated by Th2-related factors, express high levels of anti-inflammatory cytokines such as IL-10, and promote tumor progression (Biswas and Mantovani; Nat Immunol. 2010 Oct; 11 (10): 889-96). The pro-tumor effects of M2 include promoting angiogenesis, promoting invasion and metastasis, and protecting tumor cells from chemotherapy-induced apoptosis (Hu et al., Tumour Biol. 2015 Dec; 36 (12): 9119-9126, and references therein). Tumor-associated macrophages are considered to have an M2-like phenotype and have a pro-tumor effect. Galectin-9 has been shown to mediate differentiation of bone marrow cells to the M2 phenotype (Enninga et al., Melanoma Res. 2016 Oct; 26 (5): 429-41). Galectin-9 binding to CD206 may result in reprogramming of TAMs to an M2 phenotype, similar to results previously shown for Dectin. Without wishing to be bound by theory, blocking the interaction of Galectin-9 with CD206 may provide a mechanism by which anti-Galectin-9 antibodies, such as G9.2-17 antibodies, may be therapeutically beneficial. Thus, in some embodiments, the anti-Galectin-9 antibodies described herein disrupt the interaction between Galectin-9 and CD206.

[0042] Galectin-9 has also been shown to interact with protein disulfide isomerase (PDI) and 4-1BB (Bi S et al. Proc Natl Acad Sci US A. 2011; 108(26): 10650-5; Madireddi et al. J Exp Med. 2014; 211(7): 1433-48).

[0043] Anti-Galectin-9 antibodies can be used as therapeutic agents for treating diseases associated with Galectin-9 (e.g., diseases in which Galectin-9 signaling plays a role). Without being bound by theory, anti-Galectin-9 antibodies can block Galectin-9 mediated signaling pathways. For example, the antibody can interfere with the interaction between Galectin-9 and its binding partner (e.g., Dectin-1, TIM-3, or CD206), thereby blocking the signaling triggered by the Galectin-9 / ligand interaction. Alternatively or additionally, anti-Galectin-9 antibodies can also exert their therapeutic effects by inducing blocking and / or cytotoxicity, such as ADCC, CDC, or ADCP, against pathological cells expressing Galectin-9. Pathological cells refer to cells that directly or indirectly contribute to the occurrence and / or development of a disease.

[0044] The anti-Galectin-9 antibodies disclosed herein are capable of inhibiting Galectin-9 mediated signaling (e.g., Galectin-9 / Dectin-1 or Galectin-9 / Tim-3 mediated signaling pathways) or eliminating pathological cells expressing Galectin-9 by, for example, ADCC. Therefore, the anti-Galectin-9 antibodies described herein can be used to inhibit any Galectin-9 signaling and / or eliminate Galectin-9 positive pathological cells, thereby being beneficial in treating diseases associated with Galectin-9.

[0045] It was found that anti-galectin-9 antibodies, such as G9.2-17, effectively induced apoptosis of cells expressing galectin-9. In addition, the anti-tumor effects of anti-galectin-9 antibodies (such as G9.2-17) have been validated in mouse models alone or in combination with checkpoint inhibitors (such as anti-PD-1 antibodies). As reported herein, the efficacy of G9.2-17 was tested in mouse models of PDAC and melanoma and in patient-derived organoid tumor models (PDOT). The orthotopic PDACKPC mouse model used (LSL-KrasG12D / +; LSL-Trp53R172H / +; Pdx-1-Cre) recapitulates many features of the human disease, including unresponsiveness to approved checkpoint inhibitors (Bisht and Feldmann G; Animal models for modeling pancreatic cancer and novel drug discovery; Expert Opin Drug Discov. 2019; 14(2): 127-142; Weidenhofer et al., Animal models of pancreatic cancer and their application in clinical research; Gastrointestinal Cancer: Targets and Therapy 2016; 6). The B16F10 melanoma mouse model has long been a standard for testing immunotherapies (Curran et al., PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors; Proc Natl Acad Sci US A. 2010; 107(9):4275-4280).

[0046] PDOT isolated from fresh human tumor samples retains autologous lymphoid and myeloid cell populations, including antigen-experienced tumor-infiltrating CD4 and CD8 T lymphocytes, and responds to immunotherapy in short-term ex vivo culture (Jenkins et al. ExVivo Profiling of PD-1Blockade Using Organotypic Tumor Spheroids. Cancer Discov. 2018; 8(2): 196-215; Aref et al., 3D microfluidic ex vivo culture oforganotypic tumor spheroids to model immune checkpoint blockade; LabChip. 2018; 18(20): 3129-3143). As reported herein, expression of galectin-9 on cancer cells was observed in patient-derived organoid assays.

[0047] In vivo studies using G9.2-17 mouse IgG1 (G9.2-17mIgG1 contains the exact same binding epitope as G9.2-17 human IgG4 and has the same effector function) achieved significant reductions in tumor growth as a single agent in an orthotopic KPC model in which approved checkpoint inhibitors were ineffective. G9.2-17 significantly exceeded the efficacy of anti-PD1 in the B16F10 model. In both models, the use of G9.2-17mIgG1 was demonstrated to modulate the intratumoral immune microenvironment by upregulating effector T cell activity and inhibiting immunosuppressive signals as well as enhancing intratumoral CD8 T cell infiltration.

[0048] These results demonstrate that the anti-tumor approaches disclosed herein (involving anti-Galectin-9 antibodies, optionally in combination with checkpoint inhibitors) will achieve superior therapeutic efficacy against target solid tumors.

[0049] Thus, described herein are therapeutic uses of anti-Galectin-9 antibodies for treating certain cancers disclosed herein.

[0050] Antibodies that bind to Galectin-9

[0051] The present disclosure provides anti-Galectin-9 antibody G9.2-17 and functional variants thereof for use in the therapeutic methods disclosed herein.

[0052] Antibodies (plural forms are used interchangeably) are immunoglobulin molecules that are able to specifically bind to targets, such as carbohydrates, polynucleotides, lipids, polypeptides, etc., through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. As used herein, the term "antibody", such as an anti-Galectin-9 antibody, includes not only complete (e.g., full-length) polyclonal or monoclonal antibodies, but also antigen-binding fragments thereof (e.g., Fab, Fab', F(ab')2, Fv), single chains (scFv), mutants thereof, fusion proteins comprising antibody portions, humanized antibodies, chimeric antibodies, diabodies, nanobodies, linear antibodies, single-chain antibodies, multispecific antibodies (e.g., bispecific antibodies), and any other modified configurations of immunoglobulin molecules comprising an antigen recognition site of desired specificity, including antibody glycosylation variants, antibody amino acid sequence variants, and covalently modified antibodies. Antibodies (e.g., anti-galectin-9 antibodies) include antibodies of any class, such as IgD, IgE, IgG, IgA, or IgM (or subclasses thereof), and the antibody need not belong to any particular class. Immunoglobulins can be divided into different classes depending on the amino acid sequence of the constant domain of the heavy chain of the antibody. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, some of which can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively. The subunit structures and three-dimensional configurations of the different classes of immunoglobulins are well known.

[0053] A typical antibody molecule contains a heavy chain variable region (V H ) and light chain variable region (V L ), which are usually involved in antigen binding. H and V L The V region can be further subdivided into regions of hypervariability, also called "complementarity determining regions" ("CDR"), interspersed with regions that are more conserved, called "framework regions" ("FR"). H and V LIt is usually composed of three CDRs and four FRs, arranged in the following order from amino terminus to carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The scope of the framework region and CDR can be accurately identified using methods known in the art, such as by Kabat definition, Chothia definition, AbM definition, EU definition, "Contact" numbering scheme, "IMGT" numbering scheme, "AHo" numbering scheme and / or contact definition, all of which are well known in the art. See, e.g., Kabat, EA et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, US Department of Health and Human Services, NIH Publication No. 91-3242, Chothia et al., (1989) Nature 342:877; Chothia, C. et al. (1987) J. Mol. Biol. 196:901-917, Al-lazikani et al. (1997) J. Molec. Biol. 273:927-948; Edelman et al., Proc Natl Acad Sci US A. 1969 May; 63(1):78-85; and Almagro, J. Mol. Recognit. 17: 132-143 (2004); MacCallum et al., J. Mol. Biol. 262: 732-745 (1996), Lefranc MP et al., Dev Comp Immunol, 2003 January; 27(1): 55-77; and Honegger A and Pluckthun A, J Mol Biol, 2001 Jun. 8; 309(3): 657-70. See also hgmp.mrc.ac.uk and bioinf.org.uk / abs.

[0054] In some embodiments, the anti-galectin-9 antibody described herein is a full-length antibody comprising two heavy chains and two light chains, each chain comprising a variable domain and a constant domain. Alternatively, the anti-galectin-9 antibody may be an antigen-binding fragment of a full-length antibody. Examples of binding fragments encompassed by the term "antigen-binding fragment" of a full-length antibody include (i) a Fab fragment, which consists of a V L 、V H , C L and C H1 domain; (ii) F(ab')2 fragment, a bivalent fragment consisting of two Fab fragments linked by a disulfide bond at the hinge region; (iii) H and C H 1 domain; (iv) a V fragment consisting of a single arm of the antibody L and V H Fv fragments composed of V and V domains, (v) dAb fragments (Ward et al., (1989) Nature 341: 544-546), which are composed of V H domain composition; and (vi) separate complementary determining regions (CDRs) that retain function. In addition, although the two domains V L and V H are encoded by different genes, but they can be joined using recombinant methods via synthetic linkers, allowing them to be made into a single protein chain, with V L and V H The domains pair to form monovalent molecules, termed single-chain Fv (scFv). See, e.g., Bird et al. (1988) Science 242:423-426; and Huston et al. (1988) Proc. Natl. Acad. Sci. USA 85:5879-5883.

[0055] Any antibody described herein, such as an anti-galectin-9 antibody, can be monoclonal or polyclonal. "Monoclonal antibody" refers to a homogeneous antibody population, and "polyclonal antibody" refers to a heterogeneous antibody population. These two terms do not limit the source of the antibody or how it is made.

[0056] Reference antibody G9.2-17 refers to an antibody capable of binding to human galectin-9 and comprises a heavy chain variable region of SEQ ID NO: 7 and a light chain variable region of SEQ ID NO: 8, both of which are provided below. In some embodiments, the anti-galectin-9 antibody used in the methods disclosed herein is a G9.2-17 antibody. In some embodiments, the anti-galectin-9 antibody used in the methods disclosed herein is an antibody having the same heavy chain complementary determining region (CDR) as the reference antibody G9.2-17 and / or the same light chain complementary determining region as the reference antibody G9.2-17. H and / or V L CDRs of two antibodies means that their CDRs are identical when determined by the same method (eg, the Kabat method, Chothia method, AbM method, Contact method or IMGT method known in the art, see, eg, bioinf.org.uk / abs / ).

[0057] The heavy and light chain CDRs of the reference antibody G9.2-17 are provided in Table 1 below (determined using the Kabat method):

[0058] Table 1. Heavy and light chain CDRs of G9.2-17

[0059]

[0060]

[0061] In some examples, the anti-galectin-9 antibody used in the methods disclosed herein may comprise (according to the Kabat scheme) the heavy chain complementary determining region 1 (CDR1) of SEQ ID NO: 4, the heavy chain complementary determining region 2 (CDR2) of SEQ ID NO: 5, and the heavy chain complementary determining region 3 (CDR3) of SEQ ID NO: 6 and / or may comprise the light chain complementary determining region 1 (CDR1) of SEQ ID NO: 1, the light chain complementary determining region 2 (CDR2) of SEQ ID NO: 2, and the light chain complementary determining region 3 (CDR3) of SEQ ID NO: 3. Anti-galectin-9 antibodies, including reference antibody G9.2-17, may be in any form disclosed herein, such as a full-length antibody or Fab. The term "G9.2-17 (Ig4)" used herein refers to the G9.2-17 antibody as an IgG4 molecule. Similarly, the term "G9.2-17 (Fab)" refers to the G9.2-17 antibody, which is a Fab molecule.

[0062] In some embodiments, the anti-galectin-9 antibody or binding portion thereof comprises heavy and light chain variable regions, wherein the light chain variable region CDR1, CDR2 and CDR3 amino acid sequences have at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to the light chain variable region CDR1, CDR2 and CDR3 amino acid sequences set forth in SEQ ID NOs: 1, 2 and 3, respectively. In some embodiments, the anti-galectin-9 antibody or binding portion thereof comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region CDR1, CDR2 and CDR3 amino acid sequences have at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to the heavy chain variable region CDR1, CDR2 and CDR3 amino acid sequences set forth in SEQ ID NOs: 4, 5 and 6, respectively.

[0063] Additional Galectin-9 antibodies, e.g., that bind to the CRD1 and / or CRD2 regions of Galectin-9, are described in co-owned co-pending U.S. patent application Ser. No. 16 / 173,970 and co-owned co-pending International patent applications PCT / US18 / 58028 and PCT / US2020 / 024767, the contents of each of which are incorporated herein by reference in their entirety.

[0064] In some embodiments, the anti-galectin-9 antibodies disclosed herein comprise V sequences corresponding to the reference antibody G9.2-17. L The light chain CDRs have at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity, individually or collectively, to the reference antibody G9.2-17. Alternatively or additionally, in some embodiments, the anti-Galectin-9 antibody comprises a corresponding V H The CDRs are compared to heavy chain CDRs that individually or collectively have at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity.

[0065] The "percent identity" of two amino acid sequences is determined using the algorithm of Karlin and Altschul Proc. Natl. Acad. Sci. USA 87:2264-68, 1990, as modified in Karlin and Altschul Proc. Natl. Acad. Sci. USA 90:5873-77, 1993. Such an algorithm is incorporated into the NBLAST and XBLAST programs (version 2.0) of Altschul et al. J. Mol. Biol. 215:403-10, 1990. BLAST protein searches can be performed with the XBLAST program (score = 50, wordlength = 3) to obtain amino acid sequences homologous to protein molecules of the invention. When gaps exist between the two sequences, Gapped BLAST can be used as described in Altschul et al., Nucleic Acids Res. 25(17):3389-3402, 1997. When utilizing BLAST and Gapped BLAST programs, the default parameters of the respective programs (eg, XBLAST and NBLAST) can be used.

[0066] In other embodiments, the anti-Galectin-9 antibodies described herein contain a V region comprising HC CDR1, HC CDR2, and HC CDR3. H, which collectively comprise up to 8 amino acid residue variations (8, 7, 6, 5, 4, 3, 2 or 1 variation, including additions, deletions and / or substitutions) of HC CDR1, HC CDR2 and HC CDR3 relative to the reference antibody G9.2-17. Alternatively or additionally, in some embodiments, the anti-galectin-9 antibodies described herein contain a V comprising LC CDR1, LC CDR2 and LC CDR3. H , which collectively comprise up to 8 amino acid residue variations (8, 7, 6, 5, 4, 3, 2 or 1 variations, including additions, deletions and / or substitutions) in LC CDR1, LC CDR2 and LC CDR3 relative to the reference antibody G9.2-17.

[0067] In one example, the amino acid residue variation is a conservative amino acid residue substitution. As used herein, "conservative amino acid substitution" refers to an amino acid substitution that does not change the relative charge or size characteristics of the protein to which the amino acid substitution is made. Variants can be prepared according to methods known to those of ordinary skill in the art for altering polypeptide sequences, such as those found in reference materials compiling such methods, for example, Molecular Cloning: A Laboratory Manual, J. Sambrook et al., eds., Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989, or Current Protocols in Molecular Biology, FM Ausubel et al., eds., John Wiley & Sons, Inc., New York. Conservative substitutions of amino acids include substitutions between amino acids within the following groups: (a) M, I, L, V; (b) F, Y, W; (c) K, R, H; (d) A, G; (e) S, T; (f) Q, N; and (g) E, D.

[0068] In some embodiments, the anti-Galectin-9 antibodies disclosed herein having heavy chain CDRs disclosed herein comprise a germline V H The framework regions of the subclass of fragments. Such germline V HRegions are well known in the art. See, for example, the IMGT database (www.imgt.org) or www.vbase2.org / vbstat.php. Examples include the IGHV1 subfamily (e.g., IGHV1-2, IGHV1-3, IGHV1-8, IGHV1-18, IGHV1-24, IGHV1-45, IGHV1-46, IGHV1-58, and IGHV1-69), the IGHV2 subfamily (e.g., IGHV2-5, IGHV2-26, and IGHV2-70), the IGHV3 subfamily (e.g., IGHV3-7, IGHV3-9, IGHV3-11, IGHV3-13, IGHV3-15, IGHV3-20, IGHV3-21, IGHV3-23, IGHV3-30, IGHV3-31, IGHV3-32, IGHV3-33, IGHV3-34, IGHV3-35, IGHV3-36, IGHV3-37, IGHV3-38, IGHV3-39, IGHV40, IGHV41, IGHV42, IGHV43, IGHV44, IGHV45, IGHV46, IGHV47, IGHV48, IGHV49, IGHV50, IGHV51, IGHV5 IGHV3-33, IGHV3-43, IGHV3-48, IGHV3-49, IGHV3-53, IGHV3-64, IGHV3-66, IGHV3-72 and IGHV3-73, IGHV3-74), the IGHV4 subfamily (e.g., IGHV4-4, IGHV4-28, IGHV4-31, IGHV4-34, IGHV4-39, IGHV4-59, IGHV4-61 and IGHV4-B), the IGHV subfamily (e.g., IGHV5-51, or IGHV6-1), and the IGHV7 subfamily (e.g., IGHV7-4-1).

[0069] Alternatively or additionally, in some embodiments, the anti-galectin-9 antibodies having light chain CDRs disclosed herein comprise framework regions derived from germline Vκ fragments. Examples include IGKV1 frameworks (e.g., IGKV1-05, IGKV1-12, IGKV1-27, IGKV1-33, or IGKV1-39), IGKV2 frameworks (e.g., IGKV2-28), IGKV3 frameworks (e.g., IGKV3-11, IGKV3-15, or IGKV3-20), and IGKV4 frameworks (e.g., IGKV4-1). In other cases, the anti-galectin-9 antibodies comprise a light chain variable region containing a framework derived from a germline Vλ fragment. Examples include the IGλ1 framework (e.g., IGλV1-36, IGλV1-40, IGλV1-44, IGλV1-47, IGλV1-51), the IGλ2 framework (e.g., IGλV2-8, IGλV2-11, IGλV2-14, IGλV2-18, IGλV2-23), the IGλ3 framework (e.g., IGλV3-1, IGλV3-9, IGλV3-10, IGλV3-12, IGλV3-16, IGλV3-19, IGλV3-21, I GλV3-25, IGλV3-27), IGλ4 framework (for example IGλV4-3, IGλV4-60, IGλV4-69), IGλ5 framework (for example IGλV5-39, IGλV5-45), IGλ6 framework (for example IGλV6-57,), IGλ7 framework (for example IGλV7-43, IGλV7-46,), IGλ8 framework (for example IGλV8-61), IGλ9 framework (such as IGλV9-49) or IGλ10 framework (such as IGλV10-54).

[0070] In some embodiments, the anti-galectin-9 antibody used in the methods disclosed herein may be a reference antibody G9.2-17 having the same heavy chain variable region (V H ) and / or the same light chain variable region (V L ) antibodies, V H and V L The amino acid sequence of the region is provided below:

[0071] V H :

[0072] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSS(SEQ ID NO:7)

[0073] V L :

[0074] DIQMTQSPSSSLSASVGDRVTITCRASQSVSSAVAWYQQKPG KAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYY CQQSSTDPITFGQGTKVEIKR(SEQ ID NO:8)

[0075] In some embodiments, the anti-Galectin-9 antibody has at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 80%, 98%, or 99% identity) to the heavy chain variable region of SEQ ID NO: 7. Alternatively or additionally, the anti-Galectin-9 antibody has at least 80% sequence identity (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity) to the light chain variable region of SEQ ID NO: 8.

[0076] In some cases, the anti-galectin-9 antibodies disclosed herein are functional variants of the reference antibody G9.2-17. The functional variant can be structurally similar to the reference antibody (e.g., comprising a limited number of amino acid residue variations in one or more heavy chain and / or light chain CDRs of G9.2-17 disclosed herein, or relative to the heavy chain and / or light chain CDRs of G9.2-17 or V sequences of G9.2-17 as disclosed herein). H and / or V L ), have substantially similar binding affinity to human galectin-9 (e.g., have a KD value of the same order).

[0077] In some embodiments, an anti-Galectin-9 antibody as described herein can bind to and inhibit the activity of Galectin-9 by at least 20% (e.g., 31%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). The apparent inhibition constant (Ki app or K i,app ) (which provides a measure of inhibitor potency) is related to the concentration of inhibitor required to reduce enzyme activity and is independent of enzyme concentration. The inhibitory activity of the anti-Galectin-9 antibodies described herein can be determined by routine methods known in the art.

[0078]

[0079] Antibody K i,app The Ki value can be determined by measuring the degree of inhibition of a reaction (e.g., enzyme activity) by varying concentrations of the antibody; the change in the pseudo-first-order rate constant (v) as a function of inhibitor concentration is fitted to the modified Morrison equation (Equation 1) to yield an estimate of the apparent Ki value. For competitive inhibitors, Ki app From K i, app The y-intercept was obtained by extracting the linear regression analysis of the plot of substrate concentration. (Equation 1)

[0080] Where A is equal to v o / E, that is, the initial rate of the enzymatic reaction in the absence of inhibitor (I) (v o ) divided by the total enzyme concentration (E). In some embodiments, the Ki of the anti-galectin-9 antibodies described herein for the target antigen or antigenic epitope is app In some embodiments, the anti-galectin-9 antibody has a lower Ki for a first target (e.g., CRD2 of galectin-9) than for a second target (e.g., CRD1 of galectin-9). app . Ki app The difference (e.g., for specificity or other comparisons) can be at least 1.5, 2, 3, 4, 5, 10, 15, 20, 37.5, 50, 70, 80, 91, 100, 500, 1000, 10000, or 10 5 In some examples, the anti-Galectin-9 antibody inhibits the first antigen (e.g., the first protein or its mimetic in the first conformation) to a greater extent relative to the second antigen (e.g., the same first protein or its mimetic in the second conformation; or the second protein). In some embodiments, any anti-Galectin-9 antibody is further affinity matured to reduce the Ki of the antibody to the target antigen or its antigenic epitope. app .

[0081] In some embodiments, the anti-galectin-9 antibody inhibits Dectin-1 signaling, for example in tumor-infiltrating immune cells such as macrophages. In some embodiments, the anti-galectin-9 antibody inhibits Dectin-1 signaling triggered by galectin-9 by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). Such inhibitory activity can be determined by conventional methods, such as conventional assays. Alternatively or additionally, the anti-galectin-9 antibody inhibits T cell immunoglobulin mucin 3 (TIM-3) signaling initiated by galectin-9. In some embodiments, the anti-galectin-9 antibody inhibits T cell immunoglobulin mucin-3 (TIM-3) signaling, e.g., in tumor infiltrating immune cells, e.g., in some embodiments, by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). Such inhibitory activity can be determined by conventional methods, e.g., conventional assays.

[0082] In some embodiments, the anti-galectin-9 antibody inhibits CD206 signaling, for example, in tumor-infiltrating immune cells. In some embodiments, the anti-galectin-9 antibody inhibits CD206 signaling triggered by galectin-9 by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). Such inhibitory activity can be determined by conventional methods, such as conventional assays. In some embodiments, the anti-galectin-9 antibody blocks or prevents the binding of galectin-9 to CD206 by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). Such inhibitory activity can be determined by conventional methods, such as conventional assays.

[0083] In some embodiments, the anti-galectin-9 antibody induces cytotoxicity, such as ADCC, in a target cell expressing galectin-9, for example, wherein the target cell is a cancer cell or an immunosuppressive immune cell. In some embodiments, the anti-galectin-9 antibody induces apoptosis in an immune cell, such as a T cell or a cancer cell, by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). Such inhibitory activity can be determined by conventional methods, such as conventional assays. In some embodiments, any anti-galectin-9 antibody described herein induces cellular cytotoxicity, such as complement-dependent cytotoxicity (CDC) against a target cell expressing galectin-9.

[0084] Antibody-dependent cell-mediated phagocytosis (ADCP) is an important mechanism of action of antibodies that mediates some or all of their effects through phagocytosis. In that case, antibodies mediate the uptake of specific antigens by antigen-presenting cells. ADCP can be mediated by monocytes, macrophages, neutrophils, and dendritic cells through FcγRIIa, FcγRI, and FcγRIIIa, with FcγRIIa (CD32a) on macrophages representing the major pathway.

[0085] In some embodiments, the anti-Galectin-9 antibody induces phagocytosis (ADCP) of target cells, such as cancer cells or immunosuppressive immune cells expressing Galectin-9. In some embodiments, the anti-Galectin-9 antibody increases phagocytosis of target cells, such as cancer cells or immunosuppressive immune cells, by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein).

[0086] In some embodiments, the anti-galectin-9 antibodies described herein induce cellular cytotoxicity, such as complement-dependent cytotoxicity (CDC) against target cells, such as cancer cells or immunosuppressive immune cells. In some embodiments, the anti-galectin-9 antibodies increase CDC against target cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein).

[0087] In some embodiments, anti-galectin-9 antibodies induce T cell activation in, for example, tumor-infiltrating T cells, i.e., directly or indirectly inhibit galectin-9-mediated T cell activation inhibition. In some embodiments, anti-galectin-9 antibodies promote T cell activation by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). T cell activation can be determined by conventional methods, such as using well-known assays for measuring cytokines and checkpoint inhibitors (e.g., CD44, TNFα, IFNγ and / or PD-1 measurements). In some embodiments, anti-galectin-9 antibodies promote CD4+ cell activation by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). In a non-limiting example, an anti-galectin antibody induces CD44 expression in CD4+ cells. In some embodiments, an anti-galectin-9 antibody increases CD44 expression in CD4+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). In a non-limiting example, an anti-galectin antibody induces IFNγ expression in CD4+ cells. In some embodiments, an anti-galectin-9 antibody increases IFNγ expression in CD4+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). In a non-limiting example, an anti-galectin antibody induces TNFα expression in CD4+ cells. In some embodiments, the anti-Galectin-9 antibody increases the expression of TNFα in CD4+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or greater, including any increments therein).

[0088] In some embodiments, the anti-galectin-9 antibody promotes CD8+ cell activation by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or greater, including any increments therein). In a non-limiting example, the anti-galectin antibody induces CD44 expression in CD8+ cells. In some embodiments, the anti-galectin-9 antibody increases CD44 expression in CD8+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or greater, including any increments therein). In a non-limiting example, the anti-galectin antibody induces IFNγ expression in CD8+ cells. In some embodiments, the anti-galectin-9 antibody increases IFNγ expression in CD8+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein). In a non-limiting example, the anti-galectin antibody induces TNFα expression in CD8+ cells. In some embodiments, the anti-galectin-9 antibody increases TNFα expression in CD8+ cells by at least 30% (e.g., 31%, 35%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more, including any increments therein).

[0089] In some embodiments, the anti-galectin-9 antibodies described herein have a suitable binding affinity for the target antigen (e.g., galectin-9) or an antigenic epitope thereof. As used herein, "binding affinity" refers to the apparent binding constant or K A . K A is the dissociation constant (K D ). The anti-galectin-9 antibodies described herein may have at least 10 -5 ,10 -6 ,10 -7 ,10 -8 ,10 -9 ,10 -10 M or lower binding affinity (K D ). Increased binding affinity corresponds to a decreased K D Binding affinity (or binding specificity) can be determined by a variety of methods, including equilibrium dialysis, equilibrium binding, gel filtration, ELISA, surface plasmon resonance, or spectroscopy (e.g., using fluorescence). Exemplary conditions for assessing binding affinity are in HBS-P buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 0.005% (v / v) surfactant P20).

[0090] These techniques can be used to measure the concentration of bound binding protein as a function of the concentration of target protein. Under certain conditions, the fractional concentration of bound binding protein ([bound] / [total]) is generally related to the concentration of total target protein ([target]) by the following equation:

[0091] [Bound] / [Total] = [Target] / (Kd+[Target])

[0092] However, it is not always necessary to determine K exactly. A , because sometimes it is sufficient to obtain a quantitative measure of affinity, for example, using methods such as ELISA or FACS analysis, which is related to K A In some cases, in vitro binding assays indicate in vivo activity. In other cases, in vitro binding assays do not necessarily indicate in vivo activity. In some cases, tight binding is beneficial, but in other cases, tight binding is not ideal in vivo, and it is more ideal to bind antibodies with lower affinity.

[0093] In some embodiments, the heavy chain of any of the anti-galectin-9 antibodies as described herein further comprises a heavy chain constant region (CH) or a portion thereof (e.g., CH1, CH2, CH3, or a combination thereof). The heavy chain constant region can be of any suitable origin, such as human, mouse, rat, or rabbit. In a specific example, the heavy chain constant region is from human IgG (γ heavy chain) of any IgG subfamily as described herein.

[0094] In some embodiments, the heavy chain constant region of the antibodies described herein comprises a single domain (e.g., CH1, CH2 or CH3) of the constant region (e.g., SEQ ID NO: 4, 5, 6) or a combination of any single domains. In some embodiments, the light chain constant region of the antibodies described herein comprises a single domain (e.g., CL) of the constant region. Exemplary light and heavy chain sequences are listed below. Exemplary light and heavy chain sequences are listed below. The hIgG1 LALA sequence includes two mutations (L234A and L235A (EU numbering), which inhibit FcgR binding) and a P329G mutation (EU numbering) to eliminate complement C1q binding, thereby eliminating all immune effector functions. The hIgG4 Fab arm exchange mutation sequence includes a mutation (S228P; EU numbering) that inhibits Fab arm exchange. The IL2 signal sequence (MYRMQLLSCIALSLALVTNS; SEQ ID NO: 9) can be located at the N-terminus of the variable region. It is used in expression vectors, which are cut during secretion and are therefore not in mature antibody molecules. The heavy chain of the mature protein (after secretion) begins with "EVQ" and the light chain begins with "DIM". The amino acid sequence of an exemplary heavy chain constant region is provided below:

[0095] hIgG1 heavy chain constant region (SEQ ID NO: 10)

[0096] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG

[0097] ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

[0098] SNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDT

[0099] LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE

[0100] EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTIS

[0101] KAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE

[0102] WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0103] hIgG1 LALA heavy chain constant region (SEQ ID NO:12)

[0104] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG

[0105] ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKP

[0106] SNTKVDKKVEPKSCDKTHTCPPCPAPE AA GGPSVFLFPPKPKDT

[0107] LMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPRE

[0108] EQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL G APIEKTI

[0109] SKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVE

[0110] WESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0111] hIgG4 heavy chain constant region (SEQ ID NO:13)

[0112] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

[0113] LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

[0114] NTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISR

[0115] TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS

[0116] TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG

[0117] QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG

[0118] QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0119] hIgG4 heavy chain constant region (SEQ ID NO:20)

[0120] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

[0121] LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

[0122] NTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISR

[0123] TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS

[0124] TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG

[0125] QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG

[0126] QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK*

[0127] hIgG4 mutant heavy chain constant region (SEQ ID NO:14)

[0128] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

[0129] LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

[0130] NTKVDKRVESKYGPPCP P CPAPEFLGGPSVFLFPPKPKDTLMIS

[0131] RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN

[0132] STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG

[0133] QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG

[0134] QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0135] hIgG4 mutant heavy chain constant region (SEQ ID NO: 21)

[0136] ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA

[0137] LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS

[0138] NTKVDKRVESKYGPPCP P CPAPEFLGGPSVFLFPPKPKDTLMIS

[0139] RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN

[0140] STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKG

[0141] QPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNG

[0142] QPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK*

[0143] In some embodiments, an anti-Galectin-9 antibody having any of the above heavy chain constant regions is paired with a light chain having the following light chain constant regions:

[0144] Light chain constant region (SEQ ID NO: 11)

[0145] TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDN

[0146] ALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV

[0147] THQGLSSPVTKSFNRGEC

[0148] Exemplary full-length anti-galectin-9 antibodies are provided below:

[0149] G9.2-17 hIgG1 heavy chain (SEQ ID NO: 16)

[0150] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0151] G9.2-17 hIgG1 LALA heavy chain (SEQ ID NO: 17)

[0152] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPE AA GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKAL G APIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0153] G9.2-17 hIgG4 heavy chain (SEQ ID NO: 18)

[0154] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0155] G9.2-17hIgG4 heavy chain (SEQ ID NO: 22)

[0156] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK*

[0157] G9.2-17hIgG4 Fab-arm exchange mutant heavy chain (SEQ ID NO: 19)

[0158] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP P CPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSPGK*

[0159] G9.2-17hIgG4 Fab-arm exchange mutant heavy chain (SEQ ID NO: 23)

[0160] EVQLVESGGGLVQPGGSLRLSCAASGFTVSSSSIHWVRQAPGKGLEWVAYISSSSGYTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARYWSYPSWWPYRGMDYWGQGTLVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCP PCPAPEFLGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISK AKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK*

[0161] Any of the above heavy chains can be paired with a light chain as shown below (SEQ ID NO: 15):

[0162] DIQMTQSPSSSLSASVGDRVTITCRASQSVSSAVAWYQQKPGKAPKLLIYSASSLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQSSTDPITFGQGTKVEIK RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC*

[0163] In some embodiments, the anti-Galectin-9 antibody comprises a heavy chain IgG1 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% and any increments therein) sequence identity to SEQ ID NO: 10. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 10. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG1 constant region consisting of SEQ ID NO: 10.

[0164] In some embodiments, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% and any increments therein) sequence identity to SEQ ID NO: 20. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 20. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region consisting of SEQ ID NO: 20.

[0165] In some embodiments, the constant region is from human IgG4. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 13. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 13. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region consisting of SEQ ID NO: 13.

[0166] In some embodiments, the constant region is from human IgG4. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 20. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 20. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region consisting of SEQ ID NO: 20.

[0167] In any of these embodiments, the anti-Galectin-9 antibody comprises a light chain constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% and any increments therein) sequence identity to SEQ ID NO: 11. In some embodiments, the anti-Galectin-9 antibody contains a light chain constant region comprising SEQ ID NO: 11. In some embodiments, the anti-Galectin-9 antibody comprises a light chain constant region consisting of SEQ ID NO: 11.

[0168] In some embodiments, the IgG is a mutant with minimal Fc receptor binding. In one example, the constant region is from human IgG1 LALA. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG1 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 12. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG1 constant region comprising SEQ ID NO: 12. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG1 constant region consisting of SEQ ID NO: 12.

[0169] In some embodiments, the anti-galectin-9 antibody comprises a modified constant region. In some embodiments, the anti-galectin-9 antibody comprises a modified constant region that is immunologically inert, for example, does not trigger complement-mediated lysis, or does not stimulate antibody-dependent cell-mediated cytotoxicity (ADCC). ADCC activity can be assessed using the method disclosed in U.S. Patent No. 5,500,362. In other embodiments, the constant region is modified as described in Eur. J. Immunol. (1999) 29: 2613-2624; PCT Application No. PCT / GB99 / 01441; and / or UK Patent Application No. 9809951.8. In some embodiments, the IgG4 constant region is a mutant with reduced heavy chain exchange. In some embodiments, the constant region is from human IgG4 Fab arm exchange mutant S228P.

[0170] In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 14. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 14. In one embodiment, the constant region of the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region consisting of SEQ ID NO: 14.

[0171] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 21. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region comprising SEQ ID NO: 21. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain IgG4 constant region consisting of SEQ ID NO: 21.

[0172] In some embodiments, the light chain of the anti-Galectin-9 antibody has a chain corresponding to SEQ ID NO: 15; the amino acid sequence of the exemplary heavy chain corresponds to SEQ ID NO: 10 (hIgG1); 12 (hIgG1 LALA); 13 (hIgG4); 20 (hIgG4); 14 (hIgG4 mutant); and 21 (hIgG4 mutant).

[0173] In some embodiments, the anti-Galectin-9 antibody has a light chain comprising, consisting essentially of, or consisting of SEQ ID NO: 15. In some embodiments, the anti-Galectin-9 antibody has a heavy chain comprising, consisting essentially of, or consisting of any one of the sequences selected from SEQ ID NOs: 16-19, 22, and 23. In some embodiments, the anti-Galectin-9 antibody has a light chain comprising, consisting essentially of, or consisting of SEQ ID NO: 15 and a heavy chain comprising, consisting essentially of, or consisting of any one of the sequences selected from SEQ ID NOs: 16-19. In some embodiments, the anti-Galectin-9 antibody has a light chain comprising SEQ ID NO: 15 and a heavy chain comprising any one of the sequences selected from SEQ ID NOs: 16-19, 22, and 23. In some embodiments, the anti-Galectin-9 antibody has a light chain consisting essentially of SEQ ID NO: 15 and a heavy chain consisting essentially of any one of the sequences selected from SEQ ID NOs: 16-19, 22, and 23. In some embodiments, the anti-Galectin-9 antibody has a light chain consisting of SEQ ID NO: 15 and a heavy chain consisting of any one of SEQ ID NOs: 16-19, 22, and 23. In a specific embodiment, the anti-Galectin-9 antibody has a light chain consisting essentially of SEQ ID NO: 15 and a heavy chain consisting essentially of SEQ ID NO: 19. In another specific embodiment, the anti-Galectin-9 antibody has a light chain consisting essentially of SEQ ID NO: 15 and a heavy chain consisting essentially of SEQ ID NO: 20.

[0174] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 16. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 16. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 16.

[0175] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 17. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 17. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 17.

[0176] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 18. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 18. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 18.

[0177] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% and any increments therein) sequence identity to SEQ ID NO: 22. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 22. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 22.

[0178] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 19. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 19. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 19.

[0179] In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% and any increments therein) sequence identity to SEQ ID NO: 23. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence comprising SEQ ID NO: 23. In one embodiment, the anti-Galectin-9 antibody comprises a heavy chain sequence consisting of SEQ ID NO: 23.

[0180] In any of these embodiments, the anti-Galectin-9 antibody comprises a light chain sequence having at least 80% (e.g., 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% and any increments therein) sequence identity to SEQ ID NO: 15. In some embodiments, the anti-Galectin-9 antibody contains a light chain sequence comprising SEQ ID NO: 15. In some embodiments, the anti-Galectin-9 antibody comprises a light chain sequence consisting of SEQ ID NO: 15.

[0181] In a specific example, the anti-Galectin-9 antibody used in the treatment methods disclosed herein has a heavy chain of SEQ ID NO: 19 and a light chain of SEQ ID NO: 15. In some embodiments, the anti-Galectin-9 antibody used in the treatment methods disclosed herein is G9.2-17IgG4.

[0182] Preparation of anti-galectin-9 antibody

[0183] Antibodies capable of binding to Galectin-9 as described herein can be prepared by any method known in the art, including but not limited to recombinant techniques. An example is provided below.

[0184] The nucleic acid encoding the heavy and light chains of the anti-galectin-9 antibodies as described herein can be cloned into an expression vector, and each nucleotide sequence is operably linked to a suitable promoter. In one example, each nucleotide sequence encoding the heavy and light chains is operably linked to a different promoter. Alternatively, the nucleotide sequence encoding the heavy and light chains can be operably linked to a single promoter so that both the heavy and light chains are expressed from the same promoter. If necessary, an internal ribosome entry site (IRES) can be inserted between the heavy and light chain coding sequences.

[0185] In some examples, the nucleotide sequences encoding the two chains of the antibody are cloned into two vectors, which can be introduced into the same or different cells. When the two chains are expressed in different cells, each of them can be isolated from the host cells expressing them, and the isolated heavy and light chains can be mixed and incubated under appropriate conditions that allow the formation of antibodies.

[0186] Generally, methods known in the art can be used to clone the nucleic acid sequence of one or all chains of the encoding antibody into a suitable expression vector and operably connected to a suitable promoter. For example, the nucleotide sequence and the vector can be contacted with a restriction enzyme under suitable conditions to produce complementary ends on each molecule, and the complementary ends can be paired with each other and connected together with a ligase. Alternatively, a synthetic nucleic acid adapter can be connected to the end of the gene. These synthetic adapters include nucleic acid sequences corresponding to specific restriction sites in the vector. The selection of expression vector / promoter will depend on the type of host cell used to produce the antibody.

[0187] A variety of promoters can be used to express the antibodies described herein, including but not limited to the cytomegalovirus (CMV) intermediate early promoter, viral LTRs such as Rous sarcoma virus LTR, HIV-LTR, HTLV-1 LTR, simian virus 40 (SV40) early promoter, Escherichia coli lac UV5 promoter, and herpes simplex tk virus promoter.

[0188] Regulatable promoters can also be used. Such regulatable promoters include those that use the lac repressor from E. coli as a transcriptional regulator to regulate transcription from mammalian cell promoters with the lac operon [Brown, M. et al., Cell, 49:603-612 (1987)], those that use the tetracycline repressor (tetR) [Gossen, M., and Bujard, H., Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992); Yao, F. et al., Human Gene Therapy, 9:1939-1950 (1998); Shockelt, P. et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526 (1995)]. Other systems include VP16 or p65 using astradiol, FK506 dimer, RU486, diphenol murislerone, or rapamycin. Inducible systems are available from Invitrogen, Clontech, and Ariad.

[0189] The regulatable promoter of the operon containing the repressor can be used. In one embodiment, the lac repressor from Escherichia coli can be used as a transcriptional regulator to regulate the transcription from the mammalian cell promoter with the lac operon (M. Brown et al., Cell, 49: 603-612 (1987); Gossen and Bujard (1992); M. Gossen et al., Natl. Acad. Sci. USA, 89: 5547-5551 (1992)), the tetracycline repressor (tetR) is combined with a transcription activator (VP 16) to create a tetR-mammalian cell transcription activator fusion protein tTa (tetR-VP 16), with a minimal promoter with tetO derived from the major immediate early promoter of human cytomegalovirus (hCMV), to create a tetR-tet operating system to control gene expression in mammalian cells. In one embodiment, a tetracycline-inducible switch is used. When the tetracycline operator is appropriately positioned downstream of the TATA element of the CMVIE promoter, a single tetracycline repressor (tetR), rather than a tetR-mammalian cell transcription factor fusion derivative, can be used as an effective trans-regulator to regulate gene expression in mammalian cells (Yao et al., Human Gene Therapy, 10(16):1392-1399(2003)). A special advantage of this tetracycline-inducible switch is that it does not require the use of a tetracycline repressor-mammalian cell transactivator or repressor fusion protein, which can be toxic to cells in some cases (Gossen et al., Natl. Acad. Sci. USA, 89:5547-5551(1992); Shockett et al., Proc. Natl. Acad. Sci. USA, 92:6522-6526(1995)), to achieve its regulatable effect.

[0190] In addition, the vector may include, for example, part or all of the following: a selection marker gene, such as a neomycin gene for selecting stable or transient transfectants in mammalian cells; an enhancer / promoter sequence from the immediate early gene of human CMV for high-level transcription; transcription termination and RNA processing signals from SV40 for mRNA stability; SV40 polyoma replication origin and ColE1 for correct episomal replication; an internal ribosome binding site (IRES), a multifunctional multiple cloning site; and T7 and SP6 RNA promoters for in vitro transcription of sense and antisense RNA. Suitable vectors and methods for producing vectors containing transgenes are well known and available in the art.

[0191] Examples of polyadenylation signals that can be used to practice the methods described herein include, but are not limited to, the human collagen I polyadenylation signal, the human collagen II polyadenylation signal, and the SV40 polyadenylation signal.

[0192] One or more vectors (e.g., expression vectors) comprising nucleic acids encoding any antibody can be introduced into suitable host cells to produce the antibody. The host cell can be cultured under conditions suitable for expressing the antibody or any of its polypeptide chains. Such antibodies or their polypeptide chains can be recovered (e.g., from cells or culture supernatants) by conventional methods (e.g., affinity purification) from cultured cells. If desired, the polypeptide chains of the antibody can be incubated under suitable conditions for a suitable time to allow the production of the antibody.

[0193] In some embodiments, the method of preparing the antibodies described herein involves recombinant expression vectors encoding the heavy and light chains of the anti-galectin-9 antibody, also as described herein. The recombinant expression vector can be introduced into a suitable host cell (e.g., dhfr-CHO cells) by conventional methods, such as calcium phosphate-mediated transfection. Positively transformed host cells can be selected and cultured under suitable conditions allowing the expression of the two polypeptide chains that form the antibody, which can be recovered from the cells or from the culture medium. If necessary, the two chains recovered from the host cells can be incubated under suitable conditions allowing the formation of the antibody.

[0194] In one example, two recombinant expression vectors are provided, one encoding the heavy chain of an anti-galectin-9 antibody and the other encoding the light chain of an anti-galectin-9 antibody. Both recombinant expression vectors can be introduced into suitable host cells (e.g., dhfr-CHO cells) by conventional methods (e.g., calcium phosphate-mediated transfection). Alternatively, each expression vector can be introduced into a suitable host cell. Positive transformants can be selected and cultured under suitable conditions that allow expression of the antibody polypeptide chain. When the two expression vectors are introduced into the same host cell, the antibodies produced therein can be recovered from the host cell or from the culture medium. If necessary, the polypeptide chain can be recovered from the host cell or the culture medium and then incubated under suitable conditions that allow the formation of the antibody. When the two expression vectors are introduced into different host cells, each of them can be recovered from the corresponding host cell or from the corresponding culture medium. The two polypeptide chains can then be incubated under suitable conditions to form the antibody.

[0195] Standard molecular biology techniques are used to prepare recombinant expression vectors, transfect host cells, select transformants, culture host cells, and recover antibodies from the culture medium. For example, some antibodies can be isolated by affinity chromatography with protein A or protein G coupled matrices.

[0196] Any nucleic acids encoding the heavy chain, light chain, or both of the anti-Galectin-9 antibodies as described herein, vectors (eg, expression vectors) comprising them, and host cells comprising the vectors are within the scope of the present disclosure.

[0197] The anti-Galectin-9 antibodies thus prepared can be characterized using methods known in the art, thereby detecting and / or measuring the reduction, improvement or neutralization of Galectin-9 biological activity. For example, in some embodiments, ELISA-type assays are suitable for qualitative or quantitative measurement of Galectin-9 inhibition of Dectin-1 or TIM-3 signaling.

[0198] The biological activity of the anti-galectin-9 antibody can be verified by incubating the candidate antibody with Dectin-1 and galectin-9 and monitoring any one or more of the following characteristics: (a) binding between Dectin-1 and galectin-9 and inhibition of signal transduction mediated by binding; (b) prevention, improvement or treatment of any aspect of solid tumors; (c) blocking or reducing the activation of Dectin-1; (d) inhibiting (reducing) the synthesis, production or release of galectin-9. Alternatively, TIM-3 can be used to verify the biological activity of the anti-galectin-9 antibody using the above protocol. Alternatively, CD206 can be used to verify the biological activity of the anti-galectin-9 antibody using the above protocol.

[0199] In some embodiments, biological activity or efficacy is assessed in a subject, for example, by measuring peripheral and intratumoral T cell ratios, T cell activation, or by macrophage typing.

[0200] Other assays to determine the biological activity of anti-Galectin-9 antibodies include measurement of CD8+ and CD4+ (conventional) T cell activation (in in vitro or in vivo assays, e.g., by measuring levels of inflammatory cytokines, e.g., IFNγ, TNFα, CD44, ICOS granzyme B, perforin, IL2 (upregulated); CD26L and IL-10 (downregulated)); measurement of macrophage reprogramming (in vitro or in vivo), e.g., from an M2 to an M1 phenotype (e.g., increased MHCII, decreased CD206, increased TNF-α and iNOS), or, the level of ADCC can be assessed, e.g., in an in vitro assay, as described herein.

[0201] Pharmaceutical composition

[0202] Anti-galectin-9 antibodies and encoding nucleic acids or nucleic acid groups, vectors containing them, or host cells containing vectors as described herein can be mixed with a pharmaceutically acceptable carrier (excipient) to form a pharmaceutical composition for treating a target disease. "Acceptable" means that the carrier must be compatible with the active ingredient of the composition (and preferably, capable of stabilizing the active ingredient) and harmless to the subject to be treated. Pharmaceutically acceptable excipients (carriers) include buffers well known in the art. See, for example, Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Areiams and Wilkins, Ed. KE Hoover.

[0203] The pharmaceutical composition used in the present method may include a pharmaceutically acceptable carrier, excipient or stabilizer in the form of a lyophilized formulation or an aqueous solution. (Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Areiams and Wilkins, Ed. KE Hoover). Acceptable carriers, excipients or stabilizers are nontoxic to recipients at the dosages and concentrations used, and include buffers such as phosphates, citrates and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl alcohol or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) (e.g., sucrose, mannitol, trehalose, or sorbitol); salt-forming counterions such as sodium; metal complexes (e.g., zinc-protein complexes); and / or nonionic surfactants such as TWEEN®. TM 、PLURONICS TMOr polyethylene glycol (PEG). In some examples, the pharmaceutical compositions described herein include liposomes containing antibodies (or encoding nucleic acids), which can be prepared by methods known in the art, such as Epstein et al., Proc. Natl. Acad. Sci. USA 82: 3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030 (1980); and described in U.S. Patent Nos. 4,485,045 and 4,544,545. Liposomes with extended circulation time are disclosed in U.S. Patent No. 5,013,556. Particularly useful liposomes can be produced by reverse phase evaporation with a lipid composition comprising phosphatidylcholine, cholesterol and PEG-derived phosphatidylethanolamine (PEG-PE). Liposomes are extruded through a filter with a limited pore size to produce liposomes with a desired diameter.

[0204] In some embodiments, the anti-galectin-9 antibody or encoding nucleic acid is encapsulated in microcapsules (e.g., hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively), colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules), or macroemulsions, prepared, for example, by coacervation techniques or by interfacial polymerization. Such techniques are known in the art, see, for example, Remington, The Science and Practice of Pharmacy 20th Ed. Mack Publishing (2000).

[0205] In other examples, the pharmaceutical compositions described herein can be formulated in a sustained release form. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing antibodies, which are in the form of shaped articles, such as films or microcapsules. Examples of sustained release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl methacrylate) or poly(vinyl alcohol)), polylactides (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and 7 ethyl-L-glutamic acid, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers such as LUPRON DEPOT TM (injectable microspheres composed of lactic acid-glycolic acid copolymer and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.

[0206] Pharmaceutical compositions for in vivo administration must be sterile. This is easily achieved, for example, by filtering through a sterile filtration membrane. Therapeutic antibody compositions are typically placed in a container with a sterile access port, such as an intravenous solution bag or vial with a stopper that can be pierced by a hypodermic injection needle.

[0207] The pharmaceutical compositions described herein may be in unit dosage form, such as tablets, pills, capsules, powders, granules, solutions or suspensions, or suppositories, for oral, parenteral or rectal administration, or administration by inhalation or insufflation.

[0208] In order to prepare solid compositions such as tablets, the main active ingredient can be mixed with a pharmaceutical carrier, such as conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate or gum, and other pharmaceutical diluents, such as water, to form a solid preformulation composition containing a uniform mixture of the compound of the present invention or its nontoxic pharmaceutically acceptable salt. When these preformulation compositions are referred to as homogeneous, it means that the active ingredient is evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills and capsules. The solid preformulation composition is then subdivided into unit dosage forms of the above type containing 0.1 to about 500 mg of the active ingredient of the present invention. The tablets or pills of the new composition can be coated or otherwise mixed to provide a dosage form with an extended effect advantage. For example, a tablet or pill can include an internal dose and an external dose component, the latter being a coating form on the former. These two components can be separated by an enteric layer, which is used to resist disintegration in the stomach and allow the internal component to enter the duodenum intact or delay release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate. Suitable surfactants include especially nonionic agents such as polyoxyethylene sorbitan (e.g., Tween TM 20, 40, 60, 80 or 85) and other sorbitans (such as Span TM 20, 40, 60, 80 or 85). Compositions with surfactant conveniently contain 0.05 to 5% surfactant, and may be 0.1 to 2.5%. It should be understood that other ingredients, such as mannitol or other pharmaceutically acceptable carriers, may be added if desired.

[0209] Suitable emulsions can be prepared using commercially available fat emulsions, such as Intralipid TM ,Liposyn TM ,Infonutrol TM ,Lipofundin TMLipiphysan TM . The active ingredient can be dissolved in a premixed emulsion composition, or it can be dissolved in an oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil or almond oil) and mixed with a phospholipid (e.g., lecithin, soybean lecithin or soybean lecithin) and water to form an emulsion. It should be understood that other ingredients, such as glycerol or glucose, can be added to adjust the tension of the emulsion. Suitable emulsions typically contain up to 20% oil, such as 5% to 20%. The fat emulsion may contain 0.1 to 1.0.im, particularly 0.1 to 0.5.im fat droplets, and have a pH in the range of 5.5 to 8.0.

[0210] The emulsion composition can be prepared by combining the antibody with Intralipid TM Or those prepared by mixing its components (soybean oil, lecithin, glycerin and water).

[0211] Pharmaceutical compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect.

[0212] Compositions in preferably sterile pharmaceutically acceptable solvents can be aerosolized using gases. Nebulized solutions can be breathed directly from the aerosol device, or the aerosol device can be connected to a mask, tent, or intermittent positive pressure breathing machine. Solutions, suspensions, or powder compositions can be administered from a device that delivers the formulation in an appropriate manner, preferably orally or nasally.

[0213] Treatment

[0214] The present disclosure provides methods of using any anti-galectin antibody (e.g., G9.2-17, e.g., G9.2-17IgG4) alone or in combination with a checkpoint inhibitor, e.g., an anti-PD-1 antibody, to treat solid tumors such as PDA, CRC, HCC, and cholangiocarcinoma. Any anti-galectin-9 antibody described herein can be used in any of the methods described herein. In some embodiments, the anti-galectin-9 antibody is G9.2-17. Such antibodies can be used to treat diseases associated with galectin-9.

[0215] In some aspects, the present invention provides methods for treating cancer. In some embodiments, the methods of the present disclosure are used to reduce, ameliorate or eliminate one or more symptoms associated with cancer.

[0216] In some embodiments, the present disclosure provides a method of treating a solid tumor in a subject, the method comprising administering to a subject in need thereof an effective amount of an anti-galectin-9 antibody or an effective amount of a pharmaceutical composition comprising an anti-galectin-9 antibody or an antigen-binding fragment thereof as described herein. In some embodiments, the anti-galectin-9 antibody is an antibody having the same heavy chain CDR sequence and / or the same light chain CDR sequence as the reference antibody G9.2-17. In some embodiments, the anti-galectin-9 antibody is an antibody having the same V sequence as the reference antibody G9.2-17. H and V LIn some embodiments, such antibodies are IgG1 molecules (e.g., having wild-type IgG1 constant regions or mutants thereof as those disclosed herein). Alternatively, the antibody is an IgG4 molecule (e.g., having wild-type IgG4 constant regions or mutants thereof as those described herein). In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody contains a light chain comprising SEQ ID NO: 15. In a specific example, the anti-galectin-9 antibody used herein has a heavy chain of SEQ ID NO: 19 and a light chain of SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to a subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example, by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0217] Also included within the scope of the present disclosure are pharmaceutical compositions for treating solid tumors (e.g., those described herein and including metastatic solid tumors), and the use of any anti-galectin-9 antibody for the manufacture of a medicament for treating solid tumors, wherein in some embodiments, the uses disclosed herein involve one or more treatment conditions (e.g., dosage, dosing regimen, route of administration, etc.), as also disclosed herein. In some embodiments, the antibody for the manufacture of a medicament for treating solid tumors comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain variable region comprising SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody contains a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19 and a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody for the manufacture of a medicament for the treatment of solid tumors is administered to a subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody for the manufacture of a medicament for the treatment of solid tumors is administered once every two weeks, for example, by intravenous infusion. In some embodiments, the anti-galectin-9 antibody is administered once every 2 weeks for one cycle, once every 2 weeks for two cycles, once every 2 weeks for three cycles, once every 2 weeks for four cycles, or once every 2 weeks for more than four cycles. In some embodiments, the anti-galectin-9 antibody is administered once every 2 weeks for a total of 4 cycles. In some embodiments, the duration of treatment is 12-24 months or longer. In some embodiments, the cycle extends for a duration of 3 months to 6 months, or 6 months to 12 months, or 12 months to 24 months or longer. In some embodiments, the cycle length is modified, for example, temporarily or permanently modified to a longer duration, such as 3 weeks or 4 weeks.In some embodiments, as described herein, the use further comprises administering to the subject an immune checkpoint inhibitor, such as an anti-PD1 antibody, for example, according to the regimen described herein. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0218] Given that the tumor-promoting effects of galectin-9 are mediated through interactions with immune cells (e.g., with lymphoid cells through TIM-3, CD44, and 41BB, and with macrophages through dectin-1 and CD206) and given that galectin-9 is expressed in a large number of tumors, targeting galectin-9 (e.g., using galectin-9 binding antibodies) to inhibit the interaction with its receptors provides a therapeutic approach that can be applied to a variety of different tumor types.

[0219] In some embodiments, the present disclosure provides a method for treating a solid tumor in a subject, the method comprising administering to a subject in need thereof an effective amount of an anti-galectin-9 antibody described herein, including but not limited to G9.2-17IgG4. In some instances, the methods disclosed herein are applied to human patients with pancreatic cancer, such as ductal adenocarcinoma (PDA). In some cases, PDA patients may suffer from metastatic cancer. In some instances, the methods disclosed herein are applied to human patients with colorectal cancer (CRC). In some embodiments, colorectal cancer is metastatic. In some instances, the methods disclosed herein are applied to human patients with hepatocellular carcinoma melanoma. In some embodiments, hepatocellular carcinoma is metastatic. In other instances, the methods disclosed herein are applied to human patients with cholangiocarcinoma. In some embodiments, cholangiocarcinoma is metastatic.

[0220] Pancreatic ductal adenocarcinoma (PDA) is a devastating disease with few long-term survivors (Yadav et al., Gastroenterology, 2013, 144, 1252-1261). Inflammation is crucial in the progression of PDA because, in the absence of accompanying inflammation, oncogenic mutations alone are not sufficient to cause tumorigenesis (Guerra et al., Cancer Cell, 2007, 11, 291-302). Innate immunity and adaptive immunity synergistically promote tumor progression in PDA. In particular, specific innate immune subsets within the tumor microenvironment (TME) tend to cultivate adaptive immune effector cells into tumor-permitting phenotypes. Antigen presenting cell (APC) populations (including M2 polarized tumor-associated macrophages (TAMs) and myeloid dendritic cells (DCs)) induce the generation of immunosuppressive Th2 cells in favor of tumor protective Th1 cells (Ochi et al., J of Exp Med., 2012, 209, 1671-1687; Zhu et al., Cancer Res., 2014, 74, 5057-5069). Similarly, myeloid-derived suppressor cells (MDSCs) have been shown to abrogate anti-tumor CD8+ cytotoxic T lymphocyte (CTL) responses and promote metastatic progression in PDA (Connolly et al., J Leuk Biol., 2010, 87, 713-725; Pylayeva-Gupta et al., Cancer Cell, 2012, 21, 836-847; Bayne et al., Cancer Cell, 2012, 21, 822-835).

[0221] Pancreatic cancer remains a difficult disease to treat due to its often late detection, relatively high resistance to chemotherapy, and lack of effective immune and targeted therapies. Globally, approximately 455,000 new cases of pancreatic cancer were reported in 2018, with an estimated 355,000 new cases occurring annually by 2040, and nearly as many deaths reported annually. It is projected to become the second leading cause of cancer-related death in the United States by 2030. Despite intervention, the median life expectancy of patients with metastatic pancreatic cancer is less than one year with current treatments, and the majority of patients (up to 80%) present at an advanced / metastatic stage when the disease is not curatively resectable. Despite advances in the detection and management of pancreatic cancer, the five-year survival rate for metastatic disease remains at 10%. The current standard of care for metastatic pancreatic cancer is primarily chemotherapy, while a distinct minority of patients (less than 10%) with BRCA1 / 2-mutated and mismatch repair-deficient tumors may benefit from PARP inhibitors and potentially anti-PD-1 therapy. However, for the vast majority of patients with this disease, currently approved immunotherapies are often unsuccessful due to the highly immunosuppressive milieu.

[0222] Colorectal cancer (CRC), also known as intestinal cancer, colon cancer or rectal cancer, is any cancer affecting the colon and rectum. CRC is known to be driven by genetic alterations in tumor cells and is also influenced by tumor-host interactions. Recent reports have demonstrated a direct correlation between the density of certain T lymphocyte subsets and a favorable clinical outcome in CRC, supporting a major role for T cell-mediated immunity in suppressing CRC tumor progression.

[0223] Colorectal cancer is one of the largest cancer burdens in the world, with approximately 700,000 people diagnosed each year worldwide. Despite significant advances in standard care therapy, the five-year survival rate of metastatic colorectal cancer (CRC) is still approximately 12%. It is estimated that the number of deaths from CRC will nearly double in the next 20 years. The current standard of care for CRC is a chemotherapy regimen, combined with anti-angiogenic therapy and anti-EGFR methods and / or performed sequentially. In addition, current immunotherapy is only effective for patients whose tumors show mismatch repair defects (although a profound and lasting response will be produced). The immunotherapy results of microsatellite stable CRC (which is the majority of CRC patients) are unsatisfactory and require new treatment strategies.

[0224] Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma is most common in people with chronic liver disease (e.g., cirrhosis caused by hepatitis B or hepatitis C infection). Due to chronic viral infection, HCC is often accompanied by cirrhosis and extensive lymphocyte infiltration. Many studies have shown that tumor-infiltrating effector CD8+T cells and T helper 17 (Th17) cells are associated with improved survival after surgical resection of tumors. However, tumor-infiltrating effector T cells cannot control tumor growth and metastasis (Pang et al., Cancer Immunol Immunother 2009; 58: 877-886).

[0225] Cholangiocarcinoma is a group of cancers that start in the bile ducts. Cholangiocarcinomas are often classified based on their location relative to the liver. For example, intrahepatic cholangiocarcinoma, which accounts for less than 10% of all cholangiocarcinoma cases, starts in the small bile ducts inside the liver. In another example, perihilar cholangiocarcinoma (also called Klatskin tumor), which accounts for more than half of cholangiocarcinoma cases, starts in the hilum of the liver, where the two main bile ducts join and leave the liver. Others are classified as distal cholangiocarcinomas, which start in the bile ducts outside the liver.

[0226] Cholangiocarcinoma is an aggressive tumor, and most patients present with advanced disease. The incidence of cholangiocarcinoma is increasing, and effective treatments are urgently needed. Gemcitabine plus cisplatin remains the standard first-line systemic treatment for advanced cholangiocarcinoma, although it leaves much to be desired, as the median survival is less than one year. There is little available evidence to guide treatment decisions beyond failed first-line therapy. Triple chemotherapy (nab-paclitaxel plus gemcitabine-cisplatin) regimens and the use of FGFR2 inhibitors in selected cohorts may be approved in the future. However, suboptimal response rates to immunotherapy in human clinical trials mean that cholangiocarcinoma is favored by immune “cold” tumors with a non-T cell-infiltrating microenvironment. In fact, to date, response rates to immunotherapy have not exceeded 17%, and as of the filing date of this application, no immuno-oncology drugs have been approved.

[0227] Subjects with any of the above cancers can be identified by conventional medical examinations, such as laboratory tests, organ function tests, genetic tests, interventional procedures (biopsy, surgery) and any and all related imaging methods. In some embodiments, the subject to be treated by the methods described herein is a human cancer patient who has received or is receiving anti-cancer therapy such as chemotherapy, radiotherapy, immunotherapy or surgery. In some embodiments, the subject has received previous immunomodulatory anti-tumor agents. Non-limiting examples of such immunomodulators include, but are not limited to, anti-PD1, anti-PD-L1, anti-CTLA-4, anti-OX40, anti-CD137, etc. In some embodiments, the subject shows disease progression by treatment. In other embodiments, the subject is resistant to treatment (de novo or acquired). In some embodiments, such subjects are shown to suffer from advanced malignancies (e.g., inoperable or metastatic). Alternatively or additionally, in some embodiments, the subject does not have available standard treatment options or is not suitable for standard treatment options, and standard treatment options refer to the therapy commonly used in clinical settings for treating corresponding solid tumors.

[0228] In some cases, the subject may be a human patient with a refractory disease, such as refractory PDA, refractory CRC, refractory HCC or refractory cholangiocarcinoma. As used herein, "refractory" refers to a tumor that is unresponsive to treatment or becomes resistant to treatment. In some cases, the subject may be a human patient with a recurrent disease (e.g., recurrent PDA, recurrent CRC, recurrent HCC or recurrent cholangiocarcinoma). As used herein, "recurrence" or "recurrent" refers to a tumor that recurs or progresses after a period of improvement (e.g., partial or complete response) using treatment.

[0229] In some embodiments, the human patient to be treated by the methods disclosed herein meets one or more inclusion and exclusion criteria disclosed in Example 1 below. For example, the human patient may be 18 years of age or older; have histologically confirmed unresectable metastatic or inoperable cancer (e.g., no standard treatment options), have a life expectancy of >3 months, have a recent archived tumor sample available for biomarker analysis (e.g., by IHC to assess the expression level of galectin-9 tumor tissue in archived species); have measurable disease, have Eastern Cooperative Oncology status according to RECIST v1.1; Oncology Group (ECOG) performance status 0-1 or Karnofsky score>70; no standard of care options available, with MSI-H (microsatellite instability high and MSS (microsatellite stable); received at least one line of systemic therapy in the advanced / metastatic setting; have adequate hematologic and end-organ function (defined in Example 1 below); have completed treatment for brain metastases, if any (see Example 1 below); have no evidence of active infection and no serious infection within the past month; have at least four (4) weeks or 5 half-lives (whichever is shorter) since the last dose of anti-cancer therapy before the first anti-Gal-9 antibody administration; if applicable, continue to use bisphosphonate treatment (zolamdronic acid) or denosumab for bone metastases. CCR or CCA patients receiving immediate treatment may require at least one prior line of treatment in the metastatic setting. In some embodiments, CCR or CCA patients receiving immediate treatment already have at least one prior line of treatment in the metastatic setting.

[0230] Alternatively or additionally, subjects suitable for treatment disclosed herein may not have one or more of the following: diagnosed with metastatic cancer of unknown primary; any active uncontrolled bleeding, and any patient with a bleeding factor (e.g., active peptic ulcer disease); receiving any other study drug within 4 weeks or 5 half-lives of anti-galectin-9 antibody administration; receiving radiation therapy within 4 weeks of the first dose of anti-galectin-9 antibody, except for palliative radiation therapy to a limited area, such as for the treatment of bone pain or a tumor mass with focal pain; having a fungal tumor mass; for patients with PDAC, receiving a prior gemcitabine-containing treatment regimen within 6 months of the start of treatment, patients with locally advanced PDAC; having an active clinically severe infection > grade 2 NCI-CTCAE Version 5.0; symptomatic or active brain metastases; ≥CTCAE grade 3 toxicity (see Example 1 for details and exceptions); history of a second malignancy (see Example 1 for exceptions); evidence of severe or uncontrolled systemic illness, congestive heart failure; severe non-healing wounds, active ulcers, or untreated fractures; uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage procedures; spinal cord compression that has not been definitively treated with surgery and / or radiation. Leptomeningeal disease, active or previously treated; severe vascular disease; active autoimmune disease (see exceptions in Example 1); requiring systemic immunosuppressive therapy; tumor-related pain (> Grade 3) that is unresponsive to extensive analgesic interventions (oral and / or patch); uncontrolled hypercalcemia despite the use of bisphosphonates; history of any immune-related Grade 4 adverse event attributed to prior checkpoint inhibitor therapy (CIT); recipient of an organ transplant; and / or receiving dialysis; for HCC patients and / or CCA patients, any ablative therapy prior to treatment; hepatic encephalopathy or severe hepatic adenoma; Child-Pugh score ≥ 7; metastatic hepatocellular carcinoma that has progressed on at least one prior line of systemic therapy; refused or was intolerant of sorafenib; or had received standard therapy that was considered ineffective, intolerant, or inappropriate, or no effective standard therapy is available.

[0231] In some cases, the subject is a human patient with elevated galectin-9 levels relative to a control level. The level of galectin-9 may be the plasma or serum level of galectin-9 in a human patient. In other examples, the level of galectin-9 may be the level of cell surface galectin-9, such as the level of galectin-9 on cancer cells. In one embodiment, the level of galectin-9 may be the level of surface galectin-9 expressed on cancer cells in patient-derived organotypic tumor spheres (PDOTs), which may be prepared by methods such as those disclosed in the following examples. The control level may refer to the level of galectin-9 in a matched sample of a subject of the same species (e.g., a human) without a solid tumor. In some examples, the control level represents the level of galectin-9 in a healthy subject.

[0232] To identify such subjects, a suitable biological sample can be obtained from a subject suspected of having a solid tumor, and the biological sample can be analyzed to determine the level of galectin-9 (e.g., free, cell surface expressed, or total) contained therein using conventional methods such as ELISA or FACS. In some embodiments, organoid cultures are prepared, for example, as described herein, and used to assess the level of galectin-9 in a subject. Single cells derived from certain fractions obtained as part of the organoid preparation process are also suitable for assessing the level of galectin-9 in a subject. In some cases, an assay for measuring the level of galectin-9 in free form or expressed on the cell surface involves the use of an antibody that specifically binds to galectin-9 (e.g., specifically binds to human galectin-9). Any anti-galectin-9 antibody known in the art can be tested for suitability in any of the above assays and then used in such assays in a conventional manner. In some embodiments, the antibodies described herein (e.g., G9.2-17 antibodies) can be used in assays such as. In some embodiments, the antibodies described in U.S. Pat. No. 10,344,091 and WO2019 / 084553, their respective related disclosures are incorporated by reference for the purposes and subject matter cited herein. In some instances, the anti-Galectin-9 antibody is a Fab molecule. Assays for determining Galectin-9 levels as disclosed herein are also within the scope of the present disclosure.

[0233] An effective amount of the pharmaceutical composition described herein can be administered systemically or topically to a subject (e.g., a human) in need of treatment by a suitable route. In some embodiments, the anti-galectin-9 antibody is administered intravenously, for example as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarterial, intraarticular, intrasynovial, intrathecal, intratumoral, oral, inhaled, or topical routes. In one embodiment, the anti-galectin-9 antibody is administered to the subject by intravenous infusion. Commercially available nebulizers for liquid preparations, including jet nebulizers and ultrasonic nebulizers, can be used for administration. Liquid preparations can be directly nebulized, and lyophilized powders can be reconstituted and then nebulized. Alternatively, antibodies as described herein can be nebulized using fluorocarbon formulations and metered dose inhalers, or inhaled as lyophilized and ground powders.

[0234] As used herein, "effective amount" refers to the amount of each active agent required to give a subject a therapeutic effect alone or in combination with one or more other active agents. In some embodiments, the therapeutic effect is reduced galectin-9 activity and / or amount / expression in the tumor microenvironment, reduced Dectin-1 signaling, reduced TIM-3 signaling, reduced CD206 signaling, or increased anti-tumor immune response. Non-limiting examples of increased anti-tumor responses include increased activation levels of effector T cells, or TAM conversion from M2 phenotype to M1 phenotype. In some cases, the anti-tumor response includes increased ADCC reactions. Whether a certain amount of antibody achieves a therapeutic effect is obvious to those skilled in the art. As recognized by those skilled in the art, the effective amount varies according to the specific condition being treated, the severity of the condition, individual patient parameters (including age, physical condition, body shape, sex and weight), the duration of treatment, the nature of concurrent treatment (if any), specific routes of administration, and similar factors within the scope of health practitioners' knowledge and expertise. These factors are well known to those of ordinary skill in the art and can be solved by routine experiments. It is generally preferred to use the maximum dose of the individual components or combinations thereof, ie, the highest safe dose based on sound medical judgment.

[0235] Empirical considerations (e.g., half-life) generally help determine dosage. For example, antibodies (e.g., humanized antibodies or fully human antibodies) that are compatible with the human immune system are used in some cases to extend the half-life of the antibody and to prevent the antibody from being attacked by the host immune system. The frequency of administration can be determined and adjusted during treatment, and is generally but not necessarily based on the treatment and / or suppression and / or improvement and / or delay of the target disease / disorder. Alternatively, a sustained continuous release formulation of the antibody may be suitable. Various preparations and devices for achieving sustained release are known in the art.

[0236] In one example, the dosage of an antibody described herein is determined empirically in an individual who has been given one or more administrations of the antibody. Increasing doses of the antagonist are administered to the individual. In order to assess the efficacy of the antagonist, an indicator of the disease / disorder may be followed.

[0237] In some cases, an anti-galectin-9 antibody disclosed herein (e.g., G9.2-17) can be administered to a subject at a suitable dose, such as about 1 to about 32 mg / kg. Examples include 1 mg / kg to 3 mg / kg, 3 mg / kg to 4 mg / kg, 4 mg / kg to 8 mg / kg, 8 mg / kg to 12 mg / kg, 12 mg / kg to 16 mg / kg, 16 mg / kg to 20 mg / kg, 20 mg / kg to 24 mg / kg, 24 mg / kg to 28 mg / kg, or 28 mg / kg to 32 mg / kg (e.g., 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 16 mg / kg, 16 mg / kg to 20 mg / kg, 20 mg / kg to 24 mg / kg, 24 mg / kg to 28 mg / kg, or 28 mg / kg to 32 mg / kg (e.g., 1 mg / kg, 2 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, In some embodiments, the galectin-9 antibody is administered at 2 mg / kg. In some embodiments, the galectin-9 antibody is administered at 4 mg / kg. In some embodiments, the galectin-9 antibody is administered at 8 mg / kg. In some embodiments, the galectin-9 antibody is administered at 12 mg / kg. In some embodiments, the galectin-9 antibody is administered at 16 mg / kg. In some cases, multiple doses of the anti-galectin-9 antibody may be administered to the subject at appropriate intervals or cycles, such as once every two to four weeks (e.g., every two, three, or four weeks). Treatment may continue for a suitable period, such as up to 3 months, up to 6 months, or up to 12 months, or up to 24 months.

[0238] In certain embodiments, the interval or cycle is 2 weeks. In some embodiments, the regimen is once every 2 weeks for one cycle, once every 2 weeks for two cycles, once every 2 weeks for three cycles, once every 2 weeks for four cycles, or once every 2 weeks for more than four cycles. In some embodiments, the treatment is once every 2 weeks for 1 to 3 months, once every 2 weeks for 3 to 6 months, once every 2 weeks for 6 to 12 months, or once every 2 weeks for 12 to 24 months or longer.

[0239] In certain embodiments, the interval or cycle is 3 weeks. In some embodiments, the regimen is once every three weeks for one cycle, once every three weeks for two cycles, once every three weeks for three cycles, once every three weeks for four cycles, or once every three weeks for more than four cycles. In some embodiments, the treatment is once every 3 weeks for 1 to 3 months, once every 3 weeks for 3 to 6 months, once every 3 weeks for 6 to 12 months, or once every 3 weeks for 12 to 24 months or longer.

[0240] In certain embodiments, interval or cycle is 4 weeks or more weeks.In some embodiments, scheme is to continue one cycle once every 4 weeks or more weeks, to continue two cycles once every 4 weeks or more weeks, to continue three cycles once every 4 weeks or more weeks, to continue four cycles once every 4 weeks or more weeks, or to continue more than four cycles once every 4 weeks or more weeks.In some embodiments, treatment is to continue 1 to 3 months once every 4 weeks or more weeks, to continue 3 to 6 months once every 4 weeks or more weeks, to continue 6 to 12 months once every 4 weeks or more weeks, or to continue 12 to 24 months or longer once every 4 weeks or more weeks.In some embodiments, treatment is the combination of treatment at different times, for example, 2 weeks, 3 weeks, 4 or the combination of more than 4 weeks.In some embodiments, treatment interval is adjusted according to the patient's reaction to treatment.In some embodiments, dosage is adjusted according to the patient's reaction to treatment.In some embodiments, dosage changes between treatment intervals.In some embodiments, treatment can be temporarily stopped.

[0241] In some examples, the anti-galectin-9 antibody is administered to a human patient with a target solid tumor disclosed herein (e.g., PDA, CRC, HCC, or cholangiocarcinoma) by intravenous infusion at a dose of about 3 mg / kg once every two weeks. In other examples, the anti-galectin-9 antibody is administered to a human patient with a target solid tumor by intravenous infusion at a dose of about 15 mg / kg once every two weeks.

[0242] The term "about" or "approximately" means within an acceptable error range for a particular value as determined by one of ordinary skill in the art, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to the practice in the art, "about" can mean within an acceptable standard deviation. Alternatively, "about" can mean a range of up to ±20%, preferably up to ±10%, more preferably up to ±5%, and more preferably up to ±1% of a given value. Alternatively, particularly for biological systems or processes, the term can mean within an order of magnitude of a value, preferably within 2 times of a value. Where specific values ​​are described in the present application and claims, the term "about" is implicit, unless otherwise stated, and in this context means within an acceptable error range for a particular value.

[0243] In some embodiments, the methods of the present disclosure increase anti-tumor activity (e.g., reduction of cell proliferation, tumor growth, tumor volume, and / or tumor burden or load or reduction of the number of metastatic lesions (over time)) by at least about 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95% or more, compared to levels before treatment or in a control subject. In some embodiments, the reduction is measured by comparing cell proliferation, tumor growth, and / or tumor volume in a subject before and after administration of the pharmaceutical composition. In some embodiments, the methods of treating or ameliorating cancer in a subject allow for improvement of one or more symptoms of cancer by at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95% or more. In some embodiments, before, during, and after the administration of the pharmaceutical composition, the subject's cancer cells and / or biomarkers are measured in a biological sample (e.g., blood, serum, plasma, urine, peritoneal fluid, and / or a biopsy from a tissue or organ). In some embodiments, the method includes administering a composition of the present invention to reduce the subject's tumor volume, size, burden, or load to an undetectable size, or to less than about 1%, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% of the subject's tumor volume, size, burden, or load before treatment. In other embodiments, the method includes administering a composition of the present invention to reduce the subject's cell proliferation rate or tumor growth rate to an undetectable rate, or to less than about 1%, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 90% of the ratio before treatment. In other embodiments, the method comprises administering a composition of the invention to reduce the development of metastatic lesions or the number or size of metastatic lesions in a subject to an undetectable rate, or to less than about 1%, 2%, 5%, 10%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 75%, 80% or 90% of the pre-treatment rate.

[0244] As used herein, the term "treat," ...

[0245] Alleviating the target disease / disorder includes delaying the development or progression of the disease, or reducing the severity of the disease or prolonging survival. Alleviating the disease or prolonging survival does not necessarily require a cure. As used herein, "delaying" the development of the target disease or disorder refers to postponing, hindering, slowing down, delaying, stabilizing and / or slowing the progression of the disease. This delay can be a different length of time, depending on the history of the disease and / or the individual being treated. A method of "delaying" or alleviating the development of a disease or delaying the onset of a disease is a method that reduces the likelihood of one or more symptoms of the disease occurring within a given time frame and / or alleviates the extent of the symptoms within a given time frame compared to not using the method. Such comparisons are typically based on clinical studies, using a sufficient number of subjects to produce statistically significant results.

[0246] "Development" or "progression" of a disease refers to the initial manifestation of the disease and / or the subsequent progression. The development of a disease can be detected and assessed using standard clinical techniques known in the art. However, development also refers to progression that may not be detected. For the purposes of this disclosure, development or progression refers to the biological course of symptoms. "Development" includes occurrence, recurrence, and onset. As used herein, "onset" or "occurrence" of a target disease or condition includes initial onset and / or recurrence.

[0247] Response to treatment (e.g., treatment of solid tumors described herein) can be assessed according to RECIST or the updated RECIST 1.1 criteria, as described in Example 1 below and in Eisenhower et al., New response evaluation criteria in solid tumors: Revised RECIST guideline (version 1.1); European Journal Of Cancer 45 (2009) 228-247 (the contents of which are incorporated herein by reference in their entirety).

[0248] In some embodiments, treatment can improve overall response (e.g., at 3, 6 or 12 months, or later), for example, compared to the baseline level before the start of treatment or compared to a control group that did not receive treatment. In some embodiments, treatment can result in a complete response, a partial response, or a stable disease (e.g., as measured at 3 months, 6 months or 12 months, or at a later time). This response can be a temporary response over a period of time, or a permanent response. In some embodiments, treatment can increase the likelihood of a complete response, a partial response, or a stable disease (e.g., as measured at 3 months, 6 months or 12 months, or at a later time), for example, compared to a control group that did not receive treatment. This response can be a temporary response over a period of time, or a permanent response. In some embodiments, treatment can result in a reduction or attenuation of progressive disease (e.g., as measured at 3 months, 6 months or 12 months, or at a later time), for example, compared to a control group that did not receive treatment. This attenuation can be temporary or permanent.

[0249] Partial response is compared with the baseline level before treatment starts, the tumor size of response treatment or the reduction of cancer degree (i.e. tumor load) in vivo.For example, according to RECIST response criteria, partial response is defined as the sum of target lesion diameter reduces at least 30%, with baseline total diameter as reference.Progressive disease is a disease that is growing, spreading or worsening.For example, according to RECIST response criteria, progressive disease includes the disease that wherein observes that the target lesion diameter summation increases at least 20% and the summation must also show the absolute increase of at least 5mm.In addition, the appearance of one or more new lesions is also considered to be progress.Compared with the baseline level before treatment starts, the tumor that neither reduces nor increases in degree or severity is considered to be stable disease.For example, according to RECIST response criteria, when neither enough shrinkage to meet the condition of partial response, nor enough increase to meet the condition of progressive disease, stable disease occurs, with the minimum total diameter during research as reference.

[0250] Therefore, in some embodiments, treatment can permanently or in the shortest period of time lead to a reduction in overall tumor size, maintenance of tumor size (e.g., as measured at 3 months, 6 months or 12 months or at a later time) relative to the baseline tumor size before the start of treatment. In some embodiments, treatment can permanently or in the shortest period of time lead to a greater likelihood of overall tumor size reduction or tumor size maintenance (e.g., as measured at 3 months, 6 months or 12 months or at a later time) compared to a control group that did not receive treatment. Tumor size (e.g., the diameter of a tumor) can be measured according to methods known in the art, including measurements from CT and MRI images in combination with various software tools, according to a specific measurement scheme, such as described by Eisenhower et al., referenced above. Therefore, in some embodiments, tumor size is measured in regularly scheduled restaging scans (e.g., CT with contrast, MRI with contrast, PET-CT (diagnostic CT) and / or X-rays). In some embodiments, tumor size reduction, maintenance of tumor size refers to the size of the target lesion. In some embodiments, tumor size reduction, maintenance of tumor size refers to the size of non-target lesions. According to RECIST 1.1, when more than one measurable lesion is present at baseline, all lesions representing a maximum of five lesions in all affected organs (and a maximum of two lesions per organ) should be identified as target lesions. All other lesions (or disease sites), including pathological lymph nodes, should be identified as non-target lesions.

[0251] In some embodiments, treatment may result in a reduction in tumor load or maintenance of tumor load (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time) compared to the baseline level before treatment begins. The reduction in tumor load may be temporary or may be permanent over a period of time. In some embodiments, treatment may result in a greater likelihood of a reduction in tumor load or maintenance of tumor load, for example, compared to an untreated control group (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). As used herein, tumor load refers to the amount of cancer accounting for all parts of the disease, the size or volume of the tumor (in the subject's body). Tumor load may be measured using methods known in the art (including but not limited to FDG positron emission tomography (FDG-PET), magnetic resonance imaging (MRI), and optical imaging, including bioluminescent imaging (BLI) and fluorescent imaging (FLI)).

[0252] In some embodiments, treatment may result in an increase in the time until disease progression or progression-free survival (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time) compared to an untreated control group. Progression-free survival may be permanent or progression-free survival over a certain period of time. In some embodiments, treatment may result in a greater likelihood of progression-free survival (permanent progression-free survival or progression-free survival over a certain period of time, e.g., 3, 6, or 12 months, or, for example, as measured at 3 months, 6 months, or 12 months after the start of treatment, or at a later time. Progression-free survival (PFS) is defined as the time randomly assigned from a clinical trial, such as the time from the start of treatment to disease progression or death from any cause. In some embodiments, treatment may result in longer survival or a greater likelihood of survival (e.g., at a certain time, e.g., at 6 or 12 months).

[0253] The response to treatment (e.g., treatment of solid tumors described herein) can be evaluated according to the iRECIST criteria, as described in Seymour et al., iRECIST: guidelines for response criteria for use in trials; The Lancet, Vol 18, March 2017, the contents of which are incorporated herein by reference in their entirety. iRECIST was developed to use modified RECIST 1.1 criteria, particularly in cancer immunotherapy trials, to ensure consistent design and data collection, and can be used as a guide to standard methods for solid tumor measurement, as well as the definition of objective changes in tumor size used in trials using immunotherapy. iRECIST is based on RECIST 1.1. The response assigned using iRECIST has a prefix "i" (i.e., immune), for example, "immune" complete response (iCR) or partial response (iPR), and unconfirmed progressive disease (iUPD) or confirmed progressive disease (iCPD) or stable disease (iSD) to distinguish them from responses assigned using RECIST 1.1, all of which are defined in Seymour et al.

[0254] Thus, in some embodiments, treatment may result in an "immune" complete response (iCR), partial response (iPR) or stable disease (iSD) (e.g., as measured at 3 months, 6 months or 12 months or at a later time) compared to the baseline level of the disease before the start of treatment. The reduction of an "immune" response (e.g., iCR, iPR or iSD) may be temporary or permanent over a period of time. In some embodiments, treatment may increase the likelihood of a complete response (iCR), partial response (iPR) or stable disease (iSD) (e.g., as measured at 3 months, 6 months or 12 months or at a later time), for example, compared to a control group that did not receive treatment. In some embodiments, treatment may result in an overall reduction in unconfirmed progressive disease (iUPD) or confirmed progressive disease (iCPD) (e.g., as measured at 3 months, 6 months or 12 months or at a later time), for example, compared to the baseline before the start of treatment. The reduction of iUPD or iCPD may be temporary or permanent over a period of time. In some embodiments, treatment may result in a greater likelihood of an overall reduction in unconfirmed progressive disease (iUPD) or confirmed progressive disease (iCPD) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), for example, compared to an untreated control group. In some embodiments, treatment may result in a reduction in the overall number of new lesions according to iRECIST criteria compared to an untreated control group or compared to a baseline before treatment begins (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). The reduction in lesions may be temporary or permanent over a period of time.

[0255] Response to treatment can also be characterized by one or more of the following: immunophenotype in blood and tumor, cytokine profile (serum), soluble galectin-9 levels in blood (serum or plasma), galectin-9 tumor tissue expression levels and expression patterns by immunohistochemistry (tumor, stroma, immune cells), tumor mutation burden (TMB), PDL-1 expression (e.g., by immunohistochemistry), mismatch repair status, or disease-associated tumor markers (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). Non-limiting examples of such tumor markers include Ca15-3, CA-125, CEA, CA19-9, alpha-fetoprotein. These parameters can be compared to baseline levels before the start of treatment, or can be compared to a control group that did not receive treatment.

[0256] In some embodiments, treatment may result in changes in the levels of immune cells and immune cell markers in blood or tumors, for example, may result in immune activation. Such changes may be measured in patient blood and tissue samples using methods known in the art (e.g., multiplex flow cytometry and multiplex immunohistochemistry). For example, a set of phenotypic and functional PBMC immune markers may be evaluated at baseline before treatment begins and at different time points during treatment. Table A lists non-limiting examples of markers useful for these evaluation methods. Flow cytometry (FC) is a fast and informative selection technique for analyzing cell phenotype and function, and has gained prominence in immunophenotypic monitoring. It allows characterization of many cell subpopulations in complex mixtures (e.g., blood), including rare subpopulations, and represents a fast method for obtaining a large amount of data. The advantages of FC are high speed, sensitivity, and specificity. Standardized antibody panels and procedures can be used to analyze and classify immune cell subtypes. Multiplex IHC is a powerful investigative tool that provides objective quantitative data, describes the tumor immune environment of the number and location of immune subpopulations, and allows multiple markers to be evaluated on a single tissue section. Computer algorithms can be used to quantify IHC-based biomarker content from whole slide images of patient biopsies, combining chromogenic IHC methods and staining with digital pathology methods.

[0257] Table A. PBMC typing markers

[0258]

[0259] Thus, in some embodiments, treatment results in the regulation of immune activation markers (e.g., those in Table A), such as treatment resulting in one or more of the following: (1) an increase in more CD8 cells in plasma or tumor tissue, (2) a decrease in T regulatory cells (Treg) in plasma or tumor tissue, (3) an increase in M1 macrophages in plasma or tumor tissue, and (4) a decrease in MDSC in plasma or tumor tissue, and (5) a decrease in M2 macrophages in plasma or tumor tissue (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). In some embodiments, markers evaluated using the above techniques or known in the art are selected from CD4, CD8, CD14, CD11b / c, and CD25. These parameters can be compared to baseline levels before the start of treatment, or can be compared to a control group that has not received treatment.

[0260] In some embodiments, treatment as described herein results in changes in pro-inflammatory and anti-inflammatory cytokines. In some embodiments, treatment as described herein results in one or more of the following: (1) an increase in IFNγ levels in plasma or tumor tissue; (2) an increase in TNFα levels in plasma or tumor tissue; (3) a decrease in IL-10 levels in plasma or tumor tissue (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). These parameters can be compared to baseline levels before the start of treatment, or can be compared to a control group that has not received treatment.

[0261] In some embodiments, changes in cytokines or immune cells can be assessed between a tumor biopsy before the dose and a repeat biopsy performed at a feasible time. In some embodiments, changes in cytokines or immune cells can be assessed between two repeat biopsies. In some embodiments, treatment results in changes in one or more of the soluble galectin-9 level in the blood (serum or plasma) or the galectin-9 tumor tissue expression level and expression pattern (by immunohistochemistry) (tumor, stroma, immune cells) (e.g., as measured at 3 months, 6 months or 12 months or at a later time). In some embodiments, treatment results in a decrease in one or more of the soluble galectin-9 level in the blood (serum or plasma) or the galectin-9 tumor tissue expression level and expression pattern (by immunohistochemistry) (tumor, stroma, immune cells) (e.g., as measured at 3 months, 6 months or 12 months or at a later time). These galectin-9 levels can be compared with the baseline level before the start of treatment, or can be compared with a control group that has not received treatment.

[0262] In some embodiments, treatment results in a change in PDL-1 expression, for example, as assessed by immunohistochemistry. In some embodiments, treatment results in a change (increase or decrease) in one or more tumor markers associated with the disease (e.g., as measured at 3 months, 6 months or 12 months or at a later time). Non-limiting examples of such tumor markers include Ca15-3, CA-125, CEA, CA19-9, alpha-fetoprotein. These parameters can be compared with baseline levels before the start of treatment, or can be compared with a control group that has not received treatment.

[0263] In some embodiments, treatment results in improved quality of life and symptom control (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time) compared to a baseline before treatment begins or compared to a control group that did not receive treatment. In some embodiments, improvement can be measured on the ECOG scale described in Example 1 herein.

[0264] In any of the above embodiments, treatment may include administering an anti-galectin-9 antibody described herein, alone or in combination with a checkpoint inhibitor therapy, such as an anti-PD-1 antibody. In some embodiments, the present disclosure provides a method for treating a solid tumor in a subject (including a human subject), comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody contains a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody contains a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody contains a light chain comprising SEQ ID NO: 15. In some embodiments, in some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0265] In some embodiments, the disclosure provides methods for improving the overall response (e.g., according to RECIST 1.1. criteria) in a subject, including a human subject (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. The RECIST 1.1. criteria can be compared to the baseline level before the start of treatment, or can be compared to a control group that did not receive treatment. In some embodiments, the disclosure provides methods for achieving a complete response, a partial response, or stable disease (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. These responses can be temporary over a period of time, or can be permanent, and can be compared to the baseline level before the start of treatment, or can be compared to a control group that did not receive treatment.

[0266] In some embodiments, the methods can increase the likelihood of a complete response, partial response, or stable disease (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time; and is temporary or permanent), for example, compared to a control group that did not receive treatment. In some embodiments, the disclosure provides methods for attenuating disease progression or reducing progressive disease (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), for example, compared to a control group that did not receive treatment or compared to a baseline before the start of treatment, the method comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. The attenuation or reduction can be temporary or permanent over a period of time. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0267] In some embodiments, the disclosure provides a method of permanently or for a minimum period of time reducing or maintaining tumor size in a subject (including a human subject) relative to a baseline tumor size in the subject prior to the start of treatment (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), the method comprising administering to the subject a therapeutically effective amount of an anti-Galectin-9 antibody disclosed herein. In some embodiments, the disclosure provides a method of increasing the likelihood of permanently or for a minimum period of time reducing or maintaining tumor size in a subject (including a human subject) relative to a baseline level prior to the start of treatment or relative to a control group that did not receive treatment (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). In some embodiments, the disclosure provides a method of reducing or maintaining tumor burden in a subject (including a human subject) relative to a baseline level prior to the start of treatment or relative to a control group that did not receive treatment (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), the method comprising administering to the subject a therapeutically effective amount of an anti-Galectin-9 antibody disclosed herein. In some embodiments, the disclosure provides a method of increasing the likelihood of reducing or maintaining tumor burden (e.g., as measured at 3 months, 6 months, or 12 months or at a later time), e.g., compared to a control group that did not receive treatment, the method comprising administering to a subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. Thus, in some embodiments, tumor size and / or burden is measured in regularly scheduled restaging scans (e.g., CT with contrast, MRI with contrast, PET-CT (diagnostic CT), and / or X-ray). In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody contains a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody contains a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody contains a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17 IgG4.In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0268] In some embodiments, the disclosure provides a method of increasing the time until disease progression or increasing progression-free survival time (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time) in a subject, including a human subject, compared to a control group that did not receive treatment, the method comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. The method may result in permanent progression-free survival or progression-free survival over a certain period of time. In some embodiments, the disclosure provides a method of increasing the likelihood of progression-free survival (permanent progression-free survival or progression-free survival over a certain period of time) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time) compared to a control group that did not receive treatment. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0269] In some embodiments, the present disclosure provides a method for improving an overall response (iOR) in a subject, including a human subject (e.g., according to iRECIST criteria) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. In some embodiments, the present disclosure provides a method for achieving an "immune" complete response (iCR), a partial response (iPR), or stable disease (iSD) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), the method comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. In some embodiments, the method can increase the likelihood of an "immune" complete response (iCR), a partial response (iPR), or stable disease (iSD) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time). In some embodiments, the present disclosure provides a method for slowing disease progression or reducing progressive disease, such as reducing unconfirmed progressive disease (iUPD) or reducing confirmed progressive disease (iCPD) (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), the method comprising administering to a subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. Any of those iRECIST criteria described above can be compared to a baseline level before the start of treatment, or can be compared to a control group that did not receive treatment, and the response can be temporary or permanent over a period of time. In some embodiments, the present disclosure provides a method for increasing the likelihood of an overall reduction in unconfirmed progressive disease (iUPD) or confirmed progressive disease (iCPD) in a subject, including a human subject (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), for example, compared to a control group that did not receive treatment, the method comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody as disclosed herein. In some embodiments, the disclosure provides a method for reducing the number of new lesions in a subject (including a human subject) according to iRECIST criteria (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), the method comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. The reduction in the number of lesions may be relative to a baseline level before the start of treatment, or may be relative to a control group that did not receive treatment, and the reduction may be temporary over a certain period of time, or may be permanent.In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0270] In some embodiments, the disclosure provides methods for regulating the immune response of a subject. As used herein, the term "immune response" includes T cell-mediated and / or B cell-mediated immune responses that are regulated by immune cell activity, such as T cell activation. In one embodiment of the disclosure, the immune response is T cell-mediated. As used herein, the term "regulation" means to change or vary, and includes up-regulation and down-regulation. For example, "regulating an immune response" refers to a state that changes or changes one or more immune response parameters. Exemplary parameters of T cell-mediated immune responses include the level of T cells (e.g., an increase or decrease in effector T cells) and the level of T cell activation (e.g., an increase or decrease in the production of certain cytokines). Exemplary parameters of B cell-mediated immune responses include an increase in B cell levels, B cell activation, and B cell-mediated antibody production.

[0271] When immune response is regulated, some immune response parameters may be reduced, while others may increase.For example, in some cases, regulating immune response causes the increase (or upregulation) of one or more immune response parameters and the reduction (or downregulation) of one or more other immune response parameters, and the result is the overall increase of immune response, such as the overall increase of inflammatory immune response.In another example, regulating immune response causes the increase (or upregulation) of one or more immune response parameters and the reduction (or downregulation) of one or more other immune response parameters, and the result is the overall reduction of immune response, such as the overall reduction of inflammatory response.In some embodiments, the increase of overall immune response, i.e., the increase of overall inflammatory immune response, is determined by the reduction of tumor weight, tumor size or tumor load or any RECIST or iRECIST standards described herein.In some embodiments, the increase of overall immune response is determined by the level (one or more, two or more, etc. or most of the anti-inflammatory and / or immunosuppressive cytokines and / or one or more of the most potent anti-inflammatory or immunosuppressive cytokines) of the increase of one or more proinflammatory cytokines (for example, including two or more, three or more, etc. or most of the proinflammatory cytokines) (one or more, two or more, etc. or most of the anti-inflammatory and / or immunosuppressive cytokines and / or one or more of the most potent anti-inflammatory or immunosuppressive cytokines reduce or remain unchanged). In some embodiments, the increase in overall immune response is determined by the increased level of one or more most potent proinflammatory cytokines (one or more anti-inflammatory and / or immunosuppressive cytokines including one or more most potent cytokines are reduced or remain unchanged). In some embodiments, the increase in overall immune response is determined by one or more reduced levels including most immunosuppressive and / or anti-inflammatory cytokines (one or more or most proinflammatory cytokines including, for example, the most potent proinflammatory cytokines are increased or remain unchanged). In some embodiments, the increase in overall immune response is determined by the increased level of one or more most potent anti-inflammatory and / or immunosuppressive cytokines (one or more or most proinflammatory cytokines including, for example, the most potent proinflammatory cytokines are increased or remain unchanged). In some embodiments, the increase in overall immune response is determined by a combination of any of the above. In addition, an increase (or upregulation) in one type of immune response parameter may lead to a corresponding decrease (or downregulation) in another type of immune response parameter. For example, an increase in the production of certain proinflammatory cytokines may lead to downregulation of certain anti-inflammatory and / or immunosuppressive cytokines, and vice versa.

[0272] In some embodiments, the disclosure provides methods for modulating an immune response in a subject, including a human subject (e.g., as measured at 3 months, 6 months, or 12 months or at a later time), comprising administering to the subject a therapeutically effective amount of an anti-Galectin-9 antibody disclosed herein. In some embodiments, the disclosure provides methods for modulating the level of immune cells and immune cell markers (including, but not limited to, those described in Table A herein) in the blood or tumor of a subject (including a human subject) (e.g., compared to baseline levels before the start of treatment or compared to a control group not receiving treatment), comprising administering to the subject a therapeutically effective amount of an anti-Galectin-9 antibody disclosed herein. In some embodiments, the overall result of the modulation is upregulation of proinflammatory immune cells and / or downregulation of immunosuppressive immune cells. In some embodiments, the disclosure provides methods for modulating immune cell levels, wherein the modulation includes one or more of the following: (1) increasing CD8 cells in plasma or tumor tissue, (2) reducing Tregs in plasma or tumor tissue, (3) increasing M1 macrophages in plasma or tumor tissue and (4) reducing MDSCs in plasma or tumor tissue, and (5) reducing M2 macrophages in plasma or tumor tissue, and wherein the method comprises administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody as disclosed herein. In some embodiments, markers for assessing the level of such immune cells include, but are not limited to, CD4, CD8, CD14, CD11b / c, and CD25. In some embodiments, the disclosure provides methods for modulating the level of pro-inflammatory and immunosuppressive cytokines in the blood or tumor of a subject, including a human subject, for example, compared to baseline levels before the start of treatment, or compared to a control group that did not receive treatment (e.g., as measured at 3 months, 6 months, or 12 months, or at a later time), comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody as disclosed herein. In some embodiments, the overall result of the modulation is upregulation of proinflammatory cytokines and / or downregulation of immunosuppressive cytokines. In some embodiments, the disclosure provides methods for modulating the level of cytokine cells, wherein the modulation comprises one or more of the following: (1) increasing the level of IFNγ in plasma or tumor tissue; (2) increasing the level of TNFα in plasma or tumor tissue; (3) reducing the level of IL-10 in plasma or tumor tissue.In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0273] In some embodiments, the disclosure provides a method of altering one or more of soluble Galectin-9 levels in blood (serum or plasma) or Galectin-9 tumor tissue expression levels and expression patterns (by immunohistochemistry) (tumor, stroma, immune cells) (e.g., as measured at week 2, week 4, month 1, month 3, month 6, or month 12, or at a later time), comprising administering to a subject a therapeutically effective amount of an anti-Galectin-9 antibody disclosed herein. In some embodiments of the methods, one or more of soluble Galectin-9 levels in blood (serum or plasma) or Galectin-9 tumor tissue expression levels and expression patterns (by immunohistochemistry) (tumor, stroma, immune cells) remain unchanged. In some embodiments, the methods provided herein reduce one or more of soluble galectin-9 levels in the blood (serum or plasma) or galectin-9 tumor tissue expression levels and expression patterns (by immunohistochemistry) (tumor, stroma, immune cells) (e.g., as measured at week 2, week 4, month 1, month 3, month 6, or month 12, or at a later time). Galectin-9 levels can be compared to baseline levels before the start of treatment, or can be compared to a control group that did not receive treatment. In some embodiments, treatment results in a change in PDL-1 expression, for example, by immunohistochemistry. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, in some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject.In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0274] In some embodiments, the disclosure provides methods for altering PDL-1 expression, e.g., as assessed by immunohistochemistry (e.g., as measured at week 2, week 4, month 1, month 3, month 6, or month 12, or at a later time), comprising administering to a subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. In some embodiments of the method, PDL-1 expression (e.g., as assessed by immunohistochemistry) remains unchanged. The PD-L1 level can be compared to the baseline level before the start of treatment, or can be compared to a control group that did not receive treatment. In some embodiments, the methods provided herein reduce PDL-1 expression, e.g., as assessed by immunohistochemistry. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, in some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0275] In some embodiments, the present disclosure provides a method for changing one or more tumor markers associated with a disease (increase or decrease) (e.g., as measured at 2 weeks, 4 weeks, 1 month, 3 months, 6 months or 12 months or at a later time), comprising administering to a subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. In some embodiments of the method, one or more tumor markers associated with the disease (increase or decrease) remain unchanged. Non-limiting examples of such tumor markers include Ca15-3, CA-125, CEA, CA19-9, alpha-fetoprotein. The level of the tumor marker can be compared to the baseline level before the start of treatment, or can be compared to a control group that did not receive treatment. In some embodiments, the methods provided herein reduce the occurrence of one or more tumor markers associated with the disease. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, in some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0276] In some embodiments, the present disclosure provides methods for improving quality of life and / or improving symptom control (e.g., as measured at 1 month, 3 months, 6 months, or 12 months or at a later time) in a subject, including a human subject, comprising administering to the subject a therapeutically effective amount of an anti-galectin-9 antibody disclosed herein. Quality of life and symptom control are improved compared to a baseline before the start of treatment or compared to a control group that did not receive treatment. The improvement in quality of life may be temporary for a period of time, or may be permanent. In some embodiments, the improvement may be measured on the ECOG scale. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody contains a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody contains a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody contains a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody contains a light chain comprising SEQ ID NO: 15. In some embodiments, in some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose can be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor.

[0277] In some embodiments, an antibody described herein, such as G9.2-17, is administered to a subject in need of treatment in an amount sufficient to inhibit the activity of galectin-9 (and / or Dectin-1 or TIM-3 or CD206) in immunosuppressive immune cells in tumors by at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) (in vivo). In other embodiments, an antibody described herein, such as G9.2-17, is administered in an amount effective to reduce the level of activity of galectin-9 (and / or Dectin-1 or TIM-3 or CD206) in immunosuppressive immune cells in tumors by at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) (compared to the level before treatment or in a control subject). In some embodiments, an antibody described herein, such as G9.2-17, is administered to a subject in need of treatment in an amount sufficient to promote M1-like programming in TAMs by at least 20% (e.g., 30%, 40%, 50%, 60%, 70%, 80%, 90% or more) (in vivo) (compared to levels before treatment or in control subjects).

[0278] Depending on the type of disease or disease site to be treated, the pharmaceutical composition can be administered to the subject using conventional methods known to those of ordinary skill in the medical field. In some embodiments, the anti-Galectin-9 antibody can be administered to the subject by intravenous infusion.

[0279] Injectable compositions may include various carriers, such as vegetable oils, dimethylactamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, and polyols (glycerol, propylene glycol, liquid polyethylene glycol, etc.). For intravenous injection, water-soluble antibodies may be administered by drip infusion, whereby a pharmaceutical preparation containing the antibody and a physiologically acceptable excipient is injected. Physiologically acceptable excipients may include, for example, 5% glucose, 0.9% saline, Ringer's solution, or other suitable excipients. Intramuscular preparations of antibodies, such as sterile preparations in the form of suitable soluble salts, may be dissolved and administered in a pharmaceutical excipient (e.g., water for injection, 0.9% saline, or 5% glucose solution).

[0280] In some embodiments, the anti-Galectin-9 antibodies described herein are used as a monotherapy to treat a target cancer disclosed herein, i.e., there is no other anti-cancer therapy concurrently with the therapy using the anti-Galectin-9 antibody.

[0281] In other embodiments, the method of treatment further includes administering to the subject a checkpoint molecule such as an inhibitor of PD-1. Examples of PD-1 inhibitors include anti-PD-1 antibodies, such as pembrolizumab, nivolumab, tislelizumab, and cimiprilimumab. Such checkpoint inhibitors can be administered simultaneously or sequentially (in any order) with an anti-galectin-9 antibody according to the present disclosure. In some embodiments, the checkpoint molecule is PD-L1. Examples of PD-L1 inhibitors include anti-PD-L1 antibodies, such as durvalumab, avelumab, and atezolizumab. In some embodiments, the checkpoint molecule is CTLA-4. An example of a CTLA-4 inhibitor is the anti-CTLA-4 antibody ipilimumab. In some embodiments, the inhibitor targets a checkpoint molecule selected from CD40, GITR, LAG-3, OX40, TIGIT, and TIM-3.

[0282] In some embodiments, the anti-galectin-9 antibody improves overall response, e.g., at 3 months, relative to a regimen comprising a checkpoint molecule inhibitor (e.g., anti-PD1, e.g., nivilumab) alone.

[0283] In some embodiments, the anti-PD-1 antibody is PD-1 is nivolumab, and the methods described herein comprise administering nivolumab to the subject at a dose of 240 mg intravenously once every two weeks.

[0284] In some embodiments, the antibody that binds to PD-1 is administered using a fixed dose. In some embodiments, the antibody that binds to PD-1 is nivolumab, which is administered to the subject at a dose of 480 mg once every 4 weeks. In some embodiments, the antibody that binds to PD-1 is pembrolizumab, which is administered at a dose of 200 mg once every 3 weeks. In some embodiments, the antibody that binds to PD-1 is cimiprilimab. In some embodiments, the antibody that binds to PD-1 is cimiprilimab. In some embodiments, the methods described herein include administering cimiprilimab intravenously to the subject at a dose of 350 mg once every 3 weeks. In some embodiments, the antibody that binds to PD-1 is tislelizumab. In some embodiments, the methods described herein include administering tislelizumab intravenously to the subject at a dose of 200 mg once every 3 weeks.

[0285] In some embodiments, the antibody that binds to PD-L1 is administered using a fixed dose. In some embodiments, the antibody that binds to PD-L1 is atezolizumab. In some embodiments, the methods described herein include administering atezolizumab intravenously to a subject at a dose of 1200 mg once every 3 weeks. In some embodiments, the antibody that binds to PD-L1 is avelumab. In some embodiments, the methods described herein include administering avelumab intravenously to a subject at a dose of 10 mg / kg every 2 weeks. In some embodiments, the antibody that binds to PD-1 is durvalumab. In some embodiments, the methods described herein include administering durvalumab intravenously to a subject at a dose of 1500 mg every 4 weeks.

[0286] In a specific example, any of the methods disclosed herein include (i) administering any anti-Galectin-9 antibody disclosed herein (e.g., G9.2-17 or an antibody having a heavy chain of SEQ ID NO: 19 and a light chain of SEQ ID NO: 5) to a human patient having a target solid tumor disclosed herein (e.g., pancreatic ductal adenocarcinoma (PDA or PDAC), CRC, HCC, or CCA) at a dose of about 1 to about 32 mg / kg (e.g., about 3 mg / kg or about 15 mg / kg) once every two weeks; and (ii) administering an effective amount of an anti-PD-1 antibody (e.g., nivolumab, pembrolizumab, tislelizumab or cemiplizumab, durvalumab, avelumab, and atezolizumab) to the human patient. In some embodiments, the antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6. In some embodiments, the antibody comprises a heavy chain variable region comprising SEQ ID NO: 7. In some embodiments, the antibody comprises a light chain variable region comprising SEQ ID NO: 8. In some embodiments, the antibody comprises a heavy chain comprising SEQ ID NO: 19. In some embodiments, the antibody comprises a light chain comprising SEQ ID NO: 15. In some embodiments, the antibody is G9.2-17IgG4. In some embodiments, the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg, for example, the dose may be selected from 2 mg / kg, 4 mg / kg, 8 mg / kg, 12 mg / kg and 16 mg / kg. In some embodiments, the antibody is administered once every two weeks, for example by intravenous infusion. In some embodiments, the method further comprises administering an immune checkpoint inhibitor, such as an anti-PD1 antibody, to the subject. In some embodiments, the solid tumor is selected from pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC) or cholangiocarcinoma (CCA), and in some embodiments, the solid tumor is a metastatic tumor. When using nivolumab, a suitable dosing regimen may be about 480 mg once every 4 weeks. When using pembrolizumab, a suitable dosing regimen may be about 200 mg once every 3 weeks. When using simiprilimumab, a suitable dosing regimen may be about 350 mg intravenously once every three weeks. When tislelizumab is used, a suitable dosing regimen may be about 200 mg intravenously once every 3 weeks.In some embodiments, an anti-PD-L1 antibody is used instead of an anti-PD-1 antibody.When using atezolizumab, a suitable dosing regimen may be about 1200 mg intravenously once every 3 weeks. When using avelumab, a suitable dosing regimen may be about 10 mg / kg intravenously every 2 weeks. When using durvalumab, a suitable dosing regimen may be about 1500 mg intravenously every 4 weeks.

[0287] Without being bound by theory, it is believed that by inhibiting Dectin-1, anti-Galectin-9 antibodies can reprogram immune responses against tumor cells, for example by inhibiting the activity of γδ T cells that infiltrate the tumor microenvironment, and / or by, for example, activating CD4+ and / or CD8+ T cells to enhance immune surveillance against tumor cells. Therefore, it is expected that the combined use of anti-Galectin-9 antibodies and immunomodulators (such as those described herein) will significantly enhance anti-tumor efficacy.

[0288] In some embodiments, the method provided is to administer an anti-galectin-9 antibody simultaneously with a checkpoint inhibitor. In some embodiments, the anti-galectin-9 antibody is administered before or after the checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is administered systemically. In some embodiments, the checkpoint inhibitor is administered locally. In some embodiments, the checkpoint inhibitor is administered intravenously, for example as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebrospinal, subcutaneous, intraarterial, intraarticular, intrasynovial, intrathecal, intratumoral, oral, inhaled or topical routes. In one embodiment, the checkpoint inhibitor is administered to the subject by intravenous infusion.

[0289] In any of the method embodiments described herein, the anti-galectin-9 antibody can be administered (alone or in combination with an anti-PD1 antibody) once every 2 weeks for one cycle, once every 2 weeks for two cycles, once every 2 weeks for three cycles, once every two weeks for four cycles, or once every two weeks for more than four cycles. In some embodiments, the treatment is 1 to 3 months, 3 to 6 months, 6 to 12 months, 12 to 24 months or longer. In some embodiments, the treatment is once every 2 weeks for 1 to 3 months, once every 2 weeks for 3 to 6 months, once every 2 weeks for 6 to 12 months, or once every 2 weeks for 12 to 24 months or longer.

[0290] The occurrence of adverse reactions (e.g., serious adverse reactions) in subjects receiving treatment with any anti-galectin-9 antibody (e.g., G9.2-17) disclosed herein, alone or in combination with a checkpoint inhibitor disclosed herein (e.g., an anti-PD-1 or anti-PD-L1 antibody) can be monitored. Exemplary adverse reactions to be monitored are provided in Example 1 below. If the occurrence of adverse reactions is observed, the treatment conditions of the subject can be changed. For example, the dose of the anti-galectin-9 antibody can be reduced and / or the administration interval can be extended. The appropriateness and extent of the reduction can be assessed by a qualified clinician. In a specific example, a reduction in the level assessed by the clinician or at least 30% is implemented. If necessary, a further dose reduction (dose level -2) of 30% of dose level -1 is implemented. Alternatively or additionally, the dose of the checkpoint inhibitor can be reduced and / or the administration interval of the checkpoint inhibitor can be extended. In some cases (e.g., life-threatening adverse reactions occur), treatment may be terminated.

[0291] Kit for treating diseases associated with galectin-9

[0292] The present disclosure also provides kits for treating or alleviating diseases associated with galectin-9, such as galectin-9 that binds to cell surface glycoproteins (e.g., Dectin-1, TIM3, CD206, etc.) or pathological cells (e.g., cancer cells) expressing galectin-9. Examples include solid tumors, such as PDA, CRC, HCC, or cholangiocarcinoma, and others described herein and others described herein. Such kits may include one or more containers containing an anti-galectin-9 antibody, such as any of the antibodies described herein, and optionally a second therapeutic agent (e.g., a checkpoint inhibitor, such as an anti-PD-1 antibody disclosed herein) for use with the anti-galectin-9 antibody also described herein.

[0293] In some embodiments, the kit may include instructions for use according to any of the methods described herein. The included instructions may include a description of administering an anti-galectin-9 antibody and optionally a second therapeutic agent to treat, delay the onset, or ameliorate a target disease as described herein. In some embodiments, the kit further includes instructions for selecting an individual suitable for treatment based on identifying whether the individual has the target disease (e.g., using a diagnostic method as described herein). In other embodiments, the instructions include a description of administering the antibody to an individual at risk for the target disease.

[0294] Instructions for use of the anti-galectin-9 antibody typically include information about dosage, dosing regimen, and route of administration for the intended treatment. The container may be a unit dose, bulk package (e.g., multi-dose package), or subunit dose. The instructions provided in the kit of the invention are typically written instructions on a label or package insert (e.g., a paper sheet included in the kit), but machine-readable instructions (e.g., instructions carried on a magnetic or optical storage disk) are also acceptable.

[0295] The label or package insert indicates that the composition is used to treat, delay the onset of, and / or alleviate a disease associated with Galectin-9 (e.g., Dectin-1, TIM-3, or CD206 signaling). In some embodiments, instructions for practicing any of the methods described herein are provided.

[0296] The kit of the present invention is packaged in a suitable package. Suitable packages include, but are not limited to, vials, bottles, jars, flexible packages (e.g., sealed polyester films or plastic bags), etc. Packages used in combination with specific devices (e.g., inhalers, nasal administration devices (e.g., nebulizers), or infusion devices such as miniature pumps) are also contemplated. In some embodiments, the kit has a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). In some embodiments, the container also has a sterile access port (e.g., the container is an intravenous solution bag or a vial with a stopper that can be pierced by a hypodermic injection needle). At least one active agent in the composition is an anti-galectin-9 antibody described herein.

[0297] The kit may optionally provide additional components, such as buffer and interpretative information. Typically, the kit includes a container and a label or package insert on or associated with the container. In some embodiments, the invention provides an article comprising the contents of the above-mentioned kit.

[0298] General techniques

[0299] The practice of the present invention employs, unless otherwise indicated, conventional techniques of molecular biology (including recombinant techniques), microbiology, cell biology, biochemistry and immunology, which are within the skill of the art. Such techniques are well explained in the literature, for example, Molecular Cloning: A Laboratory Manual, second edition (Sambrook et al., 1989) Cold Spring Harbor Press; Oligonucleotide Synthesis (MJ Gait, ed., 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Notebook (JECellis, ed., 1998) Academic Press; Animal Cell Culture(RIFreshney,ed.,1987);Introduction to Cell and Tissue Culture(JPMatherand PERoberts,1998)Plenum Press;Cell and Tissue Culture:LaboratoryProcedures(A.Doyle,JBGriffiths,and DGNewell,eds.,1993-8)J.Wiley and Sons;Methods in Enzymology(Academic Press,Inc.);Handbook of ExperimentalImmunology(DMWeir and CCBlackwell, eds.); Gene Transfer Vectors for Mammalian Cells (JMMiller and MPCalos, eds., 1987); Current Protocols in Molecular Biology (FMAusubel et al., eds., 1987); PCR: The Polymerase ChainReaction, (Mullis et al., eds., 1994); Current Protocols in Immunology (JEColigan et al., eds., 1994);, 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: a practical approach (D. Catty., ed., IRL Press, 1988-1989); Monoclonal antibodies: a practical approach approach (P. Shepherd and C. Dean, eds., Oxford University Press, 2000); Using antibodies: a laboratory manual (E. Harlow and D. Lane (Cold Spring Harbor Laboratory Press, 1999)); The Antibodies (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1995).

[0300] Without further elaboration, it is believed that those skilled in the art can make the most of the present invention based on the above description. Therefore, the following specific embodiments should be interpreted as being merely illustrative and not limiting the remainder of the present disclosure in any way. For the purposes or themes cited herein, all publications cited herein are incorporated by reference. Example

[0301] Example 1. Phase I-II open-label non-randomized study of anti-galectin-9 monoclonal antibody alone or in combination with anti-PD1 antibody in patients with metastatic solid tumors

[0302] Galectin-9 is a molecule that is overexpressed in many solid tumors, including pancreatic cancer, colorectal cancer, and hepatocellular carcinoma. In addition, galectin-9 is expressed on tumor-associated macrophages as well as intratumoral immunosuppressive γδT cells, thereby acting as a potent mediator of cancer-associated immunosuppression. As described herein, monoclonal antibodies targeting galectin-9 (e.g., G9.2-17, IgG4) have been developed. The data showed that G9.2-17 prevented 50% of pancreatic tumor growth in an orthotopic KPC model and extended the survival of KPC animals by more than double. Without wishing to be bound by theory, it is believed that anti-galectin-9 antibodies reverse the M2 phenotype to the M1 phenotype, promoting intratumoral CD8 +T cell activation. Furthermore, it has been found that the antibody G9.2-17 (IgG4) (having a heavy chain of SEQ ID NO: 19 and a light chain of SEQ ID NO: 15) acts synergistically with anti-PD1.

[0303] The purpose of this Phase I / II multicenter study is to determine the safety, tolerability, maximum tolerated or maximum administered dose (MTD), and objective tumor response after three months of treatment in subjects with metastatic solid tumors such as pancreatic cancer (PDA), colorectal cancer (CRC), hepatocellular carcinoma (HCC), or cholangiocarcinoma (CCA). The study also examined progression-free survival (PFS), duration of response (by RESIST), disease stability, the proportion of subjects alive at 3, 6, and 12 months, and pharmacokinetic (PK) and pharmacodynamic (PD) parameters. Subjects received pre- and post-treatment biopsies, as well as PET-CT imaging before and every 8 weeks during the study. In addition, immunological endpoints such as peripheral and intratumoral T cell ratios, T cell activation, macrophage typing, and galectin-9 serum levels were examined. The study was conducted under the main study protocol and the study duration was 12-24 months.

[0304] In addition, preclinical proof of concept data showed that G9.2-17 (IgG4) (also known as G9.2-17IgG4) reduced pancreatic tumor growth by up to 50% as a single agent in the orthotopic ((LSL-Kras (G12D / ±); LSL-Trp53 (R172H / +); Pdx-1-Cre)-pancreatic ductal adenocarcinoma) KPC model and the B16F10 melanoma, subcutaneous model. Blocking galectin-9 also prolonged the survival of KPC animals. Mechanistically, targeting galectin-9 promoted the activation of effector T cells within the tumor. There were signs of synergy between the G9.2-17 antibody and anti-PD-1 in vivo. That is, in the B16F10 melanoma model, a significant increase in intratumoral CD8+ T cells was observed in the group treated with anti-galectin-9 antibody and anti-PD-1 compared to the group treated with either single agent alone. In non-GLP toxicity studies, G9.2-17 (IgG4) was safe in rodents and cynomolgus monkeys at doses up to and including 100 mg / kg in rodents and 300 mg / kg in monkeys. This Phase Ia / Ib investigational trial is designed to evaluate the safety and tolerability of the maximum tolerated dose, PK, PD, efficacy response outcomes, disease control and survival at 3, 6 and 12 months, and other exploratory parameters.

[0305] This Phase Ia / Ib investigational trial evaluates the safety and tolerability of the maximum tolerated dose (or maximum administered dose), PK, PD, immunogenicity, efficacy response outcomes, patient survival, and other exploratory parameters. While pancreatic cancer, colorectal cancer, and cholangiocarcinoma are planned expansion cohorts, the dose-finding portion of the clinical trial is open to all patients with metastatic solid tumors other than the above tumor types. Other cancer types other than PDAC, CRC, and CCA may benefit from anti-galectin-9 treatment and, while not currently prioritized for expansion cohorts, may show meaningful clinical benefit and mechanistic rationale in the dose-escalation portion to warrant a dedicated expansion cohort. In addition, expansion cohorts in CRC and CCA are planned for single-agent G9.2-17IgG4 and G9.2-17IgG4 in combination with approved anti-PD-1 agents for patients who have failed at least one prior line of treatment in the metastatic setting and are otherwise eligible for the study.

[0306] The primary objectives included safety, tolerability, maximum tolerated dose (MTD), and objective tumor response (ORR) at 3 months. Secondary objectives included progression-free survival (PFS), duration of response by RECIST 1.1, disease stability, proportion alive at 3, 6, and 12 months, and pharmacokinetic (PK) and pharmacodynamic (PD) parameters.

[0307] Subject, disease, and all clinical and safety data were presented descriptively as means, medians, or proportions, with appropriate variance measures (e.g., 95% confidence interval ranges). Waterfall and Swimmers plots were used to graphically present the ORR and duration of response for subjects in each study arm within each disease site, as described below. Exploratory correlation analyses were also performed to identify potential biomarkers that may be associated with ORR. All statistical analyses were performed using SAS version 9.2 (SAS, Cary, NC).

[0308] The study includes monotherapy with G9.2-17 (IgG4) and a combination of G9.2-17 and nivolumab. The dose range of G9.2-17 can be about 3 mg / kg to 15 mg / kg once every two weeks. The antibody is administered by intravenous infusion.

[0309] Study objectives, duration, and study populations are summarized in Table B.

[0310] Table B. Research Overview

[0311]

[0312]

[0313]

[0314]

[0315] Study Design

[0316] Patient Populations: All metastatic cohorts in 3+3 dose escalation Phase 1 (described below), followed by expansion in PDA, CRC, and CCA or in tumor types where mode of action and / or early efficacy signals were captured in Phase 1.

[0317] Phase 1

[0318] The dose-finding study was conducted using the Continuous Reassessment Method (CRM) - O'Quigley et al. (1990), a model-based design that uses past trial data to inform how the dose of the anti-Gal 9 antibody should be adjusted for the next patient cohort. Phase 1 of the study was 3+3 dose-finding and safety when the anti-galectin-9 antibody was administered as a single agent.

[0319] A single-parameter efficacy model was used to describe the relationship between the dose of G9.2-17 (IgG4) and the probability of observing dose-limiting toxicity (DLT). A DLT was defined as a clinically significant non-hematologic adverse event or abnormal laboratory value assessed as unrelated to metastatic neoplastic disease progression, intercurrent illness, or concomitant medications and related to study drug, and occurring within the first cycle of the study that met any one of the following criteria:

[0320] All grade 4 non-hematologic toxicities of any duration

[0321] All grade 3 non-hematologic toxicities. Exceptions are as follows:

[0322] - Grade 3 nausea, vomiting, and diarrhea that do not require hospitalization or TPN support and can be managed to <2 with supportive care within 48 hours.

[0323] - Grade 3 electrolyte abnormalities corrected to <2 within 24 hours.

[0324] DLT cycle = one (1) cycle of two doses of anti-Gal 9 antibody on Day 1 and Day 15 of each cycle.

[0325] The incidence and severity of AEs / CTAEs and SAEs, including clinically significant changes in laboratory parameters, vital signs, and ECGs

[0326] Incidence of DLT, PK, and PD

[0327] Plasma PK parameters (e.g., AUC 0-24h , C max , T max, estimated half-life); serum concentration versus time curve

[0328] Objective response rate (complete response and partial response) and clinical benefit rate (objective response and stable disease for 3 months or longer); progression-free survival (PFS), overall survival (OS), disease control rate (DCR)

[0329] Blood and tumor immunophenotyping, galectin-9 serum and plasma levels, and tissue expression levels and patterns of tumor, stroma, and immune cells, time to response (TTR) and other biomarker analysis, CT (PET) imaging / other clinically indicated imaging modalities.

[0330] The OBD was the maximum dose at which the estimated probability of DLT was less than or equal to the target toxicity level (TTL) of 25%. Two patients were dosed at a time, with a maximum available sample size of 24. As a safety precaution, at each dose escalation, new patients were entered and treated only after the first patient in each cohort had been treated with anti-Gal 9 antibody and had been at least 7 days post-treatment.

[0331] The dose range is shown in Table 2 below, and the antibodies were administered intravenously once every two weeks (Q2W).

[0332] Table 2: Dosing by cohort

[0333]

[0334] A If none of the first 3 patients experience dose-limiting toxicity (DLT), an additional 3 patients are treated at the next higher dose level. However, if one of the three patients has a DLT, an additional 3 patients are treated at the same dose level. Dose escalation continues until at least 2 patients in the cohort of 3 to 6 patients experience a DLT. The dose in Phase II is the dose just below the level that exhibits toxicity.

[0335] B When ≤ 1 patient responded, the corresponding trial arm was terminated

[0336] Dose escalation follows a modified Fibonacci sequence, with dose increases of 100% of the previous first dose, followed by 67%, 50%, 40%, and 30% of the previous dose. If none of the first three patients experience dose-limiting toxicity (DLT), an additional three subjects are treated at the next highest dose level. Alternatively, if one of the three subjects experiences DLT, an additional three subjects are treated at the same dose level. Dose escalation continues until at least two patients in the three to six patient cohorts experience DLT.

[0337] In the alternative design, Phase 1 will be completed when six consecutive patients receive the same dose and that dose will be identified as the OBD. A total of five dose levels will be evaluated in the CRM design.

[0338] 1. Dose level 1 = 2 mg / kg

[0339] 2. Dose level 2 = 4 mg / kg

[0340] 3. Dose level 3 = 8 mg / kg

[0341] 4. Dose level 4 = 12 mg / kg

[0342] 5. Dose level 5 = 16 mg / kg

[0343] 6. Dosage regimen: Q2W

[0344] 7. Administration route: Intravenous (IV)

[0345] Phase 2

[0346] Phase 2 of the study is a Simon two-stage optimization design (six arms: pancreatic ductal adenocarcinoma (PDA), CRC, and cholangiocarcinoma). The study investigated the use of anti-galectin-9 antibody alone (monotherapy arm of the study) and in combination with nivolumab (240 mg fixed dose administered once every two weeks; IO combination arm of the study). The dose of anti-galectin-9 antibody used was lower than the level found to exhibit toxicity in the Phase I stage.

[0347] In CRC and CCA, anti-Gal 9 antibodies will be tested as single agents. Alternatively, anti-Gal 9 antibodies will be tested in combination with approved anti-PD-1 mAbs (e.g., nivolumab, pembrolizumab, cemiplimab, or INDEX).

[0348] The optimal two-stage design is used to test the null hypothesis of ORR ≤ 5% against the alternative of ORR ≥ 15% (within the single-drug arm). After testing the drug in 23 patients in the first stage, if ≤ 1 patient responds, the corresponding trial arm is terminated. If the trial continues to the second part of the Simon optimized design, a total of 56 patients will be recruited in each single-drug arm. If the total number of patients with a response is ≤ 5, the drug in that arm is rejected. If ≥ 6 patients have an ORR at 3 months, the expansion cohort for that arm is activated. The above methods apply to the single-drug arms of the study.

[0349] For the IO combination arms (CRC and CCA), the starting dose of G9.2-17IgG4 was one dose lower than the RP2D dose level (RP2D-1) determined in Part 1. To ensure patient safety, the sponsor planned a safety run-in in which the first 8 patients received the combination and the arm would continue only if ≤2 patients developed a DLT that was less than 25% of the TTL. If 3 or more patients develop a DLT, the dose of G9.2-17IgG4 will be reduced by one reduction level or at least 30% (dose level -1) based on the clinician's assessment. If necessary, one more dose reduction of 30% of dose level -1 is allowed (dose level -2). No further dose reduction is allowed. Dose reductions to dose levels -1 and -2 are allowed only when the investigator assesses that clinical benefit is being obtained and can continue to be obtained under dose reduction conditions.

[0350] For the anti-PD-1 mAb combination arms in CRC and CCA, an optimal two-stage design was also used to test the null hypothesis of ORR ≤ 10% against an alternative of ORR ≥ 25%. After testing the combination in 18 patients in the first stage, the corresponding trial arm was terminated if ≤ 2 patients had a response. If the trial continued to the second part of the Simon optimized design, a total of 43 patients were recruited in each combination arm. If the total number of responding patients was ≤ 7, the combination within that arm was rejected. If ≥ 8 patients had an ORR at 3 months, the expansion cohort for that arm was activated.

[0351] Phase 3

[0352] Phase 3 includes expansion of cohorts in which early efficacy signals have been detected. If a promising efficacy signal is identified in one of the six trial arms attributable to tumor type, an expansion cohort is initiated to confirm this finding. The sample size for each expansion arm is determined based on the point estimate determined in Phase 2, combined with a predetermined level of precision for the 95% confidence interval (95% CI) around the ORR.

[0353] Pre- and post-treatment biopsy samples were analyzed in this study, for example, PET-CT imaging was performed before the study and Q6 / 8W as clinically indicated. PK, PD, and immunological endpoints included peripheral and intratumoral T cell ratios, T cell activation, macrophage phenotype, galectin-9 serum levels, and galectin-9 tissue expression levels.

[0354] Dosage and Administration

[0355] G9.2-17IgG4 is administered by intravenous (IV) infusion every two weeks (Q2W) until disease progression, unacceptable toxicity, or withdrawal of permission in Parts 1 and 2. Subjects experiencing dose-limiting toxicity may resume G9.2-17IgG4 administration if they are experiencing clinical benefit, based on the investigator's judgment and after discussion with the study medical monitor. The dose may be reduced by 30% or based on the investigator's clinical judgment and agreed to by the medical monitor and sponsor. A dose reduction of 30% will be considered dose level -1. The next dose reduction of 30% of the previous dose level will be considered dose level -2. No more than two such dose reductions are allowed.

[0356] Part 1: Subjects received G9.2-17IgG4 alone according to the CRM design.

[0357] Part 2: Subjects received the RP2D of G9.2-17IgG4 as a single agent or G9.2-17IgG4 in combination with anti-PD-1 (using the RP2D determined in Part 1). However, in the case of the combination arm, the first 8 patients were dosed and if ≤2 patients experienced a DLT that was less than 30% of the target toxicity level (TTL), the arm continued. If more than 3 patients developed a DLT determined to be related to G9.2-17IgG4 and unrelated to the drug / regimen used in combination, the dose of G9.2-17IgG4 would be reduced to the RP2D-1 dose level (30% dose reduction of G9.2-17IgG4 or based on clinician assessment).

[0358] Research objectives

[0359] (ii) Phase 1 (Phase 1a)

[0360] Primary objectives: safety, tolerability, optimal biological dose (OBD), maximum tolerated dose (MTD) or maximum administered dose (MAD), recommended phase 2 dose (RP2D)

[0361] Secondary objectives: pharmacokinetic (PK), pharmacodynamic (PD) parameters, immunogenicity

[0362] Phase 1 exploratory endpoints: In addition to the exploratory endpoints listed below: objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), 6-month and 12-month patient survival

[0363] (ii) Phase 2 and Phase 3 of CRC and CCA

[0364] Primary objective: objective response rate (ORR)

[0365] Secondary objectives: progression-free survival (PFS), disease control rate (DCR), duration and depth of response by RECIST 1.1, 6- and 12-month patient survival, duration of response, safety, and tolerability

[0366] (iii) Stage 2 and 3 of PDAC

[0367] Primary objective: Patient survival at 6 months

[0368] Secondary objectives: objective response rate (ORR), progression-free survival (PFS), disease control rate (DCR) at 3, 6, and 12 months, patient survival at 6 and 12 months, duration and depth of response by RECIST 1.1, duration of response, safety, and tolerability

[0369] (iv) Exploratory endpoints for all study parts:

[0370] iRECIST criteria, immunophenotyping from blood and tumor, cytokine profile (serum), soluble galectin-9 levels in blood (serum or plasma), galectin-9 tumor tissue expression levels and expression patterns by immunohistochemistry (tumor, stroma, immune cells), multiplex immunohistochemistry, time to response (TTR), tumor mutation burden (TMB), PDL-1 expression by immunohistochemistry, mismatch repair status, disease-related tumor markers - and the correlation of these parameters with response, quality of life, and symptom control.

[0371] Study population

[0372] (i) Phase 1: Patients with relapsed / refractory metastatic cancer, regardless of tumor type, are eligible for dose-finding studies using the continuous reassessment method (CRM) described by O'Quigley (1990).

[0373] (ii) Phase 2: Expansion is envisioned in PDAC, CRC, and CCA (planned) or in tumor types where mode of action and / or early efficacy signals were captured in Phase 1.

[0374] (iii) Phase 3: The final and third part of the study allows for further expansion of the Phase 2 cohort that demonstrates a minimum threshold of anti-tumor activity. The sample size for each expansion arm will be determined based on the point estimate determined in Phase 3, combined with a pre-determined level of precision for the 95% confidence interval (95% CI) around the ORR / patient survival rate.

[0375] Patient inclusion criteria:

[0376] 1. Written informed consent (mentally sound, able to understand and willing to sign the informed consent)

[0377] 2. Males or non-pregnant females aged > 18 years

[0378] 3. Histologically confirmed unresectable metastatic cancer

[0379] 4. The researcher determines that the patient can comply with the study protocol.

[0380] 5. Life expectancy > 3 months

[0381] 6. Recent archived tumor samples that can be used for biomarker analysis. Information on treatments received since the biopsy specimen was obtained must be provided. The investigator's judgment will be used to determine whether the archived sample itself is acceptable.

[0382] 7. If available, the level of galectin-9 tumor tissue expression assessed by IHC on archived samples according to the inclusion criteria in point 5 should be recorded.

[0383] 8. Patients are able and willing to undergo pre-treatment and on-treatment / post-treatment biopsies. Based on the investigator's judgment, planned biopsies should not expose patients to a significantly increased risk of complications. Every effort will be made to biopsy the same lesion in repeat biopsies.

[0384] 9. Measurable disease according to RECIST v1.1. Note that the lesion to be biopsied should not be the target lesion.

[0385] 10. The expected survival period is > 3 months according to the investigator's judgment

[0386] 11. For Part 1: No standard of care options available, or the patient has refused, or is ineligible for, available and indicated standard of care treatment. For Part 2: PDAC expansion cohort - patients who have received at least one line of systemic therapy in the metastatic cancer setting, and who are either gemcitabine-naive or at least 6 months removed from treatment with a gemcitabine-containing regimen. CCR and CCA expansion cohorts - patients who have received at least one prior line of therapy in the metastatic setting.

[0387] 12. COVID-19 vaccination before or during the study period is allowed. Information on the time and type of vaccination must be recorded.

[0388] 13. Eastern Cooperative Oncology Group (ECOG) performance status 0-1 / Karnofsky score>70 (please record both if possible)

[0389] 14. MSI-H and MSS patients will be allowed to enter Part 1 (Phase 1) of the study

[0390] 15. Adequate hematologic and end-organ function, defined by the following laboratory results obtained within 28 days prior to the first dose of study drug treatment and within 72 hours prior to any consecutive dose of study drug: neutrophil count ≥1x109 / L, platelet count ≥100x109 / L, and for HCC in Part 1 ≥50x109 / L. Hemoglobin ≥8.5 g / dL in the absence of blood transfusion in the previous week, creatinine ≤1.5 ULN, creatinine clearance ≥30 mL / min, AST (SGOT) ≤3X ULN (≤5x ULN when HCC or liver metastasis is present), ALT (SGPT) ≤3X ULN (≤5x ULN when HCC or liver metastasis is present), bilirubin ≤1.5X ULN (bilirubin can be ≤3.0×ULN in patients with known Gilbert's disease), albumin ≥3.0 g / d LINR and PTT ≤1.5×ULN; amylase and lipase ≤1.5×ULN.

[0391] If brain metastases have been previously diagnosed, treatment of the brain disease, either surgery or radiation therapy, must have been completed 4 weeks or more prior to screening, or the brain disease must have been stable for at least 3 months prior to study entry. In this case, a brain MRI is required to demonstrate no current evidence of progressive brain metastases and no new disease and / or leptomeningeal disease in the brain,

[0392] Patients must have stopped using steroids for brain metastases for at least 28 days prior to study entry.

[0393] 16. No evidence of active infection and no serious infection within 4 weeks before the start of the study

[0394] 17. Females of childbearing potential must have a negative pregnancy test within 72 hours before starting treatment. For females of childbearing potential: agree to maintain abstinence (avoid heterosexual intercourse) or use a contraceptive method that results in a failure rate of <1% per year during treatment and for at least 180 days after the last study treatment. A female has childbearing potential if she is postmenarche, has not reached a postmenopausal state (≥12 consecutive months of amenorrhea and no definite cause other than menopause), and has not undergone surgical sterilization (removal of the ovaries and / or uterus). Examples of contraceptive methods with a failure rate of <1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that suppress ovulation, hormone-releasing intrauterine devices, and intrauterine copper devices. The reliability of sexual abstinence should be evaluated based on the duration of the clinical trial and the patient's preferences and habitual lifestyle. Periodic abstinence (e.g., calendar, ovulation, symptom-thermal, or post-ovulation methods) and withdrawal are unacceptable contraceptive methods. Males of reproductive potential were required to use effective contraception during the study period unless there was documented infertility.

[0395] 18. Four (4) weeks or 5 half-lives (whichever is shorter) from the last dose of anticancer therapy before the first G9.2-17IgG4 administration

[0396] 19. For bone metastases that have been stable for at least 6 months before C1D1, continued use of bisphosphonate therapy (zolamdronate) or denosumab is allowed.

[0397] 20. For the CCR and CCA expansion cohorts, at least one prior line of therapy in the metastatic setting was required.

[0398] Patient exclusion criteria:

[0399] 1. Patients diagnosed with metastatic cancer of unknown primary site

[0400] 2. Unwilling or unable to comply with the requirements of the agreement

[0401] 3. Previous or current illegal drug addiction

[0402] 4. Clinically significant, active, uncontrolled bleeding, and any patient with a bleeding diathesis (e.g., active peptic ulcer disease). Prophylactic or therapeutic use of anticoagulants is permitted.

[0403] 5. Lactating women

[0404] 6. Receipt of any other investigational agent within 4 weeks or 5 half-lives (whichever is shorter) of the drug administered before Cycle 1, Day 1 of the study, or participation in any other clinical trial involving another investigational agent for the treatment of solid tumors, or other investigational treatment or major surgery within 4 weeks from the date of consent, or planned surgery (including dental surgery) within 4 weeks of the expected start of the study.

[0405] 7. Radiation therapy within 4 weeks after the first dose of study drug, except for palliative radiation therapy to a limited area, such as for the treatment of bone pain or focal painful tumor masses.

[0406] 8. Patients with fungal tumor masses

[0407] Patients with locally advanced PDAC.

[0408] 9. ≥CTCAE grade 3 toxicity due to prior cancer therapy (except alopecia and vitiligo). Grade 4 immune-mediated toxicity with prior checkpoint inhibitor use. Grade 2 or 3 pneumonitis or any other grade 3 checkpoint inhibitor-related toxicity leading to immunotherapy interruption.

[0409] 10. History of a second malignancy, except for patients who have been treated with curative intent for more than five years and have not recurred or have a low probability of recurrence (e.g., non-melanoma skin cancer, cervical cancer in situ, prostate cancer, or superficial bladder cancer)

[0410] 11. Severe or uncontrolled systemic illness, congestive heart failure > New York Heart Association (NYHA) class 2, evidence of myocardial infarction (MI) within 6 months, or laboratory findings that, in the opinion of the investigator, make the patient suboptimal for participation in the trial

[0411] 12. Any medical condition that the investigator believes seriously jeopardizes patient safety or impairs the interpretation of the G9.2-17IgG4 toxicity assessment

[0412] 13. Severe non-healing wounds, active ulcers or untreated fractures

[0413] 14. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage surgery

[0414] 15. History of severe allergic, anaphylactic or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

[0415] 16. Major vascular disease within 6 months of Cycle 1 Day 1 (e.g., aortic aneurysm requiring surgical repair or recent arterial thrombosis)

[0416] 17. History of pulmonary embolism, stroke, or transient ischemic attack within 2 or 3 months before Day 1 of Cycle 1

[0417] 18. History of abdominal fistula or gastrointestinal perforation within 6 months before Day 1 of Cycle 1

[0418] 19. Active autoimmune disease (except type 1 diabetes, hypothyroidism requiring only hormone replacement therapy, vitiligo, psoriasis, or alopecia)

[0419] 20. Requirement of systemic immunosuppressive therapy, including but not limited to (cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] drugs). Patients who have received or are currently receiving acute, low-dose, systemic immunosuppressant drugs (e.g., dexamethasone or prednisolone) may be enrolled. Replacement therapies (e.g., thyroxine for adrenal or pituitary insufficiency, insulin, physiologic corticosteroid replacement therapy (e.g., ≤10 mg / day of prednisone equivalents)) are not considered forms of systemic therapy. The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone), topical steroids, intranasal steroids, intra-articular, and ophthalmic steroids are permitted

[0420] 21. Tumor-related pain (>grade 3) unresponsive to extensive analgesic interventions (oral and / or patch).

[0421] 22. Uncontrolled hypercalcemia despite use of bisphosphonates

[0422] 23. Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that raises reasonable suspicion of a disease or condition that contraindicates the use of study drug or that may affect the interpretation of the results or place the patient at high risk for treatment complications

[0423] 24. Receiving an organ transplant

[0424] 25. Currently undergoing dialysis

[0425] Specific additional exclusion criteria for (hepato)cholangiocarcinoma (for HCC in Part 1 and CCA in Parts 1 and 2)

[0426] 1. Any ablation treatment for HCC (radiofrequency ablation or percutaneous ethanol injection) < 6 weeks before trial entry

[0427] 2. Hepatic encephalopathy or severe hepatic adenoma

[0428] 3.Child-Pugh score ≥7

[0429] 4. Metastatic hepatocellular carcinoma that has progressed on at least one prior systemic therapy (including sorafenib), or is intolerant of or refuses sorafenib after progression on standard therapy (including surgery and / or locoregional therapy), or for which standard therapy is considered ineffective, intolerant or inappropriate, or there is no effective standard therapy

[0430] 5. Bile duct or gastric outlet obstruction is allowed, provided that effective drainage is achieved through endoscopy, surgery or interventional means

[0431] 6. Pancreatic, biliary or intestinal fistulas are allowed provided they are controlled with appropriate non-infected and patent drains (if any drain or stent is in place, patency needs to be confirmed before the start of the study).

[0432] Research Assessment

[0433] The assessment schedule is divided into 2-week cycles after pre-dose screening, which can be performed up to 4 weeks before the start of treatment. Study assessments include medical and physical examinations performed by qualified physicians, practitioners, or physician assistants. The medical history collected includes tumor history, radiation therapy history, surgical history, current and past medications. Assessments include restaging scans (CT with contrast, MRI with contrast, PET-CT (diagnostic CT) and / or X-ray).

[0434] Evaluation also includes tumor biopsy (starting before dose 1 and repeated when feasible), depending on scans. Alternatively, archived tissue can be used prior to dosing.

[0435] As appropriate, relevant tumor markers for each tumor type are assessed before dosing in each cycle - e.g., Ca15-3, CA-125, CEA, CA19-9, alpha-fetoprotein, etc. (may be reduced to every 3 cycles after 6 months of treatment, on the same schedule as restaging scans). Assessments also include vital signs, ECOG, adverse events, blood counts, blood chemistry, blood coagulation (prothrombin time (PT) and partial thromboplastin time (PTT), activated partial thromboplastin time (APTT)), blood and tumor biomarker analysis (immunophenotyping, cytokine measurement), and urinalysis (specific gravity, protein, leukocyte esterase, glucose, ketones, urobilinogen, nitrite, WBC, RBC, and pH). Serum chemistry includes glucose, total protein, albumin, electrolytes [sodium, potassium, chloride, total CO2], calcium, phosphorus, magnesium, uric acid, bilirubin (total, direct), SGPT (ALT) or SGOT (AST), alkaline phosphatase, bilirubin, lactate dehydrogenase (LDH), creatinine, HgbA1c, blood urea nitrogen, CPK, TSH, fT4, lipase, amylase, PTH, testosterone, estradiol. Prolactin, FSH, LH, CRP.

[0436] CT with contrast is the modality of choice for restaging scans (MRI, PET-CT, and / or other imaging modalities are substituted for or added to CT scans if CT is not feasible or appropriate given the location of the disease).Assess every 6 to 8 weeks + / - 1 week and at the end of treatment if not performed within the past 4 to 6 weeks.

[0437] Blood samples were collected from patients for routine clinical laboratory tests, including hematology and serum chemistry.

[0438] Blood chemistries included the following: glucose, Hgb A1c, total protein, albumin, electrolytes [sodium, potassium, chloride, total CO2], calcium, phosphorus, magnesium, uric acid, bilirubin (total, direct), SGPT (ALT) or SGOT (AST), alkaline phosphatase, bilirubin, lactate dehydrogenase (LDH), creatinine, blood urea nitrogen (CPK), TSH, fT4, lipase, amylase, PTH, testosterone, estradiol. Prolactin, FSH, LH, CRP.

[0439] Study Products, Dosages, and Administration

[0440] Anti-Gal 9 antibody was administered by intravenous (IV) infusion every two weeks (Q2W) until disease progression, unacceptable toxicity, or withdrawal of permission. Subjects experiencing dose-limiting toxicity may resume administration of anti-Gal 9 antibody after discussion with the study medical monitor if the patient is experiencing benefit. The dose may be reduced by a maximum of 25% or based on the investigator's clinical judgment and with the consent of the medical monitor and sponsor.

[0441] · Phase 1 : Subjects received anti-Gal 9 antibody alone according to the CRM design.

[0442] · Phase 2 : Subjects receive the RP2D of anti-Gal 9 antibody as a single agent or antibody in combination with anti-PD-1 (using the RP2D identified in Phase 1). If the patient exhibits toxicity, reduce the dose of anti-Ga9 antibody (e.g., by 25%).

[0443] · Phase 3 : Treatment arms in which efficacy is observed in Phase 2 will be used in Phase 3 and expanded accordingly at the dose level tested in Phase 2, i.e., when ORR / patient survival (depending on tumor type) exceeds a defined minimum threshold.

[0444] Other drugs

[0445] · Combination drugs : approved anti-PD-1 mAbs (e.g., those mentioned above);

[0446] · dose : Anti-PD-1 mAb doses will depend on the approved drugs to be determined via the initial IND.

[0447] · Mode of administration : Intravenous infusion

[0448] Statistical methods

[0449] Subjects, diseases, and all clinical safety data are presented descriptively as means, medians, or proportions, with appropriate variance measures (i.e., 95% CI, range). Waterfall and Swimmers plots are used to graphically display the ORR and duration of response for patients in each study arm within each disease site. Unless otherwise stated, all efficacy analyses will be based on the ITT population. Survival curves for progression-free survival (PFS) and overall survival (OS) were generated by the Kaplan-Meier method. There was no comparative analysis between any of the six study arms. Exploratory correlation analyses were also performed to identify potential biomarkers and other predictors that may be associated with ORR, PFS, and OS. All statistical analyses will be performed using SAS version 9.2 (SAS, Cary, NC).

[0450] Study Procedures and Evaluation

[0451] The incidence and severity of AEs / CTAEs and SAEs, including clinically significant changes in laboratory parameters, vital signs, and ECGs

[0452] Incidence of DLT, PK, and PD

[0453] Plasma PK parameters (e.g., AUC0-24h, Gm., Tmax, estimated half-life); serum concentration vs. time curves

[0454] Objective response rate (complete response and partial response) (ORR) and clinical benefit rate (objective response and stable disease for 3 months or longer); progression-free survival (PFS), overall survival (OS), disease control rate (DCR)

[0455] Blood and tumor immunophenotyping, galectin-9 serum, plasma levels and tissue expression levels and patterns in tumor, stroma, and immune cells, time to response (TTR) and other biomarker analysis, CT (PET) imaging, and other clinically relevant imaging.

[0456] Safety Monitoring

[0457] Routine safety monitoring is performed by the Medical Monitor. Safety monitoring, including analysis of PK, will be conducted by a Safety Monitoring Committee (SMC) consisting of the principal investigator (and co-investigator as necessary) and sponsor representatives and the study-designated Medical Monitor. Other investigators and study team members will participate in the review as needed. This open-label study does not use an independent data monitoring committee.

[0458] In phase 1, the dose escalation phase, after reviewing cycle 1 of each cohort, dose escalation to the next cohort was performed. The SMC used safety and available PK data to evaluate dose-limiting toxicity (DLT) in all patients in each cohort. As a safety precaution, during the dose escalation period, new patients were entered and treated only after the first patient in each cohort received anti-Gal 9 antibody treatment and at least 7 days after treatment. After cycle 1 was completed, a DLT safety analysis was performed on each patient.

[0459] Dose-limiting toxicity (DLT) was defined as a clinically significant hematologic or non-hematologic adverse event or abnormal laboratory value assessed as not related to metastatic tumor disease progression, intercurrent illness, or concomitant medications and related to study drug, and occurring within the first cycle of the study that met any of the following criteria:

[0460] All grade 4 hematologic and non-hematologic toxicities of any duration

[0461] All grade 3 hematologic and non-hematologic toxicities. Exceptions are as follows:

[0462] o Grade 3 nausea, vomiting, and diarrhea that do not require hospitalization or TPN support and can be managed to ≤ 2 with supportive care within 48 hours.

[0463] o Grade 3 electrolyte abnormalities corrected to ≤ Grade 2 within 24 hours.

[0464] Other Grade 3 Asymptomatic Laboratory Abnormalities DLT Period = One (1) cycle, i.e., two doses of G9.2-17 IgG4 on Day 1 and Day 15 of each cycle.

[0465] Patients should generally remain on study treatment until confirmed radiographic progression. If a patient has radiographic progression but no clear clinical progression and no alternative treatment is initiated, the patient may continue on study treatment at the discretion of the investigator. However, if a patient has clear clinical progression without radiographic progression, study treatment is discontinued and the patient is counseled on available treatment options.

[0466] Approved checkpoint inhibitors and G9.2-17IgG4 are discontinued in the event of a severe or life-threatening immune-related adverse reaction (IMAR) or when initiation of systemic steroids is indicated, although specific exceptions (e.g., certain endocrinopathies in clinically stable patients) may be described in the approved product labeling.

[0467] If the protocol recommends continuing the investigational drug while (a) withholding the approved checkpoint inhibitor or (b) initiating systemic steroids for IMAR, provide adequate justification to support the safety of this approach.

[0468] In cases where dose reductions were used for AE management, two dose reductions were allowed. Each dose reduction was 30% of the baseline dose. Dose reductions were only made if the investigator assessed that clinical benefit was being and was likely to continue to be achieved.

[0469] Treatment-emergent adverse events (TEAEs) will be defined as events occurring at or after the first dose of study drug. The Medical Dictionary for Regulatory Activities (MedDRA) coding dictionary will be used for the coding of AEs. TEAEs, serious or CTC Grade 3 or 4 TEAEs, and treatment-related TEAEs will be summarized overall and by system organ class and treatment group preference. These will summarize the number of events and the number and percentage of patients with a given event. In addition, the number and percentage of patients with TEAEs will be provided by greatest severity. A summary of all TEAEs by system organ class and preference that occurred in at least 5% of patients in either treatment group will be provided.

[0470] Any AE of Grade ≥ 3 that is possibly, probably, or definitely related to one or more study drugs will be discussed with the medical monitor before continuing dosing, with the following exceptions that do not require discussion with the medical monitor:

[0471] Local injection site reactions lasting < 72 hours, including pain, redness, swelling, induration, or itching

[0472] Systemic injection reactions with fever, myalgia, headache, or fatigue lasting < 72 hours

[0473] If deemed appropriate by the investigator (after discussion with the medical monitor), dose delays may be required for grade ≥3 adverse events until toxicity resolves (to grade 1 or less).

[0474] In part 2 of the protocol, if one or more patients experience a DLT, the dose of G9.2-17IgG4 will be reduced to 1 dose below the recommended phase 2 dose (RP2D).

[0475] After patients completed the treatment period, overall survival was followed up every 3 months for up to 2 years. Patients who withdrew due to clinical progression underwent radiological assessment when possible.

[0476] The following procedures will be performed on day 59 or day 30 after the last dose, including for patients who discontinue treatment early.

[0477] Restaging scan (CT, MRI, PET-CT, or X-ray with contrast) - repeated if study end is >6 to 8 weeks after last cycle and at shorter intervals at the discretion of the investigator

[0478] Assess relevant tumor markers before dosing at each cycle, as appropriate - e.g., CA15-3, CA-125, CEA, CA19-9, alpha-fetoprotein, etc. (may be reduced to every 3 cycles after 6 months of treatment, following the same schedule as restaging scans), as appropriate

[0479] 12-lead ECG

[0480] Physical examination

[0481] ECOG

[0482] · Vital signs after lying supine for 5 minutes (temperature, HR, BP, RR, including weight)

[0483] Concomitant medications (name, indication, dosage, route, start and end dates)

[0484] Adverse events

[0485] If female, pregnancy test

[0486] Complete blood count (CBC), differential, platelets, hemoglobin

[0487] Blood chemistry (glucose, total protein, albumin, electrolytes [sodium, potassium, chloride, total CO2], calcium, phosphorus, magnesium, uric acid, bilirubin (total, direct), SGPT (ALT) or SGOT (AST), alkaline phosphatase, bilirubin, lactate dehydrogenase (LDH), creatinine, blood urea nitrogen, CPK), TSH, fT4, PTH, estradiol. Prolactin, testosterone, FSH, LH

[0488] Blood coagulation (PT, PTT)

[0489] Urinalysis

[0490] PD blood - biomarker analysis

[0491] PK blood sample

[0492] RECIST criteria for tumor assessment

[0493] In the baseline tumor assessment, tumor lesions / lymph nodes are classified as measurable or unmeasurable, wherein measurable tumor lesions are recorded according to the longest diameter in the measurement plane (except pathological lymph nodes, which are measured on the shortest axis). When there is more than one measurable lesion at baseline, all lesions representing a total of five lesions (up to two lesions per organ) for all affected organs should be identified as target lesions. Target lesions are selected according to their size (lesions with the longest diameter). The sum of the diameters of all target lesions is calculated and reported as the baseline total diameter.

[0494] All other lesions (or disease sites), including pathological lymph nodes, were identified as non-target lesions and were also recorded at baseline. No measurement was required, and these lesions were tracked as "present," "absent," or "definitely progressed."

[0495] Disease response (complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD)) was assessed as described below.

[0496] Disease response measures allowed calculation of overall disease control rate (DCR) (including CR, PR, and SD), objective response rate (ORR) (including CR and PR), progression-free survival (PFS), and time to progression (TTP).

[0497] Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines

[0498] The overall response according to RECIST 1.1 was derived from the time-point response assessment based on tumor burden as shown below.

[0499] Assessment of target lesions:

[0500] Complete response (CR): All target lesions disappear. Any pathological lymph node (whether target or non-target) must be reduced to <10mm in short axis.

[0501] Partial response (PR): A reduction of at least 30% in the sum of the diameters of the target lesions, based on the baseline sum diameter.

[0502] Progressive Disease (PD): An increase of at least 20% in the sum of diameters of target lesions, with the smallest sum on study as reference (this includes the baseline sum if it is the smallest on study). In addition to the 20% relative increase, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression).

[0503] Stable disease (SD): With the smallest total diameter at the time of the study as reference, there is neither enough shrinkage to meet the requirements of PR nor enough increase to meet the requirements of PD.

[0504] Assessment of non-target lesions:

[0505] Complete response (CR): disappearance of all non-target lesions and normalization of tumor marker levels. The size of all lymph nodes must be non-pathological (<10 mm short axis).

[0506] Non-CR / non-PD: persistent presence of one or more non-target lesions and / or tumor marker levels maintained above the normal range.

[0507] Progressive disease (PD): Unequivocal progression of existing non-target lesions. (Note: the appearance of one or more new lesions is also considered progression).

[0508] ECOG performance status*

[0509]

[0510]

[0511] Published in Am J Clin Oncol:

[0512] ·Oken MM, Creech RH, Tormey DC et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655

[0513] Example 2: Anti-Galectin-9 Antibody Stability Study

[0514] The candidate IgG4 antibody was subjected to stability analysis after storage under several different conditions and at different concentrations. Stability analysis was performed by size exclusion chromatography (SEC) using a TOSOHTSKgel Super SW mAb column. SEC curves before and after storage were compared to identify any issues with protein stability (e.g., aggregation or degradation).

[0515] Materials and methods

[0516] Sample preparation

[0517] Anti-galectin-9 antibody was stored at -80°C before use. Prior to analysis, samples were thawed in a room temperature water bath and stored on ice until analysis. Before processing, the absorbance at 280 nm was measured using Nanodrop. The instrument was blanked using TBS (20 mM Tris pH 8.0, 150 mM NaCl). The samples were then transferred to polypropylene microcentrifuge tubes (USA Scientific, 1615-5500) and centrifuged at 4°C, 16.1 kxg for 30 minutes. The samples were filtered through a 0.22 μm filter (Millipore; SLGV004SL). The absorbance after filtration was measured.

[0518] HPLC analysis

[0519] Sample conditions tested included: ambient stability (0 hours at room temperature, 8 hours at room temperature), refrigerated stability (0 hours at 4°C, 8 hours at 4°C, 24 hours at 4°C), and freeze / thaw stability (1 freeze / thaw, 3 freeze / thaw, 5 freeze / thaw). Each condition was run in duplicate at three different concentrations: stock, 10-fold dilution, and 100-fold dilution. One hundred μL samples were prepared for each condition and stored in polypropylene microcentrifuge tubes. Dilutions were prepared in TBS as necessary. The absorbance at 280 nm was read before analysis. Room temperature samples were stored on the bench for the specified time. 4°C samples were stored on ice or in a 4°C refrigerator for the times shown in Table 3. Freeze-thaw samples were snap frozen in liquid nitrogen and then thawed in a room temperature water bath. The freeze-thaw process was performed once, three, or five times, and the samples were then stored at 4°C until analysis.

[0520] SEC analysis was performed using a TOSOH TSKgel SuperSW mAb HR column on a Shimadzu HPLC with UV detector (at 280 nm). 25 μL of sample was loaded into the column and run at 0.5 mL / min for 40 minutes. KBI buffer formulation was used as the mobile phase.

[0521] result

[0522] Antibody concentrations (before and after filtration) were determined using UV absorbance measurements as shown in Table 3. Two 2 mL samples provided by KBI were thawed, one vial for room temperature and freeze / thaw conditions and the other vial for 4°C conditions. The absorbance readings showed almost complete recovery after filtration.

[0523] Table 3. Protein recovery after sample preparation

[0524]

[0525] Two or three high molecular weight peaks were observed eluting earlier than the main peak ( Figure 1 ). These peaks accounted for approximately 5% of the total sample under each condition tested (Table 4). No significant differences in protein concentration were observed under all conditions tested.

[0526] Table 4. Stability results

[0527]

[0528]

[0529] In summary, the anti-Galectin-9 antibody showed consistent stability after storage under all analyzed conditions, as shown by the lack of significant changes in the SEC profiles. No significant protein loss was observed after filtration, and two to three high molecular weight peaks were identified, accounting for approximately 5% of the total sample. The results indicate that the antibody is stable under all conditions tested, with no aggregate formation or degradation observed.

[0530] Example 3. Evaluation of Galectin-9 Expression in Organoid Fractions Derived from Tumor Biopsies

[0531] Tumor organoids can be used to predict patient outcomes because using tumor models with similar characteristics to the original tumor can lead to more accurate predictions of patient drug responses (see, e.g., Trends in Biotechnology; VOLUME 36, ISSUE 4, P358-371, APRIL 01, 2018).

[0532] Galectin-9 levels in tumors can be used as a predictor of drug response. Organoids derived from biopsies can be used as a proxy for assessing Galectin-9 levels in the original tumor. Therefore, the ability to assess Galectin-9 levels in single cells or organoid fractions was tested.

[0533] Biopsy is received from representative pancreatic cancer and colorectal cancer and is processed as follows. Human surgically excised tumor samples are freshly received in the DMEM culture medium on ice, and minced in a 10 cm culture dish. The minced tumor is resuspended in the DMEM+10%FBS containing 100U / mL type IV collagenase to obtain spheroids. The partially digested sample is precipitated, then resuspended in fresh DMEM+10%FBS, and filtered on 100mm and 40mm filters to generate S1 (>100mm), S2 (40-100mm) and S3 (<40mm) spheroid fractions, which are subsequently stored in ultra-low attachment tissue culture plates.

[0534] The S2 fraction was trypsinized for 15 minutes to generate single cells. For flow cytometry preparation, the cell pellets of the S2 and S3 fractions were resuspended and labeled by incubating the cells with fluorescently coupled mAbs for human CD45 (HI30), CD3 (UCHT1), CD11b (M1 / 70), Epcam (9C4) and Gal9 (9M1-3; all from Biolegend) or Gal9 Fab or Fab isoforms of G9.2-17 after Fc receptor blocking (#422301; BioLegend, San Diego, CA). Dead cells were excluded from the analysis using Zombie Yellow (BioLegend). Flow cytometry was performed on an Attune NxT flow cytometer (Thermo Scientific). Data were analyzed using FlowJo v.10.1 (Treestar, Ashland, OR).

[0535] The results are shown in Figures 2A-2F , 3A-3F, and 4A-4F, indicating that the levels of Galectin-9 detected by Gal9G9.2-17Fab in S2 single cells and S3 organoid fractions are correlated. Therefore, both S2 single cells and S3 organoids can be used to assess Galectin-9 levels in organoids derived from tumor biopsies.

[0536] Example 4. Preparation of Patient-Derived Organotypic Tumor Spheroids (PDOTs) for Cellular Analysis

[0537] Biopsy-derived organoids can serve as a useful measure to assess the ability of therapeutic agents to stimulate immune responses. Therefore, the S2 fraction used for ex vivo culture described in Example 3 above was treated with the anti-Galectin-9 antibody G9.2-17 and prepared for immunoassays.

[0538] After adding 10× PBS and phenol red and adjusting the pH using NaOH, an aliquot of the S2 fraction was precipitated and resuspended in type I rat tail collagen (Corning) at a concentration of 2.5 mg / mL. The pH was confirmed to be 7.0-7.5 using PANPEHA Whatman paper (Sigma-Aldrich). The spheroid-collagen mixture was then injected into the central gel region of a 3-D microfluidic culture device as described in Jenkins et al., Cancer Discov. 2018 Feb; 8(2): 196-215; Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids (the contents of which are incorporated herein by reference in their entirety). After 30 minutes at 37°C, collagen hydrogels containing patient-derived organotypic tumor spheroids (PDOTS) were hydrated with culture medium containing or not containing anti-galectin-9 monoclonal antibody G9.2-17. The PDOTS were then cultured at 37°C for 3 days.

[0539] Resuspend the cell pellet in FACS buffer and add 1x10 6 Cells were first stained with zombie yellow (BioLegend) to exclude dead cells. After viability staining, cells were incubated with anti-CD16 / CD32 mAb (eBiosciences, San Diego, CA) to block FcγRIII / II, followed by antibody staining with 1 μg of fluorescence-conjugated extracellular mAb. Intracellular staining of cytokines and transcription factors was performed using a fixation / permeabilization solution kit (eBiosciences). Useful human flow cytometry antibodies include CD45 (HI30), CD3 (UCHT1), CD4 (A161A1), CD8 (HIT8a), CD44 (BJ18), TNFα (MAb11), IFNγ (4S.B3), and Epcam (9C4); all from Biolegend. Flow cytometry was performed on an LSR-II flow cytometer (BD Biosciences). Data were analyzed using FlowJo v.10.1 (Treestar, Ashland, OR).

[0540] Example 5. Evaluation of Galectin-9 Levels in Plasma and Serum of Cancer Patients

[0541] Plasma and serum galectin-9 levels were assessed in patient samples and compared with healthy volunteers. Blood (10 ml) was drawn from peripheral venous access in 10 healthy controls and 10 inoperable cancer patients. Serum and plasma were extracted from each blood sample. Blood was collected in standard EDTA tubes; PicoKine was used essentially according to the manufacturer's instructions. TM ELISA Catalog Number: EK1113. The results of the individual values ​​are listed in Tables 5 and 6.

[0542] Table 5. Patient samples

[0543]

[0544] Table 6 Healthy volunteer samples

[0545] Sample No. serum plasma Comparison 1 536.4 611.97 Comparison 2 476.43 592.58 Comparison 3 612.66 651.43 Comparison 4 269.75 414.41 Control 5 460.26 602.28 Comparison 6 206.66 405.8 Comparison 7 385.88 439.85 Comparison 8 525.283 654.2 Comparison 9 711.047 718.68 Control 10 296.85 349.09 average 448.122 544.029

[0546] Example 6. Assessment of Galectin-9 Expression and Localization Using Immunohistochemical Analysis

[0547] The ability to determine the level of galectin-9 expression in tumors using immunohistochemical analysis was evaluated using paraffin-embedded biopsy-derived tumor samples.

[0548] Briefly, slides were dewaxed (xylene: 2X 3 minutes; absolute alcohol: 2X 3 minutes, methanol: 1X 3 minutes) and rinsed in cold tap water. For antigen retrieval, citrate buffer (pH 6) was preheated to 100°C in a water bath, and slides were incubated in citrate buffer for 5 minutes. The slides were cooled at room temperature for about 10 minutes and then placed in running water. The slides were washed in PBS, a paper-pencil circle was drawn around the sections, and the sections were incubated in blocking buffer (DAKO-Peroxidase Blocking Solution-S2023) for 5 minutes. Serum-free blocking agent (Novocastra serum-free protein blocking agent) was added and then rinsed off with PBS. The primary antibody (Sigma, anti-Galectin-9 clone 1G3) was used at a dilution of 1:2000 in DAKO-S2022 diluent, and the sections were incubated overnight at 4°C. The slides were washed with PBS and then incubated with secondary antibodies (anti-mouse) for 45 minutes at room temperature. The slides were washed and stained with ABC VECTOR STAIN (45 minutes), washed with PBS, stained with DAB (1 ml stable DAB buffer + 1 drop DAB) for 5 minutes, and then washed in running water. Hematoxylin was added for 1 minute, and then 70% ETOH + 1% HCL was applied to avoid over-staining. The slides were placed in running water for 2-3 minutes, then immersed in water, then in absolute alcohol, and then in xylene, 2 times for 30 seconds each. Cover slips and images were captured. Galectin-9 staining in chemotherapy-treated colorectal cancer and liver metastases of colorectal cancer as shown Figure 5A and 5B The results for galectin-9 negative cholangiocarcinoma are shown in Figure 5C shown.

[0549] Example 7. Cross-reaction of anti-galectin-9 antibody G9.2-17 with other galectins

[0550] To evaluate antibody specificity and cross-reactivity with other galectins, we tested the binding of the anti-galectin-9 antibody G9.2-17 to a human proteomics array consisting of all members of the galectin family and tested two working concentrations. Antibody specificity was assessed using CDI's HuProt human proteome microarray (approximately 75% of the human proteome). The microarray was incubated with the primary antibody, washed, incubated with a fluorescently labeled secondary antibody, and then analyzed for the amount of fluorescence detected for each target protein. The results were compiled into a microarray image. The results show that the anti-galectin-9 antibody G9.2-17 is highly specific for galectin-9 and does not cross-react with any other galectin family members.

[0551] Example 7. Anti-Galectin-9 Antibodies Protect T Cells from Galectin-9-Mediated Apoptosis

[0552] To investigate the effect of the anti-galectin-9 antibody G9.2-17, apoptosis assays were performed to determine whether T cells died due to the apoptotic process or other mechanisms.

[0553] In brief, MOLM-13 (human leukemia) cells were cultured in RPMI medium supplemented with 10% FBS, 2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate, 4.5g / L glucose and 1.5g / L sodium bicarbonate at 37°C, 5% CO2. The cells were then transferred to serum-free RPMI medium and suspended in serum-free medium at a concentration of 2.5e6 cells / mL. The cells were seeded into the wells of a tissue culture grade 96-well plate at a density of 2e5 cells / well (80 μL cell suspension per well). Monoclonal anti-galectin-9 antibodies or matching isoforms were added to each well and incubated at 37°C, 5% CO2 for 30 minutes. After incubation, recombinant full-length human galectin-9 (R&D Systems 2045-GA, diluted in PBS) was added to a final concentration of 200nM. Cells were incubated for 16 hours at 37°C, 5% CO2. Cells were then stained with Annexin V-488 and propidium iodide (PI) before analysis by flow cytometry. Each condition was performed in triplicate. PI is impermeable to live and apoptotic cells but stains dead cells with red fluorescence and binds tightly to nucleic acids in cells. After staining the cell population with Annexin V and PI, apoptotic cells showed green fluorescence, dead cells showed red and green fluorescence, and live cells showed little or no fluorescence. The cells were distinguished using a flow cytometer with a 488nm argon ion laser line for excitation. The analysis was then performed on FlowJo software. The fractions of Annexin V and propidium iodide (PI) positive cells were plotted as Figure 6 function of the antibody concentration used. Figure 6 As shown, the level of apoptotic T cells treated with anti-Gal 9 antibody was much lower than that of T cells treated with human IgG4 isotype control antibody, indicating that the anti-Galectin-9 antibody G9.2-17 protected T cells from Galectin-9-mediated apoptosis.

[0554] Example 8: Evaluation of Gal-9 Antibodies Alone or in Combination with Checkpoint Inhibitors in a Mouse Model of Pancreatic Cancer and Tumor Mass and Immune Profiles in Mice Treated with G9.2-17mIgG1

[0555] The effect of G9.2-17mIgG1 on tumor weight and immune profile was evaluated in a pancreatic cancer mouse model. 8-week-old C57BL / 6 male (Jackson Laboratory, Bar Harbor, ME) mice were administered intrapancreatic injection of FC1242 PDA cells derived from Pdx1Cre; KrasG12D; Trp53R172H (KPC) mice (Zambirinis CP et al., TLR9ligation in pancreatic stellate cells promotes tumorigenesis. J Exp Med. 2015; 212: 2077-94). Tumor cells were suspended in PBS containing 50% Matrigel (BD Biosciences, Franklin Lakes, NJ) and 1x10 5 Tumor cells were injected into the pancreas. Mice (n = 10 / group) received a pre-treatment dose (ip), followed by 3 doses (qw) of commercial αGalectin 9mAb (RG9-1, 200ug, BioXcell, Lebanon, NH) or G9.2-17mIgG1 (200μg) or paired isoforms, G9.2-Iso or rat IgG2a (LTF-2, BioXcell, Lebanon, NH) (200μg) (one dose per week for three weeks). Mice were killed after 3 weeks and tumors were harvested for flow cytometry analysis. Tissues were processed and prepared according to routine practice and flow cytometry analysis was performed. See, for example, U.S. Patent No. 10,450,374.

[0556] Tumor mass and immune profiles in mice treated with G9.2-17mIgG2a alone or in combination with αPD1 mAb

[0557] The effects of G9.2-17mIgG2a on tumor weight and immune profile were evaluated in a pancreatic cancer mouse model (alone or in combination with immunotherapy). Eight-week-old C57BL / 6 male mice (Jackson Laboratory, Bar Harbor, ME) were administered intrapancreatic injections of FC1242PDA cells derived from Pdx1Cre; KrasG12D; Trp53R172H (KPC) mice. Tumor cells were suspended in PBS containing 50% Matrigel (BD Biosciences, Franklin Lakes, NJ) and 1×10 5Tumor cells were injected into the pancreas. Mice received a pre-treatment dose (ip) followed by 3 doses (qw) of G9.2-17mIgG2a (200 μg) or neutralizing αPD-1 mAb (29F.1A12, 200 μg, BioXcell, Lebanon, NH) or paired isoforms (LTF-2 and C1.18.4, BioXcell, Lebanon, NH) alone or in combination, as indicated. Mice were sacrificed on day 26 and tumors were harvested for analysis. Tissues were processed and prepared according to routine practice and flow cytometry analysis was performed. See, e.g., US10,450,374. Each point represents one mouse; *p<0.05; **p<0.01; ***p<0.001; **p<0.0001; by unpaired Student's t test. These results indicate that monotherapy with G9.2-17mIgG2a reduced tumor growth at both dose levels, whereas anti-PD-1 alone had no effect on tumor size.

[0558] Example 9: Evaluation of anti-Gal-9 antibodies in two syngeneic models of colorectal cancer and melanoma in immunocompetent mice

[0559] Gal-9 antibodies G9.2-17 and G9.1-8m13 were evaluated in syngeneic models of colorectal cancer and melanoma in immunocompetent mice. The structures of these two antibodies are provided herein or disclosed in PCT / US2020 / 024767, the relevant disclosures of which are incorporated herein by reference for the subject matter and purposes cited herein. Test articles were prepared and prepared weekly during the study.

[0560] Experimental design

[0561] Animals (female C57BL / 6, 6–8 weeks old (Charles River Labs)) were acclimated for 3 days prior to study and then implanted unilaterally subcutaneously into the left flank with 5e5 B16.F10 (melanoma cell line) or MC38 (colorectal cancer cell line) resuspended in 100 μl PBS. Pre-study tumor volumes were recorded for each experiment starting 2–3 days after implantation. Tumors were resected when they reached 50–100 mm 3 (Preferably 50-75mm 3 ) mean tumor volume, animals were matched by tumor volume to treatment or control groups for dosing and dosing began on day 0. Tables 7 and 8 summarize the study design for testing anti-Gal9 IgG1 and anti-Gal9 IgG2.

[0562] Table 7. Anti-Gal9 IgG1 (B16F10 and MC38)

[0563]

[0564]

[0565] Table 8. Anti-Gal9 IgG2 (B16F10 and MC38)

[0566]

[0567]

[0568] Tumor volumes were obtained three times per week. Final tumor volumes were obtained on the day the study reached endpoint. If an animal was found moribund, a final tumor volume was obtained. Animals were weighed three times per week. Final weights were obtained on the day the study reached endpoint or if an animal was found moribund. Animals with a weight loss of ≥10% compared to day 0 were provided ad libitum. Any animal that exhibited >20% net weight loss over a sustained period of 7 days, or if mice exhibited >30% net weight loss (compared to day 0), was considered moribund and euthanized. The study endpoint was set when the mean tumor volume of the control group (uncensored) reached 1500mm3. If this occurred before day 28, treatment groups and individual mice were dosed and measured until day 28. If the mean tumor volume of the control group (uncensored) did not reach 1500mm3 by day 28, the endpoint for all animals was when the mean tumor volume of the control group (uncensored) reached 1500mm3 until a maximum of 60 days. Blood was collected from all animals in each group. For blood collection, as much blood as possible was collected by cardiac puncture into K2EDTA tubes (400μl) and serum separator tubes (remaining) under deep anesthesia induced by isoflurane inhalation. The blood collected into the K2EDTA tubes was placed on wet ice until used to perform the immune panel flow.

[0569] The blood collected into the serum separator tube was allowed to clot at room temperature for at least 15 minutes. The samples were centrifuged at 3500 for 10 minutes at room temperature. The resulting serum was separated, transferred to uniquely labeled clear polypropylene tubes, and immediately frozen on dry ice or in a freezer set at -80°C until shipped for bridging ADA assay (shipped within one week).

[0570] Tumors from all animals were collected as follows. Size less than 400 mm 3 Tumors were snap frozen, placed on dry ice, and stored at -80°C until used for RT-qPCR analysis. 3 For tumors larger than 500 mm, the entire tumor was harvested into MACS medium for use in the Flow Panel. 3 A small piece (about 50 mm3 ) were snap frozen on dry ice and stored at -80°C for RT-qPCR, and the remaining tumor was collected in MACS medium for flow cytometry. For flow cytometry, tumors were placed in MACS medium and stored on wet ice until processed.

[0571] Spleen, liver, colon, lung, heart and kidney of all animals were kept in 10% neutral buffered formalin (NBF) for 18-24 hours, transferred to 70% ethanol and stored at room temperature. Formalin-fixed samples were paraffin-embedded.

[0572] Example 10: Evaluation of Gal-9 Antibodies in a Cholangiocarcinoma Model

[0573] As described by S. Rizvi et al. (YAP-associated chromosomal instability and cholangiocarcinoma in mice, Oncotarget, 9 (2018) 5892-5905) (the contents of which are incorporated herein by reference in their entirety), the efficacy of the Gal-9 antibody was evaluated in a cholangiocarcinoma mouse model. In this transduction model, where oncogenes (AKT / YAP) are directly injected into the biliary tree, tumors originate from the bile ducts of immunocompetent hosts with species-matched tumor microenvironments. Administration is described in Table 9.

[0574] Table 9. Dosage

[0575]

[0576]

[0577] Briefly, murine CCA cells (described in S. Rizvi et al.) were harvested and washed in DMEM. Male C57BL / 6 mice from JacksonLabs were anesthetized using 1.5-3% isoflurane. Under deep anesthesia, the abdominal cavity was opened through a 1 cm incision below the xiphoid process. A sterile cotton-tipped applicator was used to expose the upper and outer sides of the hepatic lobe. Using a 27-gauge needle, 40 μL of standard culture medium containing 1×10^6 cells was injected into the lateral side of the lobe. The cotton-tipped applicator was fixed at the injection site to prevent cell leakage and blood loss. Subsequently, the abdominal wall and skin were sutured in an isolation layer with absorbable chromic 3-0 gut suture material.

[0578] Two weeks after implantation, animals were matched to treatment or control groups by tumor volume for dosing and began dosing on day 0. Tumor volume was measured and animals were weighed (3 times per week). Final tumor volume and weight were measured on the day when the study reached the endpoint (4 weeks or when the tumor burden of the control became 1500 mm 3 ). Blood was collected from all animals in each group.

[0579] Example 11: In vitro and in vivo characterization of anti-Gal9 antibody G9.2-17

[0580] In vivo and in vitro pharmacodynamic and pharmacological studies as well as safety pharmacology were performed as disclosed below. In vivo studies were performed using the anti-galectin-9 mAb G9.2-17 in IgG1 format for mouse studies based on the fact that this antibody was developed to have exactly the same V as G9.2-17. H and V L chain, and therefore has exactly the same binding epitope and the same cross-reactivity profile as well as cross-species binding affinity and the same functional profile as G9.2-17.

[0581] In vitro studies

[0582] G9.2-17 has multi-species cross-reactivity (human, mouse, rat, cynomolgus monkey) and has equivalent <1 nmol binding affinity when evaluated in vitro. See, for example, PCT / US2020 / 024767, the relevant disclosure of which is incorporated herein by reference for the subject matter and purposes cited herein. G9.2-17 does not cross-react with the CRD1 domain of the galectin-9 protein. It has excellent stability and purification properties and does not cross-react with any other galectin protein present in primates.

[0583] Table 10 below summarizes the results of the in vitro pharmacology studies.

[0584] Table 10. Main in vitro pharmacodynamics

[0585]

[0586]

[0587]

[0588]

[0589]

[0590]

[0591]

[0592] Studies to understand the mechanism of action included ADCC / ADCP (antibody-dependent cell-mediated cytotoxicity / antibody-dependent cellular phagocytosis) and blocking function assessments. As expected for a human IgG4 mAb, G9.2-17 did not mediate ADCC or ADCP ( Fig. 8AThis was tested against the IgG1 human counterpart of G9.2-17, which served as a positive control and mediated both ADCC and ADCP as expected ( Figure 8B ).

[0593] In addition, the blocking function of G9.2-17 was evaluated in a competitive binding ELISA assay. G9.2-17 effectively blocked the binding of the galectin-9 CRD2 domain to its binding partner CD206 human recombinant protein, confirming the expected mode of action of G9.2-17, i.e., blocking galectin-9 activity. In addition, we optimized the MOLM-13T cell apoptosis assay, in which G9.2-17 effectively rescued cells from apoptosis caused by galectin-9 protein treatment (approximately 50% of cells were apoptotic with galectin-9 treatment and approximately 10% of cells were apoptotic with galectin-9 + G9.2-17 treatment).

[0594] Further extensive in vitro characterization has been performed to compare the binding and functional characteristics of G9.2-17 to the mouse IgG1G9.2-17 mAb, which contains exactly the same CDR domains as G9.2-17 and therefore has the same binding epitope, the CRD2 galectin-9 domain. The mIgG1 G9.2-17 was developed for mouse isogenic pharmacology efficacy studies to avoid any potential for immunogenicity with G9.2-17 itself. The mIgG1 G9.2-17 has equivalent <1 nmol cross-species affinity, as well as identical cell-based binding affinity to the human cancer cell line CRL-2134. The mIgG1 G9.2-17 generated data in the MOLM-13 T cell apoptosis assay that was equivalent to that of G9.2-17 itself.

[0595] In vivo pharmacology

[0596] In vivo assays included a syngeneic mouse model using the mouse mAb-G9.2-17 binding epitope cloned into an IgG1 mouse backbone (G9.2-17 surrogate mAb for animal efficacy studies), which shared the cross-reactivity and binding affinity characteristics of G9.2-17.

[0597] The syngeneic mouse models tested were:

[0598] Orthotopic pancreatic cancer (KPC) mouse model (single agent and in combination with anti-PD-1): tumor volume assessment and flow cytometry;

[0599] Subcutaneous melanoma B16F10 model (single agent and in combination with anti-PD-1): tumor volume assessment and flow cytometry.

[0600] Subcutaneous MC38 model (single agent and in combination with anti-PD-1): tumor volume assessment

[0601] In addition, patient-derived in vitro tumor cultures (organoids) treated with G9.2-17 will be used to explore the mechanism of action of G9.2-17.

[0602] Mechanistically, G9.2-17 was found to have blocking activity rather than ADCC / ADCP activity. Blockade of the interaction of galectin-9 with its binding receptors, such as CD206 on immunosuppressive macrophages, was observed. Functionally, in vivo studies demonstrated reduced tumor growth in multiple syngeneic models (orthotopic pancreatic KPC tumor growth and subcutaneous melanoma B16F10 model) treated with G9.2-17mIgG1 replacement antibody. G9.2-17 reactivated effector T cells and reduced levels of immunosuppressive cytokines in mouse tumors treated with monotherapy anti-galectin-9 mAb and in combination with anti-PD-1. Combination studies with anti-PD-1 mAb demonstrated a higher intratumoral presence of effector T cells, supporting clinical testing of the combination approach. Importantly, the mechanistic effects of G9.2-17 have been studied and demonstrated in patient-derived tumor cultures (Jenkins et al., 2018) (tumors resected from primary and metastatic sites of PDAC, CRC, CCA, HCC), where G9.2-17 induced reproducible and robust T cell reactivation, demonstrating reversal of galectin-9-imposed intratumoral immunosuppression (ex vivo).

[0603] To evaluate the relevance of combined anti-PD-1 and anti-galectin-9 mAbs, the sc melanoma B16 model was treated with single-agent anti-PD-1 and anti-galectin-9 as well as the combination. The presence of effector T cells within the tumor was enhanced in the combination arm.

[0604] A significant increase in the level of cytotoxic T cells (CD8) was observed in the treatment with anti-galectin-9mIgG1 200μg + anti-PD-1 (p<0.01) compared with anti-galectin-9mIgG1 200μg, and between anti-galectin-9IgG1 200μg + anti-PD-1 (p<0.001) compared with anti-PD-1 alone. Such results suggest that the combination of anti-Gal9 antibody and anti-PD-1 antibody is expected to achieve excellent therapeutic effects.

[0605] Table 11 below summarizes the results of the in vivo pharmacology studies.

[0606] Table 11. Main in vivo pharmacodynamics

[0607]

[0608]

[0609]

[0610] In addition, tumor immune responses to treatment with G9.2-17IgG1 mouse mAb (also known as G9.2-17mIgG), anti-PD1 antibody, or a combination of G9.2-17IgG1 mouse mAb and anti-PD1 antibody were studied in the B16F10 subcutaneous syngeneic model described herein. Fig. 9A and Fig. 9B As shown, the combination of G9.2-17 and anti-PD1 showed synergistic effects in reducing tumor volume and increasing CD8+ cells in a mouse model. Fig. 10A and 10B The G9.2-17 antibody was shown to increase the expression of CD44 and TNFα in intratumoral T cells.

[0611] Example 12. Non-GLP monotherapy in male Sprague Dawley rats following 1-week and 3-week post-dose observation periods Dose and Range Intravenous Toxicity Studies

[0612] This study evaluated the anatomical endpoints of G9.2-17 IgG4 after a single intravenous bolus administration to Sprague Dawley rats followed by 1 week (terminal) and 3 week (recovery) necropsies on days 8 and 22. All animals survived to scheduled necropsies. There were no macroscopic findings, organ weight changes, or microscopic findings related to the test article in the terminal or recovery necropsy animals of this study.

[0613] The objective of this non-GLP exploratory, single-dose, range-finding, intravenous toxicity study was to identify and characterize the acute toxicity of G9.2-17 IgG4 in Sprague Dawley rats following a 2-minute intravenous bolus administration followed by a 1-week (terminal) and 3-week (recovery) post-dose observation period.

[0614] This non-GLP single-dose toxicity study was conducted in 24 Sprague Dawley male rats to determine the toxicokinetics and potential toxicity of G9.2-17IgG4. Animals were administered vehicle or 10mg / kg, 30mg / kg or 70mg / kg G9.2-17IgG4 by slow push intravenous injection for at least 2 minutes on the 1st day, followed by a period of 1 week (end, the 8th day) or 3 weeks (recovery, the 22nd day) after administration. The study endpoints include mortality, clinical observations, body weight and food consumption, clinical pathology (hematology, coagulation, clinical chemistry and urinalysis), toxicokinetic parameters, ADA assessments and anatomical pathology (gross autopsy, organ weights and histopathology). The summary of the experimental design is provided in Table 13 below.

[0615] Table 13. Experimental design

[0616]

[0617] a Three animals / sex / group were euthanized at terminal necropsy on day 8; the remaining three animals / sex / group were euthanized at recovery necropsy on day 22.

[0618] b The vehicle was formulation buffer (20 mM Tris, 150 mM NaCl, pH

[0619] 8.0±0.05).

[0620] All surviving animals were necropsied on day 8 or day 22. A complete necropsy was performed and organ weights were collected. Organs were weighed from all animals at the end and at retrieval. Tissues required for microscopic evaluation were trimmed, routinely processed, paraffin-embedded, and stained with hematoxylin and eosin.

[0621] There were no unexpected deaths during this study. All animals survived to the end or were recovered for autopsy. The histological changes noted were considered to be accidental findings or related to certain aspects of the experimental operation rather than the administration of the test article. There were no changes associated with the test article in the incidence, severity or histological characteristics of these accidental tissue changes. No findings related to G9.2-17IgG4 were noted in clinical observations, body weight, food consumption, clinical pathology or anatomical pathology. In summary, single intravenous administration of 10, 30 and 70 mg / kg G9.2-17IgG4 to Sprague Dawley rats was tolerable with no adverse findings. Therefore, under the conditions of this study, the NOEL was 70 mg / kg.

[0622] Example 13. Non-GLP Single-Dose, Range-Measured Intravenous Infusion Toxicity Study of G9.2-17 IgG4 in Cynomolgus Monkeys Using a 3-Week Post-Dose Observation Period

[0623] This non-GLP single-dose toxicity study was conducted in 8 cynomolgus monkeys to identify and characterize the acute toxicity of G9.2-17IgG4. Animals (1 male [M] / 1 female [F] / group) were administered vehicle or 30 mg / kg, 100 mg / kg, or 200 mg / kg G9.2-17IgG4 by 30-minute intravenous (IV) infusion, followed by a 3-week post-dose observation period. Study endpoints included: mortality, clinical observations, body weight, and qualitative food consumption; clinical pathology (hematology, coagulation, clinical chemistry, immunophenotyping, and expression of galectin-9 on leukocyte subsets, and cytokine analysis); toxicokinetic parameters; serum collection for possible antidrug antibody evaluation (ADA); and soluble galectin-9 analysis; and anatomical pathology (gross necropsy, organ weights, and histopathology).

[0624] There were no G9.2-17IgG4-related findings on clinical observations, body weight, food consumption, clinical pathology (hematology, clinical chemistry, coagulation, or cytokine analysis), immunophenotyping, galectin-9 expression on leukocyte subsets, soluble galectin-9, or anatomic pathology.

[0625] In summary, single intravenous infusion administration of 30, 100 and 200 mg / kg G9.2-17 IgG4 to cynomolgus monkeys was tolerated with no adverse findings. Therefore, under the conditions of this study, the no observed adverse effect level (NOAEL) was 200 mg / kg, which was the highest dose level evaluated. The study design is shown in Table 14.

[0626] Table 14. Experimental design

[0627]

[0628]

[0629] a Group 4 was administered 1 week after administration of Groups 1 to 3.

[0630]

[0631] a Group 4 was administered 1 week after administration of Groups 1 to 3.

[0632] During the study, the vehicle and test article were administered once by intravenous infusion for 30 minutes through a catheter placed percutaneously in the saphenous vein. The dose levels were 30, 100 and 200 mg / kg and were administered in a dose volume of 20 mL / kg. The control group received the vehicle in the same manner as the treatment group.

[0633] Animals were placed in sling restraints during dosing. Vehicle or test article was administered based on recent body weight using an infusion pump and sterile disposable syringe. The dosing syringe was filled with a suitable volume of vehicle or test article (20 mL / kg, extra 2 mL). When dosing was completed, animals were removed from the infusion system. The weight of each dosing syringe was recorded before each infusion began and ended to determine dosage responsibility.

[0634] Detailed clinical observation

[0635] Animals were removed from their cages and a detailed clinical examination was performed on each animal at 1 hour and 4.5 hours after the start of infusion (SOI) on Day 1, and then once daily during the study. Animals were removed from their cages and a detailed clinical examination was performed on each animal at 1 hour and 4.5 hours after the start of infusion (SOI) on Day 1, and then once daily during the study. Body weights of all animals were measured and recorded at transfer, before randomization, on Day -1, and weekly during the study.

[0636] Clinical pathology evaluations (hematology, coagulation, and clinical chemistry) were performed on all animals pretest and on Days 1 (pre-dose), 3, 8, and 21. Additional samples for determination of hematological parameters and peripheral blood lymphocyte and cytokine analysis samples were collected at 30 minutes (immediately after the end of the infusion) and 4.5, 8.5, 24.5, and 72.5 hours (relative to Day 1) after SOI. Bone marrow smears were collected and stored.

[0637] Blood samples (approximately 0.5 mL) were collected from all animals via the femoral vein for determination of serum concentrations of the test articles (see Table 15) (for deviations, see Appendix 1). Animals were not fasted prior to blood collection, except for intervals consistent with fasting for clinical pathology collections.

[0638] Table 15. Bioanalytical Sample Collection Schedule

[0639]

[0640] X = sample collected.

[0641] a : Only the 0.583 hour post-SOI time point from animals in Group 1 was analyzed for test article content. Additional time points may be analyzed at the discretion of the Study Director

[0642] For processing, blood samples were collected in non-additive barrier-free microtubes and centrifuged at controlled room temperature within 1 hour of collection. The resulting serum was divided into 2 approximately equal aliquots in pre-labeled cryovials. All aliquots were stored frozen at -60°C to -90°C within 2 hours of collection.

[0643] Postmortem study evaluations were performed on all euthanized animals at the time of scheduled necropsy.

[0644] Necropsy was performed under procedures approved by a veterinary pathologist. Animals were carefully examined for external abnormalities, including palpable masses. The skin was reflected from a ventral midline incision, and any subcutaneous masses were identified and correlated with antemortem findings. The abdominal, thoracic, and cranial cavities were inspected for abnormalities. Organs were removed, examined, and placed in fixative when indicated. All designated tissues were fixed in neutral buffered formalin (NBF), except for the eyes (including the optic nerve) and testes. The eyes (including the optic nerve) and testes were placed in modified Davidson's fixative and then transferred to 70% ethanol for up to three days before final placement in NBF. Formalin was instilled into the lungs through the trachea. Intact tissues and organs were collected from all animals.

[0645] Body weights and protocol-specified organ weights were recorded for all animals at scheduled necropsy and appropriate organ weight ratios (relative to body and brain weights) were calculated. Paired organs were weighed together. Combined weights of the thyroid and parathyroid glands were collected.

[0646] result

[0647] All animals survived the scheduled necropsy on Day 22. No clinical or veterinary observations related to the test article were noted in the treated animals. No test article-related body weight effects were observed in the treated animals during the treatment or recovery period. There were no G9.2-17 IgG4-related effects on hematological endpoints in either sex at any dose level at any time interval.

[0648] G9.2-17IgG4 had no effect on clotting times (i.e., activated partial thromboplastin time [APTT] and prothrombin time) or fibrinogen concentration at any dose level at any time interval. All fluctuations between individual coagulation values ​​were considered incidental, consistent with biological and procedure-related variations, and / or negligible in magnitude and unrelated to G9.2-17IgG4 administration.

[0649] There were no G9.2-17 IgG4-related effects on clinical chemistry endpoints in either sex at any dose level at any time interval. All fluctuations between individual clinical chemistry values ​​were considered incidental, consistent with biological and procedure-related variability, and / or negligible in magnitude and unrelated to G9.2-17 IgG4 administration.

[0650] There were no G9.2-17IgG4-related effects on cytokine endpoints in either sex at any dose level at any time interval. All fluctuations between individual cytokine values ​​were considered incidental, consistent with biological and procedure-related variations, and / or negligible in magnitude and unrelated to G9.2-17IgG4 administration.

[0651] Review of gross necropsy observations revealed no findings believed to be test article related. No changes in organ weights believed to be test article related. No changes believed to be test article related.

[0652] In conclusion, single intravenous infusion administration of 30, 100 and 200 mg / kg G9.2-17 IgG4 to cynomolgus monkeys was tolerated without adverse findings. Therefore, under the conditions of this study, the no observed adverse effect level (NOAEL) was 200 mg / kg, which was the highest dose level evaluated.

[0653] Animals were removed from their cages and a detailed clinical examination was performed on each animal at 1 h and 4.5 h after the start of infusion (SOI) on day 1 and then daily during the study.

[0654] Example 12: Intravenous Infusion Study of G9.2-17 in Cynomolgus Monkeys

[0655] The objectives of this study were to further characterize the toxicity and toxicokinetics of the test article G9.2-17 (hIgG4 monoclonal antibody that binds to galectin-9) in cynomolgus monkeys following weekly 30-minute intravenous (IV) infusions for 5 weeks and to assess the reversibility, progression, or delayed appearance of any observed changes after a 3-week recovery period.

[0656] Experimental design

[0657] Table 12 summarizes the study design.

[0658] Table 12. Experimental design

[0659]

[0660]

[0661] a Based on most recent actual weight measurement.

[0662] Animals (cynomolgus monkeys) used in the study were assigned to study groups by a standard, weight-based, randomization procedure designed to achieve similar group mean weights. Males and females were randomized separately. The weight of animals assigned to the study was within ±20% of the mean weight for each sex.

[0663] Formulations lacking G9.2-17 ("vehicle") or containing G9.2-17 ("test article") were administered to animals by 30-minute intravenous infusion once a week during the study for 5 weeks (Days 1, 8, 15, 22, and 29). Dose levels were 0, 100, and 300 mg / kg / dose and were administered at a dose volume of 10 mL / kg. The control group of animals received the vehicle in the same manner as the treatment group. The dose was administered via a percutaneously placed catheter through the great saphenous vein, using a new sterile disposable syringe for each administration. Dose responsibility was measured and recorded before and at the end of dosing on the toxicokinetic sample collection days (Days 1, 15, and 29) to ensure that ±10% of the target dose was administered. Individual doses were based on the most recent body weight. The last dosing site was marked for collection at the end and recovery autopsy. All doses were administered within 8 hours of test article preparation.

[0664] Living procedures, observations, and measurements were performed on the animals as follows.

[0665] Electrocardiograms were performed on all animals. Before recording the electrocardiogram (ECG), care was taken to avoid causing excessive excitement in the animals as much as possible to minimize extreme fluctuations or artifacts in these measurements. A standard ECG (10 leads) was recorded at 50 mm / sec. Using the appropriate leads, the RR, PR and QT intervals and QRS duration were measured and the heart rate was determined. The corrected QT (QTc) interval was calculated using a procedure based on the method described by Bazett (1920). All tracings were evaluated and reported by a consulting veterinary cardiologist.

[0666] To improve continuity and reliability, the Functional Observation Battery (FOB) assessment was performed by two independent raters for all occasions and consisted of detailed home cage and open field neurobehavioral assessments (Gauvin and Baird, 2008). Each technician scored the monkey independently (without sharing results) for each home cage and out-of-cage observation score and then assessed the agreement of the individual scores with their partner's scores after testing was completed. FOB assessments were performed on each animal before dosing (on Day -9 or Day 8) to establish baseline differences and 2 to 4 hours from the start of infusion on Days 1 and 15, as well as prior to terminal and recovery necropsies. Observations included, but were not limited to, assessments of activity level, posture, lacrimation, salivation, tremors, twitches, spontaneous contractions, stereotypic behaviors, facial muscle movements, eyelid closure, pupillary responses, responses to stimuli (visual, auditory, and food), body temperature, Chaddock and Babinski reflexes, proprioception, paresis, ataxia, odometry and slope assessment, locomotion, and gait.

[0667] Measure and record blood pressure for each animal, including systolic, diastolic, and mean arterial pressure. Blood pressure measurements are reported using three readings with mean arterial pressure (MAP) within 20 mmHg.

[0668] Respiratory rate was measured and recorded 3 times per animal / collection interval by visual assessment per testing facility SOP. The average of the 3 collections was the reported value.

[0669] All animals were subjected to clinical pathology assessment (e.g., immunophenotyping and cytokine assessment) at predetermined time intervals. Bone marrow smears were collected and preserved. Blood samples (approximately 0.5 mL) were collected from all animals via the femoral vein for determination of serum concentrations of the test article. Animals were not fasted before blood collection, with the exception of intervals consistent with fasting collected for clinical pathology. At the end of the study (day 36 or day 50), animals were euthanized and tissues for histological processing and microscopic evaluation were collected.

[0670] Soluble galectin-9 was evaluated as follows. Blood samples (approximately 1 mL) were collected from all animals via the femoral vein prior to dosing and 24 hours from the start of infusion on days 1, 8, 15, and 29, as well as prior to terminal and / or recovery necropsy, for the determination of serum soluble galectin-9. Animals were not fasted prior to blood collection, with the exception of fasting intervals consistent with clinical pathology collections.

[0671] Soluble Galectin-9 samples were processed as follows. Blood samples were collected in non-additive, barrier-free tubes, allowed to clot at ambient temperature, and centrifuged at ambient temperature. The resulting serum was divided into 2 aliquots (100 μL in aliquot 1 and the remainder in aliquot 2) in pre-labeled cryovials. All aliquots were snap frozen on dry ice within 2 hours of collection and stored frozen at -60°C to 90°C.

[0672] All results shown in the reported tables were calculated using non-rounded values ​​according to the original data rounding procedure and may not be exactly reproduced from the individual data provided.

[0673] result

[0674] ·mortality rate

[0675] All animals survived the scheduled terminal necropsy on day 36 and the recovery necropsy on day 50.

[0676] Detailed clinical and veterinary observations

[0677] No clinical or veterinary observations related to the test article were noted in the treated animals during the treatment or recovery period.

[0678] Functional observation group

[0679] No test article-related FOB observations were noted in treated animals during either the treatment or recovery periods.

[0680] Body weight and weight gain

[0681] No test article-related effects on body weight and body mass gain were noted in treated animals during either the treatment or recovery periods.

[0682] Eye examination

[0683] No test article-related effects on ophthalmological examinations were noted in treated animals during either the treatment or recovery period.

[0684] Blood pressure

[0685] No test article-related effects on blood pressure values ​​were noted in treated animals during either the treatment or recovery periods.

[0686] Respiratory rate value

[0687] No test article-related effects on respiratory rate values ​​were noted in treated animals during either the treatment or recovery periods.

[0688] Electrocardiology

[0689] No test article-related effects on electrocardiographic evaluations were noted in treated animals during either the treatment or recovery periods.

[0690] ·hematology

[0691] There were no G9.2-17-related effects on hematological parameters in either sex at any dose level at any time point.

[0692] ·solidification

[0693] There were no G9.2-17-related effects on coagulation parameters in either sex at any dose level at any time point.

[0694] Clinical Chemistry

[0695] There were no G9.2-17-related effects between clinical chemistry parameters in either sex at any dose level at any time point.

[0696] Urinalysis

[0697] No G9.2-17-related changes were observed between urinalysis parameters in either sex at any dose level over the 13-week period.

[0698] Cytokines

[0699] No clear G9.2-17-related effects on cytokines were observed at any dose level or time point.

[0700] Peripheral blood leukocyte analysis (PBLA)

[0701] There were no G9.2-17-related effects on the PBLA endpoints in either sex at any dose level at any time point.

[0702] Bioanalysis, Galectin-9, and toxicokinetic assessments

[0703] After dosing, G9.2-17 was quantifiable in all cynomolgus monkey samples from all G9.2-17-dosed animals. No measurable amount of G9.2-17 was detected in control cynomolgus monkey samples. Soluble galectin-9 was quantifiable in all cynomolgus monkey samples from all animals. G9.2-17 serum concentrations were below the bioassay limit of quantification (LLOQ < 0.04 ug / mL) in all serum samples obtained from most G9.2-17-treated animals on Day 1 and from control animals before dosing on Days 1 and 29.

[0704] Gross pathology and organ weights

[0705] There were no test article-related macroscopic observations identified in the main study or recovery animals. There were also no test article-related changes in organ weights for the main study or recovery animals.

[0706] Histopathology

[0707] There were no confirmed microscopic observations associated with the test article.

[0708] In conclusion, weekly intravenous infusions of 100 and 300 mg / kg of G9.2-17 for 5 weeks were well tolerated in cynomolgus monkeys without adverse findings.

[0709] Example 13: Intravenous Infusion Study of G9.2-17 in Sprague Dawley Rats

[0710] The aim of this study was to evaluate the potential toxicity of G9.2-17, an IgG4 human monoclonal antibody against galectin-9, administered to Sprague Dawley rats by intravenous injection once weekly for 4 weeks, followed by a 3-week post-dose recovery period. In addition, the toxicokinetic profile of G9.2-17 was determined.

[0711] Experimental design

[0712] Table 13 summarizes the study design.

[0713] Table 13: Study Design

[0714]

[0715] a Individual dose volumes were calculated based on most recent body weight.

[0716] b SSD animals: 3 animals / sex / group were used for TK collection after single dose administration on day 1 only.

[0717] One hundred eighty-six animals (Sprague Dawley rats) were randomly assigned to treatment groups by body weight. Control article / vehicle, formulation buffer for test article, and test article G9.2-17 were administered by single IV injection in the tail vein at dose levels of 0, 100, and 300 mg / kg on days 1, 8, 15, 22, and 29. Animals assigned to the SSD subgroup were administered the test article once on day 1 at dose levels of 100 and 300 mg / kg.

[0718] Starting from the second day of acclimatization, clinical observations were performed once every morning before cleaning the room. Mortality checks were performed twice a day to assess general animal health. Food supply and residual amount in the container were weighed once a week to estimate food consumption. Average grams (g) / animal / day was calculated from weekly food consumption. Body weight was measured before randomization, on day -1, then once a week during the entire study, and on the day of each autopsy. Functional observation group (FOB) observations of SSB animals were recorded approximately 24 hours after dosing on days 1, 35, and 49. Overnight urine was ...

Claims

1. A method for treating solid tumors, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds to human galectin-9 (anti-galectin-9 antibody), wherein the anti-galectin-9 antibody comprises a light chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 1, a light chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 2, and a light chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 3 and / or comprises a heavy chain complementary determining region 1 (CDR1) as set forth in SEQ ID NO: 4, a heavy chain complementary determining region 2 (CDR2) as set forth in SEQ ID NO: 5, and a heavy chain complementary determining region 3 (CDR3) as set forth in SEQ ID NO: 6, wherein the anti-galectin-9 antibody is administered to the subject at a dose of about 1 mg / kg to about 32 mg / kg.

Citation Information

Cited By

  • Combined medicine for preventing and / or treating prostatic cancer, application of combined medicine and pharmaceutical composition

    CN120585880A